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I. INTRODUCTION 
This chapter is partially adapted from Schmohl KA, Nelson PJ, Spitzweg C. Tetrac as an anti-angiogenic 
agent in cancer. Endocr Relat Cancer 2019;26:R287-304 and Schmohl KA, Müller AM, Nelson PJ, 
Spitzweg C. Thyroid hormone effects on mesenchymal stem cell biology in the tumour 
microenvironment. Exp Clin Endocrinol Diabetes 2019 [Epub ahead of print]. 
1.1 Cancer – an overview 
Cancer is the second leading cause of death, accounting for one in six deaths and an estimated total of 
9.6 million deaths worldwide in 2018. In many of the most developed countries, including large parts 
of Europe and North America, cancer is the leading cause for premature mortality at ages below 70 [1]. 
Though huge advances in understanding and treating cancer have been made over the past 50 years, 
many aspects of cancer biology are still poorly understood and, as the numbers above indicate, there is 
still an urge to develop effective treatment strategies.  
Cancer development and progression are highly complex, multi-stage processes that involve multiple 
genetic and epigenetic changes to transform normal cells into malignant tumour cells. As Peyton Rous 
said in his Nobel lecture of 1966, “Tumours destroy man in a unique and appalling way, as flesh of his 
own flesh which has somehow been rendered proliferative, rampant, predatory and ungovernable” [2]. 
In normal tissues, a homeostasis of cell number and thus tissue composition and function are maintained 
by the careful control of mitogenic signalling. In cancer cells, this signalling is deregulated, leading to 
sustained proliferation, circumvention of growth suppressors, and evasion of cell death. To provide the 
ever-growing cell mass with oxygen and nutrients, new tumour vasculature is established through 
angiogenesis. Ultimately, tumour cells acquire the ability to escape the primary tumour mass by invading 
adjacent tissues and disseminating to distant sites to form metastases [3, 4]. 
1.1.1 The tumour microenvironment 
Solid tumours are organ-like structures that develop within a complex microenvironment [5]. Mimicking 
chronic wounds, tumours hijack the wound healing response to recruit “migratory neighbours and distant 
invaders” as supporting cells and generate the stroma they need for survival and growth [6-9]. The 
malignant cancer cells are typically outnumbered by the ‘benign’ cells of the stromal compartment that 
is composed of a heterogeneous population of cells, including cancer-associated fibroblasts (CAFs), 
mesenchymal stem cells (MSCs), pericytes, vascular endothelial cells, and immune cells, besides non-
cellular components, i.e. signalling molecules and the extracellular matrix (Fig. 1) [10, 11]. The 
adaptation of cells of the tumour stroma to the harsh conditions a growing tumour faces, such as oxygen 
and nutrient deprivation, preserves tumour homeostasis by creating a protective niche not only shielding 
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cancer cells from metabolic stress and immune surveillance, but also fostering resistance to treatment 
[10, 12].  
 
1.1.2 Tumour hypoxia and angiogenesis 
As mentioned above, tumour growth and progression require an adequate vascular supply. Rapidly 
proliferating tumour masses, however, typically outgrow their vasculature, leading to hypoxic areas with 
low oxygen concentrations. This in turn triggers the hypoxic response, both in tumour and stromal cells, 
which is initiated by stabilisation of hypoxia-inducible factors (HIFs). HIFs mediate the expression of 
genes involved in angiogenesis, the formation of new blood vessels from the existing vasculature. 
Angiogenesis is a highly regulated process, temporally and spatially controlled by a balance between 
pro- and anti-angiogenic factors [13, 14]. In response to specific stimuli, including hypoxia and 
inflammation, the angiogenic switch occurs in the quiescent endothelium through the local release of 
vascular growth factors by tumour cells, endothelial cells, and cells of the tumour stroma, initiating 
coordinated endothelial cell proliferation, invasion, migration, and, ultimately, tube formation and 
maturation [14, 15]. Angiogenesis is closely linked to tumour progression, both sustaining tumour 
growth by providing oxygen and other nutrients, and facilitating metastasis. While physiological 
angiogenesis in the context of development, tissue growth, and wound-healing is tightly regulated and 
self-limiting, cancer-associated angiogenesis, though in principle regulated by the same pathways, is 
usually persistent and abnormal, contributing to the formation of a dysfunctional endothelium that is 
often leaky and tortuous [16, 17].  
 
Figure 1. Schematic illustration of the tumour microenvironment. Besides the malignant cancer cells, 
tumours consist of several different supporting cell types that are recruited to the tumour stroma during 
tumour growth and progression. 
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1.1.3 Mesenchymal stem cells 
MSCs are multipotent non-hematopoietic stromal cells, primarily found in the bone marrow and adipose 
tissue, that are capable of differentiating into multiple connective tissue lineages, such as osteocytes, 
chondrocytes, and adipocytes [18]. They contribute to tissue maintenance and regeneration by their 
recruitment as ‘first responders’ to sites of tissue injury and inflammation [11]. Hence, MSCs actively 
home to tumours that are disguised as wounds. The presence and function of MSCs in the tumour 
microenvironment is still incompletely understood, though our current knowledge suggests that they 
serve as progenitor cells for CAFs and blood vessel-stabilising pericytes [5, 8, 18-20]. As with 
fibroblasts associated with wound healing that remodel and regenerate tissues, CAFs are activated 
fibroblasts that support tumourigenesis by encouraging a pro-angiogenic, immunosuppressive, and pro-
inflammatory microenvironment [6, 19, 21]. In addition, they perpetually remodel the extracellular 
matrix, thus releasing sequestered proteins, besides physically creating space for proliferating and 
migrating tumour cells [21]. Pericytes, on the other hand, envelop vascular tubes formed by endothelial 
cells and serve as scaffolding. By their differentiation into pericytes, MSCs support the stabilisation and 
maturation of newly formed vessels [14]. In addition, numerous pro-angiogenic factors have been 
identified in the secretome of MSCs that induce endothelial cell proliferation, migration, invasion, and 
endothelial cell tube formation [14]. Hence, MSCs affect a broad spectrum of angiogenic processes 
through their interaction and communication with endothelial cells [22, 23]. Ultimately, MSCs and their 
differentiated progeny support tumour cell survival and growth, angiogenesis, immune evasion, 
invasion, and metastasis through cell-to-cell interactions and the secretion of tumour-promoting factors 
[24]. 
1.2 Thyroid hormones 
The thyroid hormones L-thyroxine (T4) and 3,5,3’-triiodo-L-thyronine (T3) are iodinated low molecular 
mass compounds derived from the amino acid L-tyrosine (Fig. 2). Virtually all multicellular animals, 
including primitive invertebrate species, have the capacity to respond to thyroid hormones [25]. Their 
diverse functions include the regulation of development, differentiation, growth, and metabolism. Given 
that they influence such a broad range of processes, it is not surprising that growing clinical and 
experimental evidence suggests that thyroid hormones are also implicated in cancer development and 
progression.  
In vertebrates, thyroid hormones are produced and released into the circulation by the thyroid gland 
controlled by feedback mechanisms within the hypothalamic-pituitary-thyroid axis. In response to 
thyroid-stimulating hormone (TSH; thyrotropin) released by the pituitary, thyroid follicular cells 
produce T4 and, to a lower extent, T3. Though T4 is quantitatively the major secretory product, T3 is 
generally considered the metabolically most active thyroid hormone. Relevant T3 production occurs in 
the periphery by de-iodination of T4. Besides the classical thyroid hormones, several naturally 
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occurring, biologically active metabolites have been discovered. These include the acetic acid T4 
analogue 3,3’,5,5’-tetraiodothyroacetic acid (tetrac; Fig. 2) that is generated by deamination and 
decarboxylation at the alanine side chain of the inner tyrosyl ring of T4 and circulates in the blood at 
low nanomolar concentrations [26-28]. 
1.2.1 Thyroid hormone signalling 
At the cellular level, thyroid hormone activity is mediated through specific receptors in the nucleus, but 
also the mitochondria, the cytoplasm, and the plasma membrane [29]. Classical or ‘genomic’ thyroid 
hormone signalling occurs via the nuclear thyroid hormone receptors TRα and TRβ that act as ligand-
dependent transcription factors [30, 31]. In this canonical pathway, T3 is the primary ligand, while T4 
functions as pro-hormone [32]. The term non-classical thyroid hormone signalling, in contrast, 
summarises all those effects where pathway initiation by thyroid hormones is ‘non-genomic’, i.e. not in 
the nucleus, though downstream consequences may culminate in effects on gene transcription. 
 
Integrin αvβ3 
One such non-classical pathway is initiated at integrin αvβ3, a plasma membrane thyroid hormone 
receptor identified in 2005 by Bergh et al. [33]. Integrins are a structurally related family of 
heterodimeric membrane receptors involved in cell-cell and cell-extracellular matrix protein 
interactions, and have emerged as major regulators of the activity of various cell-signalling pathways. 
Though integrins themselves are not oncogenic, their expression by tumour cells and tumour stroma-
associated cells critically contributes to tumour progression and metastasis [34]. Ligand binding to the 
extracellular domain is translated into downstream signalling events via outside-in signalling inside the 
 
 
Figure 2. Membrane-initiated thyroid hormone signalling. Left panel: Chemical structures of 3,5,3’-triiodo-
L-thyronine (T3), L-thyroxine (T4) and thyroid hormone metabolite 3,3’,5,5’-tetraiodoacetic acid (tetrac). Right 
panel: The thyroid hormone binding site on integrin αvβ3 contains two distinct binding domains, S1 and S2 that 
activate separate signalling cascades and downstream effects relevant to tumour progression. 
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cell, usually engaging signal transducing kinase cascades [35]. Integrin signalling is typically transduced 
into cell motility, adhesion, division, and angiogenesis via direct effects on the cytoskeleton and 
modulation of gene transcription. Furthermore, crosstalk between integrins and neighbouring growth 
factor and cytokine receptors, affecting their expression, ligand affinity, and signalling, seems to be 
required for many of their tumour-promoting effects [34]. 
Integrin αvβ3 is primarily expressed on cancer cells, dividing endothelial cells, and tumour stroma-
associated cells, highlighting its potential importance in oncology [20, 36]. Its prototypic ligand is the 
extracellular matrix glycoprotein vitronectin that binds to the integrin’s extracellular domain via an RGD 
(arginine-glycine-aspartic acid) sequence [37]. The thyroid hormone binding site on integrin αvβ3 is 
located near this RGD recognition site and comprises two distinct domains that are related neither 
structurally nor functionally to nuclear thyroid hormone receptors [38, 39]. The binding site S1 
exclusively binds T3 and causes activation of the phosphoinositide 3-kinase (PI3K) cascade, which has 
been proposed to stimulate HIF-1α expression and thus indirectly affect angiogenesis [39]. The S2 site, 
in contrast, binds both T3 and T4 and results in MAPK (ERK1/2) pathway activation [39]. From the 
latter site, thyroid hormones have been reported to stimulate angiogenesis and cell proliferation, and to 
inhibit apoptosis (Fig. 2) [40]. Thus, in contrast to the TR/thyroid hormone axis, both T4 and T3 act as 
active hormones at the integrin receptor. In fact, as the affinity for T4 is far higher than that for T3, and 
lies in the physiologic concentration range that is comparable to the T3 affinity for nuclear receptors, 
T4 may well be the main hormone signalling at the integrin, thus transcending its role of pro-hormone 
for T3 [41]. Tetrac binds to both thyroid hormone binding sites on the integrin and is a specific inhibitor 
of integrin-mediated thyroid hormone action [26, 42]. Within the cell, in contrast, tetrac has low-grade 
thyromimetic activity, both by itself, as well as through its conversion to triiodothyroacetic acid (triac) 
[43, 44]. Via integrin αvβ3, thyroid hormones have been shown to stimulate proliferation in various 
tumour cell lines, both in vitro and in vivo, impede apoptosis, and augment angiogenesis, inflammation, 
immune escape, and therapy resistance, while tetrac reversed these effects [29, 40, 45, 46].  
1.2.2 Thyroid hormones and cancer – the yes, the no, and the maybe 
While experimental evidence conclusively demonstrates a link between thyroid hormones and tumour 
progression, clinical evidence is more ambiguous. Several studies have examined the relationship 
between cancer and thyroid status. Hyperthyroidism has been associated with an increased risk, 
mortality, rate of recurrence, and/or progression in many different tumour entities, including 
gynaecological and gastrointestinal cancers, prostate cancer, glioma, and leukaemia, among others. In 
hepatocellular carcinoma, in contrast, hyperthyroidism has been shown to be associated with smaller 
tumours and a decreased mortality. Hypothyroidism is mostly reported to be associated with a decreased 
cancer risk and a better prognosis, with the exception of uterine and colorectal cancer, and, again, 
hepatocellular carcinoma. Studies comparing the overall risk and mortality for any type of cancer 
complicate things further, as for both hyper- and hypothyroidism results range from an increase to a 
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decrease in cancer risk and/or mortality, with some studies finding no association at all (recently 
reviewed in [47, 48]). More conclusive evidence of thyroid hormone involvement in cancer progression 
has derived from the chance observation that cancer patients that develop hypothyroidism as unwanted 
side effect of treatment often show a more favourable outcome. In addition, in rodent models, 
hypothyroidism has been reported to reduce tumour growth [31, 49-54]. Based on these findings, 
hypothyroidism was deliberately induced in cancer patients in a few pioneering studies. Indeed, 
induction of mild hypothyroidism in glioma patients was associated with tumour regression and 
prolongation of survival and time-to-progression [55-57]. Interestingly, pharmacologic induction of a 
euthyroid hypothyroxinaemic state under maintenance of normal circulating T3 levels and euthyroidism 
with substantial reduction of circulating T4 levels in advanced cancer patients was associated with a 
significant prolongation of actual versus expected survival [58].  
1.3 Targeted cancer gene therapy 
The simplest definition of gene therapy is the genetic modification of cells to produce a therapeutic 
effect [59]. As cancer is a genetic disease, high expectations have been placed on cancer gene therapy. 
Faced with obstacles such as the polygeneity and heterogeneity of tumours, progress, however, has been 
slow [60]. Trying to correct the many different genes that are abnormal for each individual tumour is 
not feasible. Instead, the selective modification of tumour cells with therapeutically active genes is a 
more promising strategy [60]. 
1.3.1 The sodium iodide symporter NIS 
One such therapeutically active gene that has evolved as a highly promising candidate for cancer gene 
therapy is the sodium iodide symporter (NIS; SLC5A5). NIS encodes an intrinsic transmembrane 
glycoprotein that mediates the cellular uptake of iodide from the bloodstream into thyroid follicular cells 
as the first and rate-limiting step of thyroid hormone synthesis [61]. NIS actively transports one iodide 
ion (I-) and two sodium ions (Na+) across the basolateral membrane of thyroid follicular cells using the 
sodium gradient generated by the Na+/K+-ATPase. Iodide transport is inhibited by the Na+/K+-ATPase 
inhibitor ouabain, and the competitive inhibitors thiocyanate and perchlorate. Thyroidal NIS expression 
is regulated by pituitary-derived TSH [61]. In addition to its role in thyroid physiology, NIS provides 
the basis for the diagnostic imaging and therapy of differentiated thyroid cancer and its metastases using 
radioactive iodine isotopes, and other radionuclides that are also transported by NIS. This has been 
successfully exploited for the treatment of thyroid cancer patients since 1946, making thyroid cancer 
one of the most manageable cancers to date [61, 62].  
Cloning of the NIS gene in 1996 marks the birth of a cytoreductive gene therapy approach based on 
targeting functional NIS expression to thyroidal and non-thyroidal tumours, thus extending a well-
established and highly effective therapeutic strategy beyond the treatment of differentiated thyroid 
tumours [61, 63, 64]. The feasibility of the NIS gene therapy concept in cancer treatment has been 
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demonstrated in several preclinical studies and as a result, it has entered clinical trials [65]. These trials 
are based on local or systemic (i.e. by intraperitoneal injection) NIS gene delivery by measles virus in 
various cancer types (NCT01503177, NCT01846091, NCT02364713, and NCT02700230) or by MSCs 
infected with a NIS-encoding measles virus in recurrent ovarian cancer (NCT02068794).  
 
The many advantages of NIS include its dual function as reporter and therapy gene. This allows the 
characterisation of vector biodistribution, localisation, level, and duration of transgene expression, as 
well as dosimetric calculations by standard non-invasive nuclear medicine imaging modalities, 
including 123I- and 99mTc-scintigraphy, as well as 124I- and 18F-TFB-positron emission tomography 
(PET), before the application of a therapeutic dose of therapeutic radionuclides 131I, 188Re, or 211At (Fig. 
3) [66]. In addition, NIS is non-immunogenic and its biodistribution, expression, and safety profile are 
well-defined due to the extensive experience gained in differentiated thyroid cancer patients [67, 68]. 
Notably, NIS-based therapy is associated with a substantial bystander effect on non-transfected cells 
that are irradiated by the crossfire emanating from adjacent transfected cells (Fig. 3). The effective range 
of the beta emission of the therapeutic radionuclide 131I, for instance, is up to 2.4 mm in tissues. The 
 
Figure 3. Schematic illustration of the theranostic NIS gene therapy concept. Cloning of thyroidal NIS 
has paved the way for NIS gene transfer to both thyroidal and extrathyroidal tumours. Application of 
diagnostic radionuclides allows diagnostic imaging and dosimetric calculations, before the application of 
therapeutic radionuclides. 
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significance of this effect is that not only NIS expressing cells are destroyed, but also neighbouring cells, 
hence compensating incomplete targeting of all tumour cells [68].  
1.3.2 Gene transfer concepts 
Clinical application of the NIS gene therapy concept depends on specific and efficient tumour targeting 
at low toxicity and requires systemic application for the treatment of disseminated cancer. The 
biostability and delivery efficiency of naked nucleic acids are very low, limiting their systemic 
applicability and making the development of gene transfer vehicles indispensable [69]. Prof. Dr. 
Christine Spitzweg’s lab has focussed on the optimisation of selective NIS gene transfer into both 
thyroidal and non-thyroidal tumours in collaboration with Prof. Dr. Ernst Wagner (Pharmaceutical 
Biotechnology, Department of Pharmacy, Centre for System-Based Drug Research and Centre for 
Nanoscience, LMU Munich) and Prof. Dr. Peter J Nelson (Clinical Biochemistry Group, Department of 
Internal Medicine IV, University Hospital of Munich, LMU Munich). To this end, different gene transfer 
vehicles that allow systemic application are being evaluated, including genetically engineered MSCs, 
viral vectors, and non-viral synthetic vectors.  
MSCs 
MSCs, based on their natural tropism for solid tumours and metastases, have been used as Trojan horses 
to deliver the NIS gene deep into the tumour microenvironment. After an initial proof-of-principle study 
using the constitutively active cytomegalovirus (CMV) promoter to drive NIS expression in MSCs and 
target hepatocellular carcinoma in a subcutaneous murine xenograft model, tumour specificity was 
enhanced in subsequent studies using promoters selectively activated in the tumour milieu [66]. These 
included the chemokine CCL5/RANTES promoter, a hypoxia-inducible promoter, a TGF-β-responsive 
promoter, and a radiation-inducible promoter [70-75]. These approaches allowed diagnostic imaging of 
MSC biodistribution and transgene expression followed by successful NIS-based radionuclide therapy 
in different tumour models, including orthotopic hepatocellular carcinoma xenografts, colon cancer liver 
metastasis xenografts, and a genetically engineered mouse model of pancreatic ductal adenocarcinoma 
[71, 72, 76]. 
Viral vectors 
A further method for systemic gene transfer is the use of viral vectors. Since viruses are nucleic acid 
transfer vehicles optimised by evolution, their transfection efficiency is unrivalled. In a radiovirotherapy 
approach, a replication-selective oncolytic adenovirus was used to successfully target NIS to 
hepatocellular carcinoma xenografts, resulting in a significant therapeutic effect [77]. To increase 
tumour specificity by reduction of off-target effects, viruses were coated with poly(amidoamine) 
dendrimers, which resulted in successful liver detargeting and effective tumour retargeting of the NIS 
gene transfer vectors [78]. Coupling these dendrimers to GE11, a ligand of the epidermal growth factor 
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receptor (EGFR), which is highly expressed on many tumour cells, further improved tumour selectivity 
of the adenoviral NIS gene therapy approach [79].  
Synthetic vectors 
Though widely used and, in principle, highly promising, viral vectors do come with a number of 
drawbacks, including safety concerns based on their potential immunogenicity and oncogenesis, in 
addition to limited payload capacity and the difficulty of large-scale production [80]. In an approach to 
imitate viruses to deliver nucleic acid payloads efficiently without the aforementioned drawbacks, the 
development of synthetic polymers has gained momentum. In this context, cationic polymers have 
emerged as the most promising class of non-viral gene delivery vehicles [81]. Polycations stabilise 
nucleic acids by forming sub-micrometre complexes called polyplexes, thus effectively protecting them 
from premature degradation and unwanted interactions with extracellular components [81]. Branched 
polycations based on pseudodendritic oligoamines demonstrated the huge potential of synthetic 
polymers for tumoural NIS gene transfer after systemic application in a syngeneic mouse model of 
neuroblastoma and a xenograft mouse model of hepatocellular carcinoma [82, 83]. Tumour targeting 
relied on the high intrinsic tumour affinity of the polyplexes due to the enhanced permeability and 
retention effect that arises from the dysfunctional and leaky endothelium of tumours and drives the 
passive accumulation of polyplexes [69, 84, 85]. To enhance tumour-targeting, polyplexes can be 
equipped with tumour-specific ligands, such as the EGFR-specific peptide GE11 mentioned above. To 
this end, GE11 was attached to one of the most widely used polycations, linear polyethylenimine (LPEI), 
via a polyethylene glycol (PEG) linker, thus reducing cytotoxicity by shielding the surface of the 
polyplex, to target NIS to a high EGFR-expressing xenograft mouse model of hepatocellular carcinoma, 
resulting in a significant therapeutic effect [81, 86, 87].  
1.4 Aims of the thesis 
Cancer is a major cause of mortality around the world. Hence, there is a drive to understand the 
mechanisms contributing to tumour progression with the aim to avoid risk factors and develop more 
target-oriented, individualised therapy approaches. These two aspects, (1) understanding tumour 
biology, and (2) development of tumour-targeted treatment strategies, are the two major topics 
underlying this thesis. 
Over the past two decades, there has been increasing evidence linking the thyroid hormones T3 and T4 
to critical aspects of tumour growth and progression, including stimulation of tumour cell proliferation, 
angiogenesis, and inflammation. These effects are thought to be mediated through integrin αvβ3 and are 
blocked by the T4 derivative tetrac. While thyroid hormone effects on tumour cells and endothelial cells 
have been described in a variety of integrin αvβ3-positive tumour models in vitro and in vivo, effects on 
other critical cells within the tumour microenvironment, including αvβ3-positive MSCs, have not been 
investigated to date.  
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Initially, the tools and thyroid hormone treatment strategies required for the analysis of thyroid hormone 
effects initiated at integrin αvβ3 had to be established in vitro and in vivo. To eliminate endogenous 
thyroid hormone synthesis in the mouse, thyroid ablation protocols needed to be devised.  
Subsequently, building on the extensive experience with adoptively applied MSCs as tumour-selective 
gene delivery vehicles in Prof. Dr. Christine Spitzweg’s and Prof. Dr. Peter J Nelson’s laboratories, the 
effects of thyroid hormones versus tetrac on the tumour homing capacity of MSCs and their 
differentiation within the tumour milieu were investigated.   
As the analysis of MSC differentiation under thyroid hormone stimulation unearthed a subset of genes 
relevant to angiogenesis, and MSCs are known to modulate angiogenesis both by paracrine and cell-cell 
contact effects, the next logical step was to investigate the angiogenic effects of thyroid hormones versus 
tetrac on MSCs in the tumour milieu in more detail. The unique reporter gene properties of NIS, a well-
established theranostic gene in the laboratory of Prof. Dr. Christine Spitzweg, provided the basis to 
examine signalling pathway activation in MSCs in the tumour microenvironment under thyroid hormone 
stimulation. 
Next, a comparison of thyroid hormone versus tetrac effects on tumour growth in an αvβ3-positive 
tumour cell line and an αvβ3-negative tumour cell line was aimed at to determine the importance of 
integrin αvβ3 expression on the tumour cells themselves for tumour growth stimulation by thyroid 
hormones, as opposed to effects on endothelial cells and the tumour stroma. 
The second major topic of this thesis is focussed on NIS gene transfer for cancer gene therapy using 
synthetic non-viral polymers as gene delivery vehicles based on previous work in the laboratories of 
Prof. Dr. Christine Spitzweg and Prof. Dr. Ernst Wagner.  
To begin with, the therapeutic efficacy of LPEI-based polymers containing an EGFR-targeting ligand 
to re-induce NIS expression in undifferentiated thyroid cancer that has lost its endogenous NIS 
expression, were tested.  
In a further step towards clinical application, these polymers were applied in a more advanced tumour 
model. To this end, a genetically engineered mouse model of pancreatic ductal adenocarcinoma was 
used that better reflects human disease and is thus highly suitable to predict the clinical effectiveness of 
a specific therapy approach.  
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2.1 Abstract 
Due to the high variance in available protocols on iodide-131 ablation in rodents, we set out to establish 
an effective method to generate a thyroid-ablated mouse model that allows the application of the sodium 
iodide symporter (NIS) as reporter gene without interference with thyroidal NIS. We tested a range of 
131I doses with and without pre-stimulation of thyroidal radioiodide uptake by low-iodine diet and TSH 
application. Efficacy of induction of hypothyroidism was tested by measurement of serum T4 
concentrations, pituitary TSHβ and liver deiodinase type 1 (DIO1) mRNA expression, body weight 
analysis and 99mTc-pertechnetate scintigraphy. 
While 200 µCi (7.4 MBq) 131I alone was not sufficient to abolish thyroidal T4 production, 500 µCi (18.5 
MBq) 131I combined with one week of low-iodine diet decreased serum concentrations below the 
detection limit. However, the high 131I dose resulted in severe side effects. A combination of one week 
of low-iodine diet, followed by injection of bovine TSH before the application of 150 µCi (5.5 MBq) 
131I, decreased serum T4 concentrations below the detection limit and significantly increased pituitary 
TSHβ concentrations. The systemic effects of induced hypothyroidism were shown by growth arrest and 
decrease in liver DIO1 expression below the detection limit. 99mTc-pertechnetate scintigraphy revealed 
absence of thyroidal 99mTc-pertechnetate uptake in ablated mice. 
In summary, we report a revised protocol for radioiodide ablation of the thyroid gland in the mouse to 
generate an in vivo model that allows the study of thyroid hormone action using NIS as reporter gene. 
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2.2 Introduction 
Mouse models of hypothyroidism increase our understanding of the mechanisms that regulate thyroid 
hormone action both during normal function and disease. Drug-induced hypothyroidism is a commonly 
used approach for assessment of thyroid hormone action in rodent models. An alternative approach 
makes use of the thyroid-lethal properties of the radionuclide iodide-131 to induce hypothyroidism. This 
is based on the ability of thyroid follicular cells to transport and concentrate radioactive iodide due to 
their expression of the sodium iodide symporter (NIS). Several non-thyroidal organs physiologically 
express NIS, such as salivary glands, gastric mucosa and lactating mammary glands and therefore 
possess the ability to actively transport iodide. They do not, however, organify and store it. These 
characteristics allow for high thyroid-specific cytotoxicity of 131I with minimal side effects [88]. 
The first report of selective destruction of thyroid tissue by iodide-131 was published by Hamilton in 
1942 [89]. Since then, numerous protocols for radioiodide ablation of the mouse thyroid gland have 
been published with broad variation of the thyroid-lethal dose of 131I administered to mice ranging from 
28 to 1000 µCi (1 to 37 MBq) in the presence or absence of stimulation of thyroidal iodide uptake by 
treatment with low-iodine diet for one to four weeks or exogenous TSH application prior to the 
administration of radioiodide [50, 90-98].  
We and others have shown the potential of NIS as reporter gene for molecular imaging with a broad 
range of possible applications [66, 70, 77-79, 82, 83, 87, 99-102]. In our previous work, the role of NIS 
as a reporter gene allowed non-invasive multimodal imaging of functional NIS expression by 99mTc or 
123I scintigraphy as well as SPECT and 124I PET imaging that correlated well with the results of ex vivo 
gamma counter measurements as well as NIS mRNA and protein analysis. Stem cells have been the 
object of research in gene and cellular therapies. To date, these studies have lacked detailed information 
about the exact in vivo biodistribution, survival and biological compartment of these cells in tissues. 
Genetically engineered mesenchymal stem cells that express NIS allow detailed, non-invasive in vivo 
tracking of stem cells from their initial deposition to survival, migration and differentiation by 123I 
scintigraphy/SPECT and 124I PET, as has been demonstrated in our previous work [66, 70]. Based on 
these studies, we are now employing this system to study thyroid hormone action on mesenchymal stem 
cell biology within the tumour microenvironment. In an effort to generate a thyroid-ablated mouse 
model for the NIS-based evaluation of thyroid hormone action avoiding interference with thyroidal NIS 
that underlies an exclusive regulation by TSH, in the current study we describe an effective protocol for 
thyroid radioiodide ablation in mice. 
Radioiodide ablation of mouse thyroid 
14 
 
2.3 Materials and Methods 
Animals 
Male CD1 nu/nu mice from Charles River (Sulzfeld, Germany) were maintained under specific 
pathogen-free conditions with access to standard nude mouse diet (2.2 mg/kg iodine; ssniff, Soest, 
Germany) or low-iodine diet (LID; < 15 µg/kg iodine; ssniff) and tap water ad libitum. Animals were 
allowed to acclimatise for one week prior to the start of treatments. At the beginning of the experiments, 
mice weighed 25-30 g with an average body weight of 26.6 g ± 1.27 g (mean ± standard deviation). 
After the end of the experiments, animals were sacrificed and tissues and blood were taken for analysis. 
The experimental protocol was approved by the regional governmental commission for animals 
(Regierung von Oberbayern, Munich, Germany). 
Thyroid radioiodide ablation 
Mice were randomly assigned to different treatment groups. For thyroid ablation, animals received a 
single i.p. injection of 200 µCi (7.4 MBq; according to [96]; n=6), 500 µCi (18.5 MBq; according to 
[90]; n=6) or 150 µCi (5.5 MBq; according to [97, 98]; n=12) of carrier-free iodide-131 in 250 µl 
phosphate-buffered saline containing sodium thiosulfate as reducing agent (GE Healthcare, 
Braunschweig, Germany) or saline for control animals (n=6 for each experiment). Animals that received 
500 µCi of 131I were additionally put on LID one week prior to radioiodide application. Before 
administration of 150 µCi of 131I, mice were fed LID for one week and, on day eight, received an i.p. 
injection of 10 mIU bovine TSH (Sigma, Munich, Germany) two hours before radioiodide application. 
A subset of radioiodide-ablated animals (n=6) received daily i.p. injections of 20 ng/g body weight T4 
(Sigma) starting the day after the application of 131I.  
Serum T4 measurements 
T4 concentrations were monitored in pooled serum samples from tail vein blood or in individual serum 
samples after sacrifice. Serum total T4 concentrations were measured in duplicate by radioimmunoassay 
using a commercially available kit (RIA-4524; DRG Instruments, Marburg, Germany) according to the 
manufacturer’s instructions. The samples and calibrators were incubated with radiolabelled tracer in 
antibody-coated tubes. After incubation, the liquid was aspirated and the antibody-bound radiolabelled 
tracer was counted in a gamma counter (1277 Gammamaster; LKB Wallac, Turku, Finland). The limit 
of quantification was at 10 nM with an intra-assay coefficient of variation (CV) of 3.6% at 80 nM and 
1.1% at 167 nM.  
Whole-body planar 99mTc-pertechnetate scintigraphy 
Two hours after i.p. injection of 500 µCi (18.5 MBq) 99mTc-pertechnetate, a gamma emitter that is also 
transported by NIS [102], 99mTc-pertechnetate accumulation was assessed using a gamma camera 
equipped with a low-energy high-resolution (LEHR) collimator (e.cam, Siemens, Munich, Germany). 
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Imaging studies were performed under inhalational anesthesia using an isofluorane vaporiser. Regions 
of interest were quantified and expressed as fraction of the injected dose of applied radionuclide in the 
cervical region. 
RNA extraction and quantitative real-time PCR 
After sacrifice, mouse pituitaries and livers were snap frozen on dry ice and stored at -80°C until further 
processing. Total RNA was prepared using the RNeasy Mini Kit with QIAshredder (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Reverse transcription was performed using 
SuperScript III First-Strand Synthesis System (Invitrogen Life Technologies, Karlsruhe, Germany). 
Quantitative real-time PCR was run in duplicate with the QuantiTect SYBR Green PCR Kit (Qiagen) in 
a Mastercycler ep gradient S PCR cycler (Eppendorf, Hamburg, Germany). Relative expression levels 
of pituitary TSHβ and liver deiodinase type 1 (DIO1) were calculated from ΔΔCt values normalised to 
internal β-actin and 18S rRNA. The following primers were used: Actb, forward 5’-
AAGAGCTATGAGCTGCCTGA-3’, reverse 5’-TACGGATGTCAACGTCACAC-3’; R18s, forward 
5’-CGCAGCTAGGAATAATGGAA-3’, reverse 5’-TCTGATCGTCTTCGAACCTC-3’; Tshb, 
forward 5’-GGGTATTGTATGACACGGGATA-3’, reverse 5’-ATTTCCACCGTTCTGTAGATGA-
3’; Dio1, forward 5’-AAGACAGGGCTGAGTTTGGG-3’, reverse 5’-
TGAGGAAATCGGCTGTGGAG-3’. 
Statistical analysis 
Every data point was generated using three to six mice per group. Values are reported as mean ± SEM 
or mean fold change ± SEM. Statistical significance of T4 and TSHβ concentrations was tested by two-
tailed Student’s t-test, that of body weight measurements by two-tailed Mann-Whitney U-test (*p<0.05; 
**p<0.01; ***p<0.001). 
2.4 Results 
131I ablation and T4 measurements 
Three different protocols for radioiodide ablation of the thyroid gland were compared with the aim to 
establish a thyroid-ablated mouse model of hypothyroidism. Four weeks after administration of a single 
dose of 200 µCi iodide-131, serum T4 concentrations had dropped by 50% in ablated mice compared to 
untreated control animals (Fig. 4A).  
By increasing the 131I dose to 500 µCi with additional treatment with LID for one week prior to 131I 
application, serum T4 concentrations dropped below the limit of detection (<10 nM) as early as two 
weeks after radioiodide administration (Fig. 4A). However, starting at approximately one week after 
ablation, mice suffered from drastic weight loss and heavy breathing despite T4 supplementation in a 
subgroup of mice, and, as a result, had to be sacrificed (Fig. 4B).  
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The combination of one week of low-iodine diet and stimulation with TSH prior to administration of 
150 µCi 131I (LID/TSH/150 µCi 131I), resulted in serum T4 concentrations below the detection limit 
within two weeks after ablation that remained stable until the end of the observation period (ten weeks 
after ablation; Fig. 4C). The ablated mice without T4 supplementation showed only minor side effects 
such as absence of weight gain (Fig. 5B) and slower movement in the cage. Therefore, all further 
experiments were conducted following this protocol. Serum T4 concentrations in the subgroup of mice 
that received T4 supplementation by daily i.p. injections of 20 ng T4 per gram body weight were in the 
same range as in the untreated euthyroid group of mice (Fig. 4C).  
Monitoring of body weight and analysis of TSHβ and DIO1 mRNA expression  
The drop in serum T4 concentrations in ablated mice coincided with a 48- and 45-fold increase, 
respectively, in pituitary TSHβ concentrations two and ten weeks after thyroid ablation, compared to 
untreated controls (Fig. 5A). 
As a drop in serum T4 and elevation of pituitary TSH do not per se prove a systemic state of 
hypothyroidism, we additionally monitored body weight gain in ablated mice versus untreated control 
mice. Radioiodide-ablated mice showed an arrest in growth from around one week after 131I injection, 
while untreated control animals continued to grow throughout the observation period (Fig. 5B). We also 
investigated expression of DIO1 in the liver as a second marker for systemic hypothyroidism. Four 
 
Figure 4. Comparison of radioiodide thyroid ablation protocols. (A) Serum T4 concentrations 4 weeks 
after injection of 200 µCi 131I and 2 weeks after injection of 500 µCi 131I combined with LID compared to 
untreated controls. The lower 131I dose resulted in a 50 % reduction in serum T4 concentrations only, while 
the higher dose decreased T4 below the detection limit (<10 nM; ***p<0.001). (B) Mice injected with 500 
µCi 131I suffered weight loss irrespective of T4 supplementation and had to be sacrificed, while untreated 
control mice showed continuous growth. Results are expressed as % of initial body weight. (C) Serum T4 
concentrations 2 and 10 weeks after treatment with LID/TSH/150 µCi 131I compared to untreated controls 
and mice that additionally received 20 ng/g body weight T4. This treatment led to undetectable serum T4 
concentrations as early as two weeks after 131I application that remained undetectable after 10 weeks. T4 
supplemented mice showed T4 concentrations in the range of the concentrations measured in untreated and 
therefore euthyroid control animals (*p<0.05; ***p<0.001). 
Radioiodide ablation of mouse thyroid 
17 
 
weeks after 131I application, liver DIO1 mRNA concentrations dropped below the detection limit with 
Ct values >40, whereas for control animals a mean Ct value of 26.11 ± 0.69 was measured with 
comparable reference gene concentrations between the two treatment groups. 
 
99mTc-pertechnetate whole body imaging 
To examine the effects of 131I ablation on thyroidal radioiodide uptake, we monitored 99mTc-
pertechnetate biodistribution by gamma camera imaging. Significant 99mTc-pertechnetate accumulation 
was observed in tissues that physiologically express NIS, i.e. thyroid, salivary glands and stomach, as 
well as the urinary bladder due to renal elimination of the radionuclide (Fig. 6A, B).  
 
 
Figure 5.  Pituitary TSHβ mRNA expression and body weight analysis. (A) 2 and 10 weeks after 
LID/TSH/150 µCi 131I treatment, pituitary TSHβ mRNA concentrations were increased significantly to 48-
fold and 45-fold, respectively, compared to untreated control mice (**p<0.01; ***p<0.001). conc.: 
concentration. (B) While control animals continued to grow throughout the observation period, 
LID/TSH/150 µCi 131I-treated mice showed a growth arrest starting from around one week after thyroid 
ablation (day 0). Results are expressed as % of initial body weight (**p<0.01). 
 
Figure 6. Whole body 99mTc-pertechnetate scintigraphy. 4 weeks after LID/TSH/150 µCi 131I treatment, 
99mTc-pertechnetate gamma camera imaging showed strongly reduced 99mTc-pertechnetate uptake in the neck 
region of ablated animals (approx. 3-5 % (A)) compared to untreated control animals (B). A representative 
image for both ablated mice and control mice is shown. SG: salivary glands. (C) Quantification of 99mTc-
uptake in the cervical region. Results are expressed as fold change compared to untreated controls 
(***p<0.001).  
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Four weeks post 131I injection, 99mTc-pertechnetate uptake was strongly reduced in the cervical region 
of ablated mice with a remaining 99mTc-pertechnetate uptake of approximately 3-5 % which was caused 
by the salivary glands that in mice are localised in the direct neighbourhood of the thyroid gland and 
physiologically express NIS (Fig. 6A, C) [103]. In comparison, untreated control mice accumulated 
approx. 35-40% of the injected dose in the cervical region (Fig. 6B, C). 
2.5 Discussion 
The aim of the current study was to generate a mouse model in which endogenous thyroid hormone 
production is abolished to create an experimental paradigm with a defined baseline for the evaluation of 
response to thyroid hormone that at the same time allows for the use of NIS as a reporter gene. While 
treatment of mice with anti-thyroid drugs in drinking water is a widely used approach to render mice 
hypothyroid, mice have to be treated throughout the experiment, a certain degree of variability remains 
due to differences in water intake and potential side effects of the drugs have to be taken into 
consideration [104, 105]. Furthermore, as this approach typically relies on a combination of thionamides 
(methimazole or propylthiouracil) that have been shown to affect thyroidal NIS expression [106], as 
well as the NIS-specific inhibitor perchlorate to block thyroid hormone synthesis, the use of NIS as 
reporter gene to study thyroid hormone action is limited in this setting.  
Therefore, a reliable method of thyroid radioiodide ablation was developed in mice that exploits the 
ability of NIS to transport 131I. This eliminates interference of reporter gene activity from thyroidal NIS 
that is exclusively regulated by TSH and therefore affected by the thyroid hormone status of the mouse. 
A literature search revealed a variety of protocols [50, 90-98]. As the “American Thyroid Association 
Guide to investigating thyroid hormone economy and action in rodent and cell models” [107] had just 
been published, we initially tested the protocol described there [96]. Here the recommended 131I dose of 
200 µCi was not sufficient to completely abolish endogenous thyroid hormone production. This was 
most likely due to insufficient accumulation of radioiodide in the thyroid, as mice were fed standard 
chow containing 2.2 mg/kg iodine, which competes with radioiodide for thyroidal uptake. We therefore 
increased the amount of 131I to 500 µCi, a dose that was reported by Gorbman [90] to destroy thyroid 
tissue within 24 days after radioiodide application. In addition, we pretreated mice with low-iodine diet 
for one week prior to 131I application to decrease thyroidal iodine content and increase thyroidal NIS 
expression to enhance the uptake of radioiodide into thyroid follicular cells. This treatment decreased 
serum T4 concentrations below the detection limit. However, mice showed severe side effects, i.e. 
drastic weight loss and breathing difficulties, starting from around one week after iodide injection 
irrespective of T4 supplementation, and had to be sacrificed prematurely. We assume that the relatively 
high dose of 131I, while specifically concentrated in the thyroid, caused severe damage to the thyroid 
surrounding tissues, in particular the radiation-sensitive trachea. Due to the close proximity of these 
tissues to the thyroid and the thyroid’s small size, the β-particles emitted by 131I that have a path length 
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of up to 2.4 mm in tissue [108], can cause lesions in the trachea, recurrent laryngeal nerve and 
parathyroid glands, as was observed by Gorbman [91]. Furthermore, transient NIS-mediated transport 
of high doses of radioiodide across epithelia in the gastrointestinal tract may impair their function and 
lead to subsequent damage. 
To avoid aforementioned problems, we adapted protocols published by Abel et al. and Barca-Mayo et 
al. [97, 98], where relatively low doses of 131I were reported to be sufficient for total ablation of the 
thyroid gland under stimulation of 131I uptake. We decided on a protocol consisting of one week of low-
iodine diet, followed by an injection of bovine TSH on day eight, two hours before injection of 150 µCi 
of 131I. We here show the efficacy of this protocol in inducing hypothyroidism in mice at the level of (1) 
the first indicators of a disruption of thyroid function, i.e. serum T4 concentrations and pituitary TSHβ 
content, (2) indicators of systemic hypothyroidism, i.e. growth arrest and decrease in liver DIO1 
concentrations and (3) the thyroid itself by 99mTc-pertechnetate gamma camera imaging. 
Two weeks after thyroid ablation serum T4 concentrations had dropped below the detection limit and 
as expected pituitary TSHβ concentrations reactively increased 48-fold compared to untreated control 
mice. At the end of the observation period, ten weeks after thyroid ablation, T4 concentrations remained 
undetectable and TSHβ concentrations remained high. As growth hormone secretion is thyroid 
hormone-sensitive in rodents [109], ablated mice showed an arrest in growth as a consequence of 
decreasing serum thyroid hormone concentrations, indicating systemic hypothyroidism. Another marker 
for systemic thyroid hormone status is the liver type 1 deiodinase that is downregulated in 
hypothyroidism [110]. Four weeks after thyroid ablation, liver DIO1 mRNA concentrations had dropped 
below the detection limit. Gamma camera imaging revealed a significant reduction in 99mTc-
pertechnetate uptake in the cervical region four weeks after thyroid ablation, despite maximal TSH 
stimulation due to thyroid hormone deficiency in ablated animals. The low residual uptake originates 
from salivary glands that also physiologically express NIS [103, 111]. In mice, the submandibular-
sublingual salivary gland complex is relatively large in relation to the thyroid and is located in the ventral 
cervical region in the direct neighbourhood of the thyroid, therefore causing an overlapping signal on 
123I or 99mTc-pertechnetate scintigraphies [112]. As salivary glands do not possess the ability to organify 
iodine, retention time of the thyroid-ablative dose of 131I is limited. Thus, salivary glands are preserved, 
at least in part, as is their ability to accumulate 99mTc-pertechnetate, while thyroidal uptake is completely 
eliminated, as was shown by whole body and neck transaxial planar SPECT imaging by Choi et al. 
[113]. 
In conclusion, our data provide an effective protocol for radioiodide ablation of the thyroid gland that 
renders mice hypothyroid within the course of two weeks and abolishes thyroidal radioiodide uptake. 
Based on our findings, we recommend stimulation of NIS-mediated thyroidal iodide uptake by 
pretreatment with low-iodine diet and TSH application to help deliver a well-tolerated dose of 150 µCi 
of 131I to mice for successful ablation of the thyroid gland. 
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3.1 Abstract 
To improve our understanding of non-genomic, integrin αvβ3-mediated thyroid hormone action in 
tumour stroma formation, we examined the effects of T3, T4 and integrin-specific inhibitor tetrac on 
differentiation, migration and invasion of mesenchymal stem cells (MSCs) that are an integral part of 
the tumour’s fibrovascular network. Primary human bone marrow-derived MSCs were treated with T3 
or T4 in the presence of hepatocellular carcinoma (HCC) cell-conditioned medium, which resulted in 
stimulation of expression of genes associated with CAF-like differentiation as determined by qPCR and 
ELISA. In addition, T3 and T4 increased migration of MSCs towards HCC cell-conditioned medium 
and invasion into the centre of three-dimensional HCC cell spheroids. All these effects were tetrac-
dependent and therefore integrin αvβ3-mediated. In a subcutaneous HCC xenograft model, MSCs 
showed significantly increased recruitment and invasion into tumours of hyperthyroid mice compared 
to euthyroid and in particular hypothyroid mice, while treatment with tetrac almost completely 
eliminated MSC recruitment. These studies significantly improve our understanding of the anti-tumour 
activity of tetrac, as well as the mechanisms that regulate MSC differentiation and recruitment in the 
context of tumour stroma formation as an important prerequisite for the utilisation of MSCs as gene 
delivery vehicles.  
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3.2 Introduction 
Tumours are composed of malignant tumour cells and the ‘benign’ stromal compartment that contains 
many distinct cell types, including endothelial cells, smooth muscle cells, cells of the immune system, 
and pericytes/cancer-associated fibroblasts (CAFs) [114, 115]. As the tumour stroma plays a key role in 
cancer progression with effects on tumour cell proliferation, angiogenesis and metastasis, it has become 
an attractive target for tumour therapy. Thus, understanding the biology of the tumour microenvironment 
is becoming as important as knowledge of the neoplastic epithelial cells themselves.  
Mesenchymal stem cells (MSCs) are multipotent non-hematopoietic progenitor cells that are 
characterised by their capacity to self-renew and differentiate into cells of connective tissue lineages 
such as bone, cartilage, muscle and adipose tissue [18, 116]. In the course of tissue injury or during 
chronic inflammation, MSCs contribute to tissue remodelling by their mobilisation and subsequent 
recruitment to the site of injury [18, 116]. Similarities between the wound healing process and tumour 
stroma formation have led to the suggestion that tumours are “wounds that do not heal” [9]. We and 
others have shown that MSCs are actively recruited to growing tumour stroma [66, 70, 117-120] 
mediated by high local concentrations of inflammatory chemokines and growth factors [18, 115, 121, 
122]. This tumour tropism constitutes the basis for the ‘Trojan horse’ approach, in which MSCs are used 
as shuttle vectors to deliver therapeutic agents into growing tumours [18, 114, 123-126], as we have 
successfully demonstrated in our previous work using the sodium iodide symporter (NIS) [66, 70, 71] 
and herpes simplex virus type 1 thymidine kinase (HSV-TK) [118-120] as therapy genes in various 
tumour models.  
Upon homing, MSCs act as important progenitors to subtypes that comprise the tumour stroma, 
including cells of the tumour vasculature and cancer-associated fibroblast- (CAF-) like cells [24]. A 
CAF-like phenotype is defined by the following sets of markers: (1) fibroblast surface markers; (2) 
indicators of tissue remodelling and invasion; (3) markers of angiogenesis; and (4) tumour promoting 
growth factors [19, 127, 128]. While it is now well established that MCSs play a major role in supporting 
tumour vasculature and forming the tumour’s fibrovascular network, the exact mechanisms behind their 
migration and differentiation in the tumour microenvironment and their impact on tumour progression 
are not yet fully understood. 
Thyroid hormones 3,3’,5-triiodo-L-thyronine (T3) and L-thyroxine (T4) are regulators of 
differentiation, growth and metabolism in most healthy tissues, but they have also been proposed to play 
a critical role in tumour stroma formation by stimulation of angiogenesis, proliferation and inflammation 
[129, 130]. These effects have been shown to be transduced by non-genomic mechanisms via a plasma 
membrane receptor for thyroid hormone on integrin αvβ3 that was identified in 2005 by P.J. Davis and 
co-workers [33]. Integrin αvβ3 is predominantly concentrated in the plasma membrane of endothelial 
cells, vascular smooth muscle cells, osteoclasts and cancer cells, and is an attractive target for attempts 
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to manipulate tumour cell proliferation and tumour-related neovascularisation [131]. 
Tetraiodothyroacetic acid (tetrac), a deaminated T4 derivative, is a specific inhibitor of thyroid hormone 
action at the integrin site [33, 130]. 
There is growing evidence that iodothyronines act as ‘non-classical’ pro-angiogenic modulators and 
induce neovascularisation. Pro-angiogenic actions of T3 and T4 are initiated at the hormone receptor on 
integrin αvβ3, transduced by the MAPK/ERK pathway, and involve effects on basic fibroblast growth 
factor (FGF2), vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) secretion 
[13, 129]. As an inhibitor of T3/T4 binding to αvβ3, tetrac has been shown to inhibit angiogenic activity 
of thyroid hormones. In addition, αvβ3-mediated proliferative activity of T3 and T4 has been reported 
in various cancer cell lines. A recent uncontrolled observational study suggests that lowering of 
circulating T4 levels is correlated with prolonged survival of terminal stage cancer patients [58]. In 
contrast, tetrac exerts a tumour growth-inhibitory effect based on the inhibition of T3/T4 effects, but 
also on agonist-independent direct anti-angiogenic and pro-apoptotic effects [130, 132]. In this context, 
an array of genes has been identified in human cancer cells that are regulated by tetrac through αvβ3. 
This regulation includes stimulation of pro-apoptosis genes and downregulation of proto-oncogenes, 
cyclin genes, the EGFR gene, as well as genes in the Wnt/β-catenin pathway, such as CTNNA1 and 
CTNNA2 [133]. 
MSCs are key players in the tumour microenvironment and thyroid hormones have been shown to play 
a critical role in the regulation of tumour stoma formation. Therefore, in the current study we sought to 
investigate the non-genomic effects of T3, T4 and tetrac on important aspects of MSC biology in the 
tumour milieu, such as differentiation, migration, recruitment and invasion as a critical prerequisite for 
the application of MSCs as gene delivery vehicles. 
3.3 Materials and Methods 
Cell lines 
Primary human bone marrow-derived CD34-negative MSCs (either prepared in house or provided by 
apceth, Munich, Germany) were isolated and characterised according to the minimal criteria for MSCs 
released by the International Society for Cellular Therapy [134]. MSCs were used from passage 2 to 8 
for experiments. The integrin αvβ3-negative human hepatocellular carcinoma cell line HuH7 was 
authenticated and purchased from JCRB Cell Bank (Osaka, Japan) and passaged up to ten times in our 
laboratories. Both cell lines were grown in DMEM (Sigma-Aldrich, St. Louis, Missouri, USA) 
containing 10 % (v/v) fetal bovine serum (FBS; FBS Superior, Biochrom/Merck Millipore, Berlin, 
Germany), 100 U/ml penicillin/100 µg/ml streptomycin (Sigma-Aldrich) and 2 mM L-glutamine 
(Sigma-Aldrich) and maintained at 37 °C in a humidified 5 % (v/v) CO2 atmosphere. 
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Thyroid hormone treatment in vitro 
T3, T4 and tetrac were dissolved in 0.1 N NaOH at 1 mg/ml. 25 µM (T3 and T4) or 100 µM (tetrac) 
stock solutions were prepared in sterile culture medium and stored in working aliquots at -20 °C 
protected from light. For the preparation of conditioned medium (CM), HuH7 were grown for 48 h to 
80 % confluence in DMEM containing 10 % (v/v) charcoal-stripped FBS (csFBS; T3: <0.2 pg/ml, T4: 
0.2-0.6 ng/dl). Supernatant was removed and centrifuged to eliminate cell debris. Prior to thyroid 
hormone treatment, MSCs were grown in DMEM/csFBS for 24 hours. Medium was changed to 80 % 
(v/v) DMEM/csFBS and 20 % (v/v) HuH7 CM for differentiation studies or DMEM/csFBS for 
migration and invasion studies and supplemented with 1 nM T3 or 1 µM T4 with and without 100 nM 
tetrac for 24 h. In a pilot study ranges of 1-100 nM T3 as well as 1-1000 nM T4 were tested and optimal 
concentrations of 1 nM total T3 (~ 30 pM free T3) and 1 µM total T4 (~ 1.5 nM free T4) were used for 
further experiments. 
Flow cytometry 
For flow cytometry, MSCs and HuH7 were harvested with EDTA (Sigma-Aldrich) and washed with 
PBS (Sigma-Aldrich) supplemented with 10 % (v/v) FBS (FACS buffer). Cells were incubated with a 
mouse monoclonal anti-integrin αvβ3 antibody (2 µg/106 cells; Abcam, Cambridge, UK) for 45 min on 
ice, washed with FACS buffer and then incubated with a Cy3-conjugated polyclonal donkey anti-mouse 
antibody (2 µg/106 cells; Jackson, Baltimore, USA) for 30 min on ice. Cells incubated without the 
primary antibody served as negative control. Analysis was performed in the FL2 channel of a BD Accuri 
C6 flow cytometer using Cflow software (BD Biosciences, Franklin Lakes, USA). 105 events were 
recorded for each sample. Cell debris was excluded from analysis by appropriate gating. 
Quantitative real-time PCR 
Total RNA from MSCs was prepared using the RNeasy Mini Kit with QIAshredder (Qiagen, Hilden, 
Germany). Reverse transcription and quantitative real-time PCR were performed as described 
previously [70] and run in a Mastercycler ep gradient S PCR cycler (Eppendorf, Hamburg, Germany). 
Relative expression levels were calculated from ΔΔCt values normalised to internal β-actin and 18S 
rRNA. Primers are listed in table 1. 
ELISA 
Supernatant from MSCs was removed, centrifuged and stored at -80 °C until assayed for EGF, FGF2, 
hepatocyte growth factor (HGF), interleukin 6 (IL-6), stromal-derived factor 1 (SDF-1), transforming 
growth factor β1 (TGF-β1), thrombospondin 1 (TSP1) and VEGF concentrations using the respective 
DuoSet ELISA kit (R&D Systems, Abingdon, UK). Contributions from medium and HuH7 CM were 
subtracted.  
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Migration assay  
MSC migration was analysed using the µ-slide Chemotaxis3D system from ibidi (Martinsried, Germany). 
MSCs were seeded in collagen I (0.3×106 cells/ml) and subjected to a gradient between serum-free 
unconditioned medium and serum-free HuH7 CM. Both media and the collagen gel contained either no 
thyroid hormone, 1 nM T3 or 1 µM T4 with and without 100 nM tetrac. Chemotaxis was monitored by 
time-lapse microscopy over a 24 h period on a Leica DM IL microscope (Leica Microsystems, Wetzlar, 
Germany). Pictures were taken every 15 min with a Jenoptik ProgRes CCD camera (Jenoptik, Jena, 
Germany) controlled by the open source ImageJ (NIH, Bethesda, Maryland, USA) plug-in µManager 
[135]. 25 randomly selected cells were manually tracked with the ImageJ plug-in Manual Tracking 
(Fabrice Cordelières, Orsay, France) and analysed with Chemotaxis and Migration Tool software (ibidi). 
The migratory behaviour of cells was quantified by forward migration index (FMI), a measure of the 
efficiency of the migration of cells in relation to the CM gradient and centre of mass (CoM) displacement 
that is calculated from the averaged point of all cell endpoints. 
Table 1. qPCR primer sequences. 
gene forward primer (5’ → 3’) reverse primer (5’ → 3’) 
ACTA2 (α-SMA) ACCCACAATGTCCCCATCTA GAAGGAATAGCCACGCTCAG 
ACTB (β-actin) AGAAAATCTGGCACCACACC TAGCACAGCCTGGATAGCAA 
CXCL12 (SDF-1) AGAGCCAACGTCAAGCATCT CTTTAGCTTCGGGTCAATGC 
DES (desmin) AAGCTGCAGGAGGAGATTCA GGCAGTGAGGTCTGGCTTAG 
EGF CAGGGAAGATGACCACCACT CAGTTCCCACCACTTCAGGT 
FAP GGTCTCCCAACAAAGGATGA CATTGCCTGGAAATCCACTT 
FGF2 GGAGAAGAGCGACCCTCAC AGCCAGGTAACGGTTAGCAC 
HGF CTGGTTCCCCTTCAATAGCA CTCCAGGGCTGACATTTGAT 
IL6 TACCCCCAGGAGAAGATTCC TTTTCTGCCAGTGCCTCTTT 
MMP3 (SL-1) GCAGTTTGCTCAGCCTATCC GAGTGTCGGAGTCCAGCTTC 
R18s CAGCCACCCGAGATTGAGCA TAGTAGCGACGGGCGGTGTG 
S100A4 (FSP1) CCCTGGATGTGATGGTGTCC CGATGCAGGACAGGAAGACA 
TGFB1 (TGF-β1) CAGCACGTGGAGCTGTACC AAGATAACCACTCTGGCGAGTC 
THBS1 (TSP1) TTGTCTTTGGAACCACACCA CTGGACAGCTCATCACAGGA 
TNC TTCACTGGAGCTGACTGTGG TAGGGCAGCTCATGTCACTG 
VEGF CTACCTCCACCATGCCAAGT ATGATTCTGCCCTCCTCCTT 
 
Spheroid invasion assay 
Invasion assays were performed as described previously [136-139]. In brief, spheroids of 200-300 µm 
in diameter were grown from HuH7 cells. Single spheroids were rolled in 2.5×104 thyroid hormone-
treated, CellTracker Green CMFDA- (5-chloromethylfluorescein diacetate, Life Technologies) labelled 
MSCs for 2 h, washed and incubated for further 24 h. Spheroids were fixed in 4% formalin, embedded 
in 1 % (w/v) 2-hydroxyethylagarose (Roth, Karlsruhe, Germany) containing green fluorescent 
microspheres (F-XC 50 Estapor, Merck, Darmstadt, Germany; 1:50,000 dilution) and aspirated into a 
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glass capillary. Imaging was performed with a 488 nm laser (2 mW laser power, 120 ms exposure time; 
Cube, Coherent, Santa Clara, California, USA) and an sCMOS camera (Orca-flash 4.0 V2, Hamamatsu, 
Hamamatsu City, Japan) from 5 different angles equally spaced over 360°, controlled via the FIJI 
µManager plug-in [135]. The subsequent registration of beads and fusion of images was performed 
using SPIM open source software on FIJI [140]. Signals from CMFDA-labelled MSCs and the 
autofluorescent spheroid were detected and segmented using the FIJI 3D object counter plugin [141]. 
Invasion depths were quantified by measurement of distances from the centre of each MSC to the border 
of the spheroid using the FIJI 3D manager plugin [142]. 
Animals  
Male CD1 nu/nu mice from Charles River (Sulzfeld, Germany) were maintained under specific 
pathogen-free conditions with access to standard nude mouse diet (ssniff, Soest, Germany) and water ad 
libitum. Animals were allowed to acclimatise for one week prior to the start of treatments. Experiments 
were conducted with animals between 5-12 weeks of age. Thyroid hormone status was regularly 
monitored in serum samples as described previously [143]. The experimental protocol was approved by 
the regional governmental commission for animals (Regierung von Oberbayern, Munich, Germany). 
MSC recruitment to tumours in vivo 
HuH7 xenograft tumours were established by subcutaneous injection of 3.5×106 HuH7 cells in 100 µl 
PBS into the flank region. Three days later, animals received drinking water supplemented with 0.02 % 
(w/v) 2-mercapto-1-methylimidazole (MMI; Sigma-Aldrich), 1 % (w/v) sodium perchlorate (Sigma-
Aldrich) and 0.3 % (w/v) saccharin (Sigma-Aldrich) [144] to induce hypothyroidism to generate the 
same baseline thyroid hormone levels for all groups. Three weeks later, once small tumours (<3 mm) 
were visible, mice were randomly assigned to different groups by daily intraperitoneal injections. The 
hyperthyroid group (n = 8) received 100 ng/g body weight L-T4 (Sigma-Aldrich), the euthyroid group 
20 ng/g body weight L-T4 with (n = 8) or without (n = 7) 10 µg/g body weight tetrac (Sigma-Aldrich), 
hypothyroid animals (n = 8) received saline only. 18 days later (tumour volume approx. 500 mm3) 5×105 
MSCs cytoplasmically labelled with 20 µM CMFDA for 30 min were injected via the tail vein in 500 
µl PBS. 72 h later, mice were sacrificed and tumours were embedded in Tissue-Tek O.C.T. compound 
(Sakura Finetek, Alphen aan den Rijn, The Netherlands), snap-frozen on dry ice and stored at -80 °C.  
Immunofluorescence microscopy  
Tissue sections were fixed in methanol/acetone, counterstained with 5 µg/ml bisbenzimide Hoechst 
33258 (Sigma-Aldrich), mounted with Dako Fluorescence Mounting Medium (Dako, Carpinteria, 
California, USA) and imaged at 10× magnification on an Axiovert 135 TV fluorescence microscope 
equipped with an AxioCam MRm CCD camera and AxioVision Rel. 4.8 software (Carl Zeiss, Munich, 
Germany). 4-7 visual fields in perivascular regions were recorded per animal and MSC recruitment was 
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quantified as percentage of CMFDA positive area using ImageJ software (NIH, Bethesda, Maryland, 
USA). 
Statistics 
All in vitro experiments were performed at least in triplicate. In vivo data were generated in two 
independent experiments. Values are reported as mean ± SEM or mean fold change ± SEM. Statistical 
significance was tested by two-tailed Student’s t-test or, for invasion assays, by Kruskal-Wallis test. p-
values <0.05 were considered significant (*p<0.05; **p<0.01; ***p<0.001).  
3.4 Results 
Expression of integrin αvβ3 is absent on HuH7 cells and not influenced by thyroid 
hormones T3 and T4 or tetrac in MSCs 
Absence of integrin αvβ3 expression on HuH7, as well as presence of αvβ3 on MSCs was confirmed by 
flow cytometry (Fig. 7). Treatment of MSCs with 1 nM T3 or 1 µM T4 in the presence or absence of 
tetrac (100 nM) or tetrac alone did not alter expression levels of the integrin (Fig. 7). 
 
Thyroid hormones T3 and T4 increase CAF-like differentiation of MSCs in vitro 
24 h stimulation of MSCs with HuH7 CM in the presence of 1 nM T3 or 1 µM T4 resulted in significantly 
increased mRNA levels for genes associated with a CAF-like phenotype. Upon T3 treatment, surface 
marker fibroblast-specific protein 1 (FSP1; S100A4), markers of angiogenesis desmin and VEGF, as 
well as tumour-promoting growth factors EGF, FGF2, HGF, IL-6, SDF-1 and TGF-β1 were expressed 
at significantly higher mRNA levels as compared to control cells treated with HuH7 CM alone. Surface 
marker fibroblast activation protein (FAP), indicators of tissue remodelling and invasion tenascin-C 
(TN-C) and TSP1 (THBS1), as well as the angiogenesis marker α-smooth muscle actin (α-SMA; 
ACTA2) showed the same trend that was, however, not significant (Fig. 8A). T4 stimulation led to 
 
Figure 7. Evaluation of integrin αvβ3 expression on HuH7 and MSCs. MSCs were treated with HuH7 
CM alone or in the presence of 1 nM T3 or 1 µM T4 with or without 100 nM tetrac, or in the presence of 
tetrac alone for 24 h. HuH7 and MSCs were analysed for integrin αvβ3 expression by flow cytometry. A 
representative image from three experiments is shown. 
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significant increases in mRNA expression for FAP, TN-C, TSP1, α-SMA and desmin, as well as FGF2, 
IL-6, SDF-1 and TGF-β1, while the same, albeit not significant trends were seen for FSP1, VEGF, EGF 
and HGF (Fig. 8B). Marker of invasion and remodelling stromelysin-1 (SL-1/MMP3) was not detected 
for any of the conditions tested (not shown).  
 
 
Figure 8. Expression of CAF-like markers in MSCs is stimulated by thyroid hormones T3 and T4 via 
integrin αvβ3. MSCs were treated with HuH7 CM alone (grey line) or in the presence of 1 nM T3 or 1 µM 
T4 with or without 100 nM tetrac, or in the presence of tetrac alone for 24 h. Expression of CAF-like markers 
was assessed at the mRNA level by qPCR ((A) T3, (B) T4) and at the protein level by ELISA (C). Results 
are expressed as mean fold change compared to control cells treated with HuH7 CM only (n = 4; two-tailed 
Student’s t-test: *p<0.05; **p<0.01; ***p<0.001). 
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Effects seen at the mRNA level were confirmed at the protein level for TSP1, VEGF, IL-6, SDF-1 and 
TGF-β1 by ELISA (Fig. 8C). Protein levels for EGF, FGF2 and HGF remained below the detection 
limit of the ELISA kits used for all treatment conditions. The T3- and T4-triggered increases in gene 
and protein concentrations were found to be tetrac-dependent and therefore αvβ3-mediated. No 
significant changes were observed when cells were treated with tetrac alone (data not shown). 
 
 
Figure 9. Migration of MSCs towards tumour cell CM is increased upon T3 and T4 treatment 
mediated by integrin αvβ3. (A) Representative trajectories of untreated MSCs without gradient influence. 
(B-G) Representative trajectories of MSCs treated with 1 nM T3 or 1 µM T4 with or without 100 nM tetrac 
or with tetrac alone for 24 h migrating along a linear gradient of HuH7 CM over 24 h compared to untreated 
control cells from six independent experiments. Centres of mass are indicated by red dots. (H, I) 
Quantification of chemotaxis parameters FMI and CoM (two-tailed Student’s t-test: *p<0.05; **p<0.01). 
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Thyroid hormones T3 and T4 increase migration of MSCs towards tumour signals 
MSCs subjected to a gradient between HuH7 CM and serum-free medium showed directed chemotaxis 
towards CM with significantly increased FMI and CoM displacement along the gradient of 0.227 ± 
0.041 (p<0.001) and 84.7 ± 18.8 µm (p<0.001), respectively (Fig. 9B, H, I), compared to untreated cells 
not subjected to a gradient that showed basal random chemokinesis (FMI -0.060 ± 0.025 and CoM -26.8 
± 11.3 µm; Fig. 9A).  This set-up was used to analyse the effects of T3, T4 and tetrac on the migratory 
behaviour of MSCs towards HuH7 CM. MSCs were pretreated with thyroid hormone with or without 
tetrac for 24 h and kept under the same T3/T4/tetrac concentrations throughout the chemotaxis assay. 
Migration of MSCs towards CM was significantly increased upon treatment with 1 nM T3 (FMI: 0.383 
± 0.049; p<0.05 and CoM 167.3 ± 21.2 µm; p<0.05; Fig. 9D, H, I) or 1 µM T4 (FMI: 0.345 ± 0.032; 
p<0.05 and CoM 160.0 ± 12.8 µm; p<0.01; Fig. 9F, H, I) compared to untreated control cells. Additional 
treatment with 100 nM tetrac inhibited the effects of T3 and T4, respectively, on MSC migration (T3 + 
tetrac: FMI: 0.219 ± 0.023; p<0.05 vs. T3 and CoM 102.5 ± 13.8 µm; p<0.05 vs. T3; Fig. 9E, H, I; T4 
+ tetrac: FMI: 0.261 ± 0.029; p=0.055 vs. T4 and CoM 127.9 ± 19.2 µm; p=0.16 vs. T4; Fig. 9G, H, I). 
Cells treated with tetrac alone showed no significant change in migratory behaviour compared to control 
cells (FMI: 0.275 ± 0.049; p=0.47 and CoM 106.3 ± 19.4 µm; p=0.44; Fig. 9C). 
 
 
Figure 10. Deeper invasion of MSCs into 3D HuH7 spheroids upon T3 and T4 treatment is reversed 
upon additional treatment with tetrac. (A-E) Representative images of CMFDA-labelled MSCs (green) 
treated with 1 nM T3 or 1 µM T4 with or without 100 nM tetrac for 24 h invading into HuH7 spheroids 
(blue). (F) Quantification of invasion depths in distance from surface of the spheroid (n = 3; Kruskal-Wallis 
test: **p<0.01). Cell clusters are indicated by asterisks. 
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Thyroid hormones T3 and T4 increase invasion of MSCs into tumour cell spheroids 
The invasive capacity of MSCs was evaluated in a three-dimensional HuH7 spheroid model. MSCs were 
pretreated with 1 nM T3 or 1 µM T4 in the presence or absence of 100 nM tetrac before attaching to 
spheroids. Both after T3 (Fig. 10B) and T4 stimulation (Fig. 10D), MSCs showed deeper invasion (T3: 
34.5 ± 7.42 µm; p=0.15 and T4: 29.00 ± 1.37 µm; p<0.01) into the centre of spheroids compared to 
untreated control cells (21.83 ± 1.79 µm; Fig. 10A, F). Cells treated with T3 or T4 in the presence of 
tetrac (T3 + tetrac: 9.00 ± 1.78 µm; p<0.05 vs. T3 and T4 + tetrac: 22.25 ± 1.55 µm; p<0.01 vs. T4) 
showed inhibition of invasion and remained at the surface (Fig. 10C, E, F). In some cases, especially 
after T3 treatment, invaded cells clustered inside the spheroid and could not be resolved to single cells. 
Clusters (marked by asterisks in Fig. 10F) were therefore counted as single cells. 
T4 increases tumour migration and invasion in vivo 
To assess the effect of thyroid hormone status and tetrac on MSC recruitment and invasion into tumours 
in vivo, nude mice harbouring HuH7 xenografts were subjected to different thyroid hormone treatments 
(euthyroid, hyperthyroid, hypothyroid and euthyroid + tetrac; for serum thyroid hormone concentrations 
see Fig. 11C) and, 72 h before sacrifice, were systemically injected with 5×105 CMFDA-labelled MSCs. 
Immunofluorescence microscopy (Fig. 11A) revealed significantly increased recruitment of MSCs to 
perivascular regions in the tumour and invasion into the surrounding tumour tissue in hyperthyroid mice 
(CMFDA positive area 25.7 ± 2.1%; p<0.001; Fig. 11B) compared to euthyroid mice (CMFDA positive 
area 12.2 ± 1.0%; Fig. 11B). In hypothyroid mice recruitment and invasion were strikingly reduced 
(CMFDA positive area 6.7 ± 0.7%; p<0.001; Fig. 11B). Treatment of euthyroid mice with tetrac resulted 
in an additional reduction in MSC recruitment revealing only a thin margin of MSCs surrounding blood 
vessels and no detectable tissue invasion (CMFDA positive area 2.0 ± 0.2%; p<0.001; Fig. 11B). Neither 
thyroid hormone status nor tetrac treatment had a significant effect on tumour growth in this model (data 
not shown). 
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Figure 11. Thyroid hormone status significantly influences MSC recruitment into tumours in vivo. In 
a HuH7 tumour xenograft model, mice were injected daily with 20 ng/g body weight L-T4 (euthyroid; n = 
7), 100 ng/g body weight L-T4 (hyperthyroid; n = 8), saline (hypothyroid; n = 8) or 20 ng/g body weight L-
T4 + 10 µg/g body weight tetrac (euthyroid + tetrac; n = 8). 72 h before sacrifice, 5×105 CMFDA-labelled 
MSCs were injected i.v. Frozen tumour sections were counterstained with Hoechst dye and imaged by 
fluorescence microscopy. (A) One representative image is shown per group. Magnification: 10×, scale bar = 
100 µm. (B) Quantification of MSC recruitment to tumours depicted as mean values of CMFDA positive 
area in % for each group (two-tailed Student’s t-test: ***p<0.001). (C) Serum total T4 levels of the different 
treatment groups compared to untreated euthyroid mice (two-tailed Student’s t-test: ***p<0.001; ns: not 
significant). 
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3.5 Discussion 
Based on the fact that both MSCs and thyroid hormones impact crucial steps of tumour stroma formation 
[24, 130], we investigated the regulation of MSC biology in the tumour microenvironment by non-
genomic effects of T3, T4 and tetrac. To distinguish between effects on MSCs/stroma biology as 
opposed to direct effects on tumour, we selected an αvβ3-negative hepatocellular carcinoma as an 
experimental model [145]. 
First we addressed the question as to whether thyroid hormones can enhance the CAF-like phenotype 
that MSCs acquire when exposed to tumour cell-conditioned medium [19, 24, 127]. Compared to MSCs 
treated with HuH7 CM alone, upon additional treatment with T3 or T4 we observed an overall enhanced 
expression of (1) fibroblast surface markers FAP and FSP; (2) indicators of tissue remodelling and 
invasion TN-C and TSP1; (3) proteins associated with angiogenesis α-SMA, desmin and VEGF; and (4) 
tumour-promoting growth factors/chemokines EGF, FGF2, HGF, IL-6, SDF-1 and TGF-β1, suggesting 
a T3/T4-enhanced CAF-like differentiation of MSCs mediated through αvβ3 as shown by inhibition of 
these effects by tetrac. 
In line with our observations, transduction of the thyroid hormone signal via integrin αvβ3 was shown 
to lead to transcription of angiogenesis relevant genes FGF2 and VEGF in the chorioallantoic membrane 
(CAM) model, as well as in heart and T-cell lymphoma [129, 146]. A direct effect of thyroid hormones 
on inflammatory mediators such as IL-6 has been tentatively proposed based on the inhibition of pro-
inflammatory cytokines by the iodothyronine antagonist tetrac [147]. Integrin αvβ3 has been shown to 
engage in crosstalk with tyrosine kinase growth factor receptors such as EGF receptor, FGF receptor, 
platelet-derived growth factor (PDGF) receptor and VEGF receptor that are all expressed by MSCs [115, 
130, 147]. Explanations for the changes in the expression levels of markers of CAF-like differentiation 
shown here could involve binding of CM-derived growth factors to their respective receptors on MSCs 
or autocrine stimulation by growth factors secreted by MSCs in response to CM, with potentiation of 
the signal through integrin αvβ3 crosstalk. A further indirect effect could involve an enhanced 
expression of hypoxia-inducible factor 1α (HIF-1α) that was shown to be increased upon T3 binding to 
integrin αvβ3 transduced by the phosphoinositide 3-kinase (PI3K) pathway, which in turn stimulates the 
secretion of HIF-responsive genes, such as VEGF, FGF2, IL6, SDF1 and TGFB1 [130, 147]. However, 
the exact mechanisms behind the synergistic effects of CM and T3/T4 on MSC differentiation remain 
to be elucidated.  
In addition, we observed enhanced chemotaxis of MSCs towards tumour signals and invasion into three-
dimensional HCC cell spheroids under thyroid hormone stimulation, mediated by αvβ3. Balzan et al. 
[148] reported similar effects on microvascular endothelial cells in a wound healing assay with increased 
migration after T3 or T4 stimulation that was abolished by treatment with tetrac. Studies on multiple 
myeloma cells and bone marrow aspirates from multiple myeloma patients by Cohen and co-workers 
[149] illustrate thyroid hormone-dependent, αvβ3-mediated regulation of cell migration. Furthermore, 
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there is growing evidence that thyroid hormones increase the motility of αvβ3-expressing immune cells, 
and, possibly by similar mechanisms, nerve cell migration [150]. An array of growth factors, including 
PDGF, insulin-like growth factor 1 (IGF-1), HGF, EGF and VEGF, as well as chemokines, such as 
RANTES/CCL5, CCL22 and, to a lower extent, SDF-1/CXCL12 and their respective receptors have 
been implicated in MSC migration [115, 121] and many of these have been shown in this and other 
studies to be regulated by thyroid hormones via differential gene expression and receptor crosstalk [130, 
147].  
Modulation of recruitment and engraftment efficiency of MSCs is of clinical interest, in settings of tissue 
regeneration, in the context of general tumour growth and the emerging field of MSC-based gene 
delivery in cancer therapy [66, 70, 151]. As the tumour stroma plays such a key role in tumour growth, 
angiogenesis and metastatic potential, it has become an important target for tumour therapy. Due to their 
natural tropism for solid tumours and metastases, as well as their relative ease of engineering and 
expansion in vitro, MSCs are excellent gene delivery vehicles to target tumour environments. In a series 
of previous studies we demonstrated active homing of HSV-TK-transduced MSCs into pancreatic, 
breast and liver cancer tumour stroma that led to a significant reduction in tumour growth and, depending 
on the targeting strategy used, reduced incidence of metastases after application of ganciclovir [118-
120]. In more recent studies we have shown that MSCs transfected with NIS under control of the CMV 
promoter or the tumour stroma-specific RANTES/CCL5 promoter are actively recruited to experimental 
hepatocellular carcinoma as well as disseminated colon cancer liver metastases and induce anti-tumour 
effects after application of 131I or 188Re based on NIS-mediated radioiodine accumulation [66, 70]. 
However, full therapeutic potential can only be exploited when MSCs are efficiently recruited to their 
site of action. Several approaches have been used to increase MSC survival, migration and 
differentiation, including the application of growth factors and overexpression of stem cell regulatory 
genes [152]. In agreement with our in vitro data, we observed a significant impact of thyroid hormone 
status on MSC recruitment and invasion in an αvβ3-negative HCC xenograft mouse model. In 
hyperthyroid animals both recruitment of MSCs and their subsequent invasion into tumours was 
markedly enhanced in comparison with euthyroid and in particular hypothyroid mice that showed low 
levels of MSC recruitment and almost no invasion. These data suggest that MSC conditioning with T3 
or T4 and/or T3 or T4 treatment of patients could serve as an effective tool to enhance MSC migration 
and engraftment in tissue engineering and gene delivery approaches.  
At the same time, it should be taken into account that the stimulatory effect of iodothyronines, shown in 
our study, on the differentiation of MSCs towards CAFs that are known to support a microenvironment 
that drives tumour progression and metastasis, could enhance tumour growth [153]. However, 
depending on the approach used, MSC-based cancer gene therapy can include the destruction of 
exogenously applied engineered MSCs in the context of therapy, which is likely to overcome any 
endogenous tumour-promoting effects of adoptively applied MSCs. This was demonstrated in our 
previous work using MSCs as delivery vehicles for tumour-selective NIS gene delivery, showing no 
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tumour growth-promoting effects in subcutaneous HuH7 or hepatic colon cancer metastasis xenograft 
mouse models where a significant therapeutic effect of 131I or 188Re was seen [66, 70]. Moreover, we did 
not observe an effect of thyroid hormone status or tetrac treatment on the growth of the HCC xenograft 
model used in this study, which we attribute to the absence of integrin αvβ3 on HuH7 cells and also to 
the short time frame for assessment of tumour stroma-mediated effects on tumour growth in our 
experimental setting. 
Further, we observed a dramatic effect of tetrac treatment in euthyroid mice that led to nearly complete 
abolishment of MSC recruitment into the tumour. Tetrac also reversed effects of T3 and T4 on CAF 
marker gene expression, migration and invasion in vitro. While tetrac is known to exert low-grade 
thyromimetic effects intracellularly [44], it was shown to have anti-tumour effects in vitro and in vivo 
in various cancer models via modulation of tumour cell proliferation, apoptosis and angiogenesis by 
T3/T4 antagonistic action mediated through integrin αvβ3 [130, 154]. Further anti-tumour activity of 
tetrac includes suppression of invasiveness/metastasis, increased radio- and chemosensitisation and 
antagonism of inflammation [130, 132, 133, 147]. These effects are thought to be largely mediated by 
αvβ3 expressed on the tumour cells themselves. Using an αvβ3-negative tumour model, our data suggest 
a novel mechanism by which tetrac can exert anti-tumoural effects, not by targeting the cancer cells per 
se, but by targeting the tumour stroma via MSCs as important stomal progenitor cells. Besides presenting 
an additional aspect of tetrac’s anti-tumour action, this effect opens the prospect of using tetrac as 
therapy agent irrespective of integrin αvβ3 expression on tumour cells. 
In conclusion, our data suggest that thyroid hormones T3 and T4 have a profound effect on the biology 
of MSCs in the tumour microenvironment through stimulation of CAF-like differentiation as well as 
migration and invasion in vitro. Tetrac-dependency demonstrates that these effects are largely mediated 
through non-genomic mechanisms via integrin αvβ3. In vivo, the thyroid status had a dramatic impact 
on MSC recruitment and tumour invasion with increased recruitment in the hyperthyroid state that was 
significantly decreased in the hypothyroid state and almost abolished upon treatment with tetrac. These 
studies enhance our understanding of the critical role of T3 and T4 in the regulation of MSC 
differentiation and migration in the context of tumour stroma formation and stroma-targeted cancer 
therapy, as well as the molecular mechanisms of the anti-tumour activity of tetrac. 
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4.1 Abstract 
Several clinical and experimental studies have implicated thyroid hormones in cancer progression. 
Cancer-relevant effects, including stimulation of tumour growth and new blood vessel formation by 
angiogenesis, are thought to be mediated by a non-classical signalling pathway initiated at integrin αvβ3 
expressed on cancer cells and proliferating endothelium. In an earlier study, we established 
mesenchymal stem cells (MSCs), important contributors to the fibrovascular network of tumours, as 
new thyroid hormone-dependent targets. Here, we evaluated the effects of thyroid hormones T3 and T4 
versus tetrac, an integrin-specific inhibitor of thyroid hormone action, on MSCs in tumour angiogenesis.  
Modulation of the expression and secretion of angiogenesis-relevant factors by thyroid hormones in 
primary human MSCs and their effect on endothelial cell tube formation was tested in vitro. We further 
engineered MSCs to express the sodium iodide symporter (NIS) reporter gene under control of a 
hypoxia-responsive promoter and the vascular endothelial growth factor (VEGF) promoter to test effects 
on these pathways in vitro and, for VEGF, in vivo in an orthotopic hepatocellular carcinoma xenograft 
mouse model by PET imaging. 
T3 and T4 increased the expression of pro-angiogenic genes in MSCs and NIS-mediated radioiodide 
uptake in both NIS reporter MSC lines in the presence of hepatocellular carcinoma cell-conditioned 
medium. Supernatant from thyroid hormone-treated MSCs significantly enhanced endothelial cell tube 
formation. Tetrac and/or inhibitors of signalling pathways downstream of the integrin reversed all of 
these effects. Tumoural radioiodide uptake in vivo demonstrated successful recruitment of MSCs to 
tumours and VEGF promoter-driven NIS expression. Hyperthyroid mice showed an increased 
radioiodide uptake compared to euthyroid mice, while tracer uptake was markedly reduced in 
hypothyroid and tetrac-treated mice.  
Our data suggest that thyroid hormones influence angiogenic signalling in MSCs via integrin αvβ3 and 
further substantiate the anti-angiogenic activity of tetrac in the tumour microenvironment.
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4.2 Introduction 
Angiogenesis, the formation of new blood vessels from the pre-existing vasculature, is a fundamental 
process during embryonic development, wound healing and tissue repair. Physiologically, angiogenesis 
is a highly regulated process controlled by the balance between pro- and anti-angiogenic regulatory 
molecules [13, 14]. The angiogenic switch occurs when this equilibrium is changed, leading to 
endothelial cell migration and proliferation from existing vessels, vascular sprouting and three 
dimensional vessel formation, followed by maturation and stabilisation of newly formed vessels through 
their coverage by pericytes and smooth muscle cells [13]. Though the endothelium remains mostly 
quiescent in adulthood, endothelial cells retain their ability to rapidly proliferate in response to specific 
stimuli such as hypoxia or inflammation - stimuli that are typically found in the tumour 
microenvironment [155]. As a tumour grows, so does its demand for oxygen and nutrients, requiring an 
expansion of the vascular network to meet this need. Hypoxia, a common feature of solid tumours, leads 
to increased activity of hypoxia-inducible transcription factors (HIFs) that in turn initiate the expression 
of target genes regulating angiogenesis [156]. Thus, pathologically activated angiogenesis contributes 
to cancer progression.  
Numerous angiogenic factors have been discovered in the secretome of mesenchymal stem cells 
(MSCs). First described by Friedenstein and co-workers in the 1960s, these multipotent non-
hematopoietic stromal-like cells migrate to sites of tissue injury and inflammation, where they contribute 
to recovery of tissue integrity [115, 157, 158]. Governed by highly similar migratory signals, MSCs also 
home to the growing tumour stroma, where they differentiate into stroma-associated cells, including 
cancer-associated fibroblast- and pericyte-like cells [19, 20, 24, 127, 128]. In the context of 
angiogenesis, MSCs influence endothelial cell proliferation, migration and tube formation through their 
secretion of pro-angiogenic chemokines and growth factors. They are further involved in blood vessel 
maturation in their function as pericytes that help stabilise newly formed vessels [14]. Further, the 
secretion of angiogenic factors by MSCs was reported to be upregulated under hypoxic conditions [14]. 
In an earlier study we observed that the thyroid hormones 3,3’,5-triiodo-L-thyronine (T3) and L-
thyroxine (T4) stimulate the differentiation of MSCs towards a cancer-associated fibroblast-/pericyte-
like phenotype. This included their upregulation of the pro-angiogenic endothelial growth factor genes 
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF2), in addition to the 
pericyte markers α-smooth muscle actin and desmin, as well as less specific factors that have been 
reported to be pro-angiogenic, such as hepatocyte growth factor, epidermal growth factor (EGF), 
transforming growth factor β1 and interleukin 6 [20]. The upregulation of these factors by thyroid 
hormones in MSCs was shown to be initiated at the cell surface at integrin αvβ3 [20]. 
Discovered as a thyroid hormone receptor in 2005, the integrin αvβ3 is present in the plasma membrane 
of proliferating endothelial cells and cancer cells, and also MSCs [20, 33, 47, 131, 159]. The role of 
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integrin αvβ3 in cancer-related angiogenesis has been known since the 1990s [160]. Subsequently, over 
the last two decades, iodothyronines have emerged as non-classical pro-angiogenic modulators mediated 
through αvβ3 and have been shown to induce neovascularisation in a variety of settings, such as the 
heart, ischemic striated muscle and tumour beds [161]. The complex pro-angiogenic actions of T4 and 
T3 include the stimulation of endothelial cell proliferation, migration and vascular tube formation. This 
involves the transcription and/or secretion of, among others, FGF2, VEGF and HIF-1α, in addition to 
the modification of vascular growth factor receptor function via crosstalk between the integrin and co-
clustered growth factor receptors [42, 47, 133, 146, 148, 161-163].  
The αvβ3 integrin contains two distinct binding sites for thyroid hormones that are localised near the 
Arg-Gly-Asp (RGD) recognition site that is essential for extracellular matrix binding [164]. Upon 
binding of T3 to the S1 site, the PI3K/Akt pathway is activated, resulting in downstream effects that 
may include the transcription of HIF-1α [13, 129, 131]. The second site, S2, binds both T4 and T3 and 
the hormone signal is transduced via the ERK1/2 (MAPK) pathway that leads to enhanced cell 
proliferation and the transcription of pro-angiogenic modulators, including FGF2 and VEGF [13, 29]. 
Of note is that in contrast to classical thyroid hormone signalling via nuclear thyroid hormone receptors 
(TRs), T4 is not merely a pro-hormone for T3, but actually functions as an active hormone at the integrin. 
3,3’,5,5’ tetraiodothyroacetic acid (tetrac), a deaminated T4 derivative, specifically inhibits thyroid 
hormone action at both binding sites on the integrin [13, 129, 131].  
Based on the observation that MSCs, in their role as progenitor cells of the tumour’s fibrovascular 
network, are sensitive to thyroid hormones and the accumulating evidence for the pro-angiogenic action 
of thyroid hormones, the aim of the current study was to evaluate the potential effects of T3 and T4 
versus tetrac on MSCs in the context of tumour angiogenesis.  
4.3 Materials and Methods 
Cell culture 
Primary human CD34-negative MSCs extracted from bone marrow (apceth GmbH, Munich, Germany) 
were cultured until passage 8 in DMEM (Sigma-Aldrich, St. Louis, Missouri, USA) containing 10% 
(v/v) FBS (FBS Superior, Biochrom/Merck Millipore, Berlin, Germany), 100 U/ml penicillin/100 µg/ml 
streptomycin (Sigma-Aldrich). For reporter gene transfection, the SV40-immortalised human bone 
marrow-derived MSC line L87 was used [66, 165]. These cells are easily engineered and expandable, 
show similar differentiation capacity, as well as homing and activation characteristics as primary MSCs 
[72, 166]. L87 were cultured in RPMI (Sigma-Aldrich) supplemented with 10% (v/v) FBS and 100 U/ml 
penicillin/100 µg/ml streptomycin. Primary human umbilical vein endothelial cells (HUVECs; provitro 
AG, Berlin, Germany) were used until passage 8 and cultured in endothelial cell proliferation medium 
(provitro AG). The human hepatocellular carcinoma (HCC) cell line HuH7 (JCRB Cell Bank, Osaka, 
Japan) was cultured in DMEM containing 10% (v/v) FBS and 100 U/ml penicillin/100 µg/ml 
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streptomycin and passaged up to 10 times. All cell lines were maintained at 37 °C in a humidified 5% 
(v/v) CO2 atmosphere. 
Stable transfection of MSCs 
For reporter gene assays, L87 MSCs transfected with the human sodium iodide symporter (NIS) gene 
under control of either a promoter containing hypoxia response elements (HRE-NIS-MSCs; established 
in [72]) or the VEGF promoter (VEGF-NIS-MSCs) were used. VEGF-NIS-MSCs were established by 
stable transfection of wildtype L87 MSCs with the expression vector 
pcDNA6.2ITR_BLASTI_Vegf2.1kb.NIS. The plasmid was generated with the MultiSite Gateway Pro 
Plus Kit (Thermo Fisher Scientific, Waltham, MA, USA) as described previously [73, 167] and contains 
the human NIS gene driven by the mouse Vegf promoter, two Sleeping Beauty transposition sites and a 
blasticidin resistance gene. Cells were transfected with 2 µg pcDNA6.2ITR_BLASTI_Vegf2.1kb.NIS 
and 1 µg pCMV(CAT)T7-SB100X (provided by Z Ivics, Max Delbrück Center for Molecular Medicine, 
Berlin, Germany), which contains the Sleeping Beauty transposase system for transgene insertion into 
the host cell genome, by electroporation using a single 30 ms pulse at 900 V on the Neon Transfection 
System (Thermo Fisher Scienific). Blasticidin (InvivoGen, Toulouse, France) was used to select for 
transfected cells. Single cell clones were isolated and analysed for NIS-mediated iodide uptake activity 
(see below). The stably transfected clone with the highest iodide uptake was used for all further 
experiments. 
Hormone treatment in vitro 
The preparation of and treatment with HuH7-conditioned medium and T3 or T4 with or without tetrac 
was performed as described previously [20]. For in vitro experiments, both T3 and T4 were used at 
physiologic and supraphysiologic concentrations, i.e. 1 nM or 10 nM T3 and 100 nM or 1000 nM T4, 
respectively. The reference ranges for total hormone concentrations in healthy, euthyroid humans are 
64-154 nM for T4 and 1.1-2.9 nM for T3 [168]. Tetrac was applied at an end concentration of 100 nM. 
As FBS, per se, contains thyroid hormones, charcoal-stripped serum was used for stimulation 
experiments (T3 concentration <0.2 pg/ml; T4 concentration 0.2-0.6 ng/dl). 
Quantitative real-time PCR 
RNA extraction, reverse transcription and quantitative real-time PCR (qPCR) were performed as 
described previously [20]. Primer sequences are listed in table 2. Relative expression levels were 
calculated from ΔΔCt values normalised to the geometric means of internal β-actin (ACTB) and 18S 
rRNA (R18S). Samples were run in duplicate for each of four independent experiments. 
ELISA 
Supernatant from MSCs after 24 h and 48 h of stimulation was centrifuged and stored at -80 °C until 
assayed for angiogenin (ANG), angiopoietin 1 (ANGPT1), angiopoietin 2 (ANGPT2), interleukin 8 
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(CXCL8), insulin-like growth factor 1 (IGF1) and placental growth factor (PGF) using the respective 
DuoSet ELISA kit (R&D Systems, Abingdon, UK). Where necessary, supernatants were diluted as 
follows to be within the linear range of the assay: ANG 24 h 1:20, 48 h 1:80; ANGPT1 48 h 1:4; CXCL8 
24 h 1:20, 48 h 1:60; IGF1 24 h and 48 h 1:10; PGF 24 h and 48 h 1:2. Samples were analysed in 
duplicate in four independent experiments. 
Table 2. qPCR primer sequences. 
gene forward primer (5' → 3') reverse primer (5' → 3') 
ACTB AGAAAATCTGGCACCACACC TAGCACAGCCTGGATAGCAA 
ANG  CATCATGAGGAGACGGGG TCCAAGTGGACAGGTAAGCC 
ANGPT1  AACATGAAGTCGGAGATGGC CAGCAGCTGTATCTCAAGTCG 
ANGPT2  GAAGAGCATGGACAGCATAGG GAGTCATCGTATTCGAGCGG 
bsd CCTCATTGAAAGAGCAACGG CTGTTCTCATTTCCGATCGC 
CCL2  AGCCACCTTCATTCCCCAAG TTGGGTTTGCTTGTCCAGGT 
CCL4 GCTGCTTTTCTTACACCGCG TACACGTACTCCTGGACCCA 
CXCL7  CCTGTAACAGTGCGAGACCA TCGACTTGGTTGCAATGGGT 
CXCL8 TCTGCAGCTCTGTGTGAAGG TTCTCCACAACCCTCTGCAC 
CYR61 TTTGGAATGGAGCCTCGCAT TTCAGGCTGCTGTACACTGG 
HIF1A  GCTTTAACTTTGCTGGCCCC TTCAGCGGTGGGTAATGGAG 
IGF1  GCTGGTGGATGCTCTTCAGT TTGAGGGGTGCGCAATACAT 
NIS TGCGGGACTTTGCAGTACATT TGCAGATAATTCCGGTGGACA 
PGF  CATCCTGTGTCTCCCTGCTG GTCTCCTCCTTTCCGGCTTC 
R18S CAGCCACCCGAGATTGAGCA TAGTAGCGACGGGCGGTGTG 
SV40 TTGCTGTGCTTACTGAGGATG CCAATTATGTCACACCACAGA 
TEK  AACTCTGTGTGCAACTGGTCC AAGTCATCTTCCGAGCTTGG 
TIMP1  CTCGTCATCAGGGCCAAGTT GCAAGAGTCCATCCTGCAGT 
TIMP2  GCTGGACGTTGGAGGAAAGA TGTGACCCAGTCCATCCAGA 
 
Radioiodide uptake in vitro 
NIS-mediated uptake of 125I (PerkinElmer, Waltham, MA, USA) by HRE-NIS-MSCs, VEGF-NIS-
MSCs and wildtype MSCs was measured according to Spitzweg et al. [169]. To test inducibility of the 
hypoxia-responsive and the VEGF promoter, cells were stimulated with 300 µM of the hypoxia-
simulating agent cobalt chloride (CoCl2; Sigma-Aldrich) or with 20% FBS, respectively, for 24 h. 
Thyroid hormone treatment was performed as described above. HRE-NIS-MSCs were additionally 
stimulated with 300 µM CoCl2 during thyroid hormone treatment. The signalling pathway inhibitors LY 
294002 (InSolution LY 294002, Calbiochem/Merck Millipore, Darmstadt, Germany) and RAF265 
(Novartis, Basel, Switzerland), both stored as 10 mM stock solutions at -20°C in DMSO, were used at 
10 µM and 1 µM end concentrations, respectively, and were added to cells simultaneously with thyroid 
hormones. For each iodide uptake assay, two to four technical replicates were performed in three 
independent experiments each. Radioiodide uptake was normalised to cell viability determined by MTS-
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assay (Promega, Mannheim, Germany) as described previously [170] using the absorbance at 620 nm 
relative to control cells.  
Tube formation assay 
HUVECs were seeded at a density of 7.5×103 cells/well in a 96 well µ-Plate Angiogenesis (ibidi, 
Martinsried, Germany) on growth factor-reduced Matrigel (Becton Dickinson Biosciences, Heidelberg, 
Germany). Five to six wells were plated for each condition in each of three or four independent 
experiments. Plates were incubated for 12 h at 37°C before photo microscopy. Images were acquired on 
a Leica DM IL microscope (Leica Microsystems, Wetzlar, Germany) equipped with a Jenoptik ProgRes 
CCD camera (Jenoptik, Jena, Germany) at 5× magnification. Tube formation was quantified in an 
automated fashion with the ImageJ (National Institutes of Health, Bethesda, Maryland, USA) plug-in 
Angiogenesis Analyzer [171]. Evaluated parameters were the mean number of meshes, junctions and 
the mean total tube length per well. 
Animals  
All experiments were conducted with approval from the regional governmental commission for animals 
(Regierung von Oberbayern, Munich, Germany). Four- to five-week old male CD1 nu/nu mice (Charles 
River, Sulzfeld, Germany) were allowed to acclimatise for one week under specific pathogen-free 
conditions with access to standard nude mouse diet (ssniff, Soest, Germany) and water ad libitum. HuH7 
tumour cells (1×106) were implanted into the livers of mice after laparotomy as described previously 
[72].  
Hormone treatment in vivo 
Starting from one week after tumour cell injection, mice received drinking water supplemented with 
0.02% (w/v) 2-mercapto-1-methylimidazole (MMI; Sigma-Aldrich) and 1% (w/v) sodium perchlorate 
(Sigma-Aldrich) to induce hypothyroidism and generate the same baseline thyroid hormone levels for 
all groups [20, 144]. 0.3% (w/v) saccharin (Sigma-Aldrich) was added as a sweetener to mask the bitter 
taste of MMI/perchlorate. Two weeks later, mice were randomly assigned to different treatment groups 
and received the following intraperitoneal (i.p.) injections daily: The hyperthyroid group (n=6) received 
100 ng/g body weight L-T4 (Sigma-Aldrich), the euthyroid group 20 ng/g body weight L-T4 with (n=7) 
or without (n=6) 10 µg/g body weight tetrac (Sigma-Aldrich), while hypothyroid mice (n=8) received 
saline only. Three days before imaging (see below), perchlorate was removed from the drinking water 
and only MMI treatment continued to prevent interference with radioiodide uptake. Thyroid hormone 
status was regularly monitored in serum samples by ELISA (DRG Diagnostics, Marburg, Germany).  
124I positron emission tomography (PET) 
Three weeks later, i.e. six weeks after tumour cell inoculation, 5×105 VEGF-NIS-MSCs or wildtype 
MSCs (n=2), were injected systemically in 500 µl phosphate-buffered saline via the tail vein. 72 h later, 
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10 MBq 124I (PerkinElmer or DSD Pharma, Purkersdorf, Austria) were applied intraperitoneally and 
radioiodide distribution assessed using an Inveon P120 microPET (Siemens Healthcare, Erlangen, 
Germany). In three mice the competitive NIS inhibitor sodium perchlorate (2 mg/mouse; Sigma-
Aldrich) was injected i.p. 30 min prior to radioiodide administration to verify that tumoural radioiodide 
accumulation was NIS-mediated. PET images were reconstructed with the software Inveon Acquisition 
Workplace (Siemens) and analysed with Inveon Research Workplace (Siemens). Three dimensional 
regions of interest were defined and quantified as mean percent of the injected dose per ml tumour (% 
ID/ml tumour). After PET imaging, mice were sacrificed and tumours embedded in Tissue-Tek O.C.T. 
compound (Sakura Finetek, Alphen aan den Rijn, The Netherlands), snap-frozen on dry ice and stored 
at -80 °C until further processing (see below). 
Ex vivo immunofluorescence staining  
Immunofluorescence staining for human NIS and  mouse CD31 on frozen tissue sections was performed 
as described previously [72, 170] using the mouse monoclonal anti-NIS antibody clone FP5A (Merck 
Millipore, Berlin, Germany) or the rat monoclonal anti-mouse CD31 antibody clone MEC 13.3 and a 
Cy3-conjugated donkey anti-mouse secondary antibody (Jackson ImmunoResearch, Cambridgeshire, 
UK) or a Cy3-conjugated donkey anti-rat secondary antibody (Jackson ImmunoResearch), respectively. 
Nuclei were counterstained with 5 µg/ml bisbenzimide Hoechst 33258 (Sigma-Aldrich). Stained 
sections were mounted with Dako Fluorescence Mounting Medium (Dako, Carpinteria, California, 
USA) and imaged at 20× (NIS) or 10× (CD31) magnification on a Leica DMI6000 B fluorescence 
microscope equipped with a Leica DFC365 FX CCD camera, and the software Leica Application Suite 
X (Leica Microsystems). A minimum of five visual fields was recorded per tumour for three to four 
mice per treatment group. The number of NIS-positive cells was counted manually, while the CD31 
positive area per visual field was quantified using ImageJ, blinded to group assignment. 
Ex vivo analysis of NIS mRNA expression 
To normalise NIS expression to MSC recruitment, total RNA was isolated from tumours (euthyroid 
n=5; hyperthyroid n=6; hypothyroid n=5; euthyroid + tetrac n=6) and quantitative real-time PCR was 
performed as described above using primers specific for NIS, SV40, which was used for MSC 
immortalisation, and the blasticidin resistance gene (bsd), which is encoded by the NIS expression 
plasmid and constitutively expressed (for primer sequences see table 2). β-actin and 18S rRNA served 
as internal controls. Results were calculated from ΔΔCt values for NIS divided by the mean of the 
respective ΔΔCt values for SV40 and bsd as a measure of the amount of MSCs present. 
Statistics 
All data are expressed as mean ± SEM or mean fold change ± SEM. Statistical significance was tested 
by one-way ANOVA followed by Tukey’s post hoc test. p-values <0.05 were considered statistically 
significant (*p<0.05; **p<0.01; ***p<0.001). 
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4.4 Results 
Thyroid hormones increase the expression of angiogenesis modulators in MSCs in vitro  
Initially, we examined the expression of angiogenesis relevant factors in MSCs. To this end, we treated 
primary human bone marrow-derived MSCs with physiologic or supraphysiologic concentrations of T3 
or T4 and HCC cell-conditioned medium to simulate the tumour environment in vitro. mRNA (Fig. 
12A, B) and protein concentrations (Fig. 13A, B) for genes associated with angiogenesis were analysed 
by qPCR or ELISA, respectively.  
 
For genes of the angiopoietin/TEK tyrosine kinase (TIE2) axis that control vessel maturation, expression 
levels of the receptor itself were reduced under stimulation with 100 nM T4, while no significant 
 
Figure 12: Expression of pro-angiogenic genes. Primary human bone marrow-derived MSCs were treated 
with hepatocellular carcinoma cell-conditioned medium and either physiological (1 nM, “T3”) and 
supraphysiological (10 nM, “T3 supra”) concentrations of T3 or physiological (100 nM “T4”) and 
supraphysiological (1000 nM “T4 supra”) concentrations of T4 with and without tetrac (100 nM). (A) mRNA 
concentrations of various genes relevant to angiogenesis were assessed by qPCR after 24 h normalised to 
(B) reference gene expression (mean-fold change ± SEM; n=4). Note that the y-axis for HIF1A and ANGPT2 
have a different scale. The dotted lines relate to cells treated with hepatocellular carcinoma cell-conditioned 
medium only (*p<0.05; **p<0.01 compared to control; #p<0.05; ##p<0.01; ###p<0.001 no tetrac treatment 
compared to tetrac treatment). 
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changes for its ligand ANGPT1 were detected at the mRNA level. ANGPT1 contributes to the 
maintenance of the resting endothelial state. In contrast, mRNA concentrations of ANGPT2, the 
naturally occurring antagonist of ANGPT1 that enhances vascular permeability and destabilises the 
endothelium, were dose-dependently increased upon T3 stimulation compared to cells treated with 
tumour cell-conditioned medium alone, an effect that was significant at 10 nM T3 and was blocked by 
tetrac. Pro-angiogenic ANG and the growth factor IGF1 showed a similar expression pattern. HIF1A 
mRNA expression was significantly upregulated by both physiological and supraphysiological 
concentrations of both T3 and T4 and T4 effects were reduced by tetrac. The chemokines CCL4, pro-
platelet basic protein (PPBP/CXCL7), and CXCL8 showed only slight, non-significant upregulation 
under T3 stimulation that was decreased by tetrac, while CCL2 expression was significantly increased 
under stimulation with 10 nM T3. No T4 effects were observed for these chemokines. PGF showed only 
weak, non-significant stimulation under T3 treatment, but was significantly increased under stimulation 
with 1000 nM T4 at the mRNA level. The extracellular matrix-associated angiogenic modulator 
cysteine-rich 61 (CYR61), as well as tissue inhibitors of metalloproteinases 1 and 2 (TIMP1/2) showed 
no significant changes in expression levels under thyroid hormone stimulation. CYR61 and TIMP1 
mRNAs were upregulated when cells were treated with HCC cell-conditioned medium and tetrac as 
compared to cells treated with HCC cell-conditioned medium alone (Fig. 12A). The reference genes 
ACTB and R18S used for normalisation were not impacted by the different treatment conditions (Fig. 
12B). 
For a subset of these genes, the concentrations of secreted proteins in MSC supernatants after 24 h (Fig. 
13A) and 48 h (Fig. 13B) of stimulation were validated by ELISA. Effects seen at the mRNA level were 
confirmed at the protein level for ANGPT1, ANG, and IGF1 by ELISA (Fig. 13A, B). ANGPT2 
expression was increased significantly and dose-dependently under T3 stimulation in a tetrac-dependent 
manner after 48 h, reflecting the effects seen at the mRNA level (Fig. 13B). At 24 h, ANGPT2 levels 
were below the detection limit of the ELISA for all treatment conditions. CXCL8 showed a significant 
increase in secreted protein at 24 h that was completely absent after 48 h. PGF expression, by contrast, 
was induced by T4 after 24 h, an effect that was even stronger after 48 h. This effect was blocked by 
additional treatment with tetrac.  
Thyroid hormones stimulate the angiogenic potential of MSCs 
48 
 
Supernatant from thyroid hormone-treated MSCs stimulates endothelial cell tube 
formation  
To examine the paracrine effects of angiogenic factors secreted by MSCs on endothelial cells, HUVECs 
were seeded on growth factor-reduced Matrigel and subjected to conditioned medium from stimulated 
MSCs. Tube formation was analysed and quantified in an automated manner on microscopy images 
after 12 h (Fig. 14A). Compared to untreated HUVECs, supernatant from MSCs enhanced tube 
formation, as evidenced by more intricate tubular networks with a larger number of meshes and junctions 
as well as a higher total tube length after 12 h (Fig. 14B, C). This effect was further enhanced when 
MSCs had been additionally treated with thyroid hormones (Fig. 14B, C). While tetrac had no effect on 
basal HUVEC tube formation, or MSC supernatant-stimulated tube formation, supernatant from MSCs 
stimulated with tetrac in addition to thyroid hormone reduced tube formation to, or even below, basal 
levels (Fig. 14B, C). To estimate potential effects of residual thyroid hormones in the MSC supernatant 
on HUVEC tube formation, HUVECs were treated with thyroid hormones alone in a further tube 
 
Figure 13: Secretion of pro-angiogenic proteins. Primary human bone marrow-derived MSCs were treated 
with hepatocellular carcinoma cell-conditioned medium and either physiological (1 nM, “T3”) and 
supraphysiological (10 nM, “T3 supra”) concentrations of T3 or physiological (100 nM “T4”) and 
supraphysiological (1000 nM “T4 supra”) concentrations of T4 with and without tetrac (100 nM). (A) Protein 
concentrations in supernatants of stimulated MSCs were measured by ELISA after 24 h or (B) 48 h (mean ± 
SEM; n=4). Note that compared to the 24 h diagrams, the y-axis at 48 h is 10× and 4× larger for ANGPT1 
and IGF1, respectively. The dotted lines relate to cells treated with hepatocellular carcinoma cell-conditioned 
medium only (*p<0.05; **p<0.01; compared to control; #p<0.05; ##p<0.01; ###p<0.001 no tetrac treatment 
compared to tetrac treatment). 
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formation experiment. No significant effects were observed at the thyroid hormone concentrations used, 
though the data do imply a slight inhibiting effect of tetrac on HUVEC tube formation under parallel T3 
stimulation (Fig. 14D). 
 
 
Figure 14: Tube formation assay. (A) HUVEC tube formation on growth factor-reduced Matrigel was 
quantified on microscope images after 12 h in an automated fashion by analysing the number of meshes and 
junctions (red arrows) and the total tube length. (B) HUVECs were subjected to supernatant from MSCs 
stimulated with hepatocellular carcinoma cell-conditioned medium and T3 (1 or 10 nM) or T4 (100 or 1000 
nM) with and without tetrac (100 nM). Representative images from supraphysiological hormone treatment 
are shown. Magnification: 5×. (C) Quantification of effects on tube formation (mean ± SEM; n=3; *p<0.05; 
**p<0.01 compared to untreated). (D) HUVECs were treated with T3 (1 or 10 nM) or T4 (100 or 1000 nM) 
with and without tetrac (100 nM) and effects on tube formation were quantified (mean ± SEM; n=4; 
*p<0.05). MSC-CM: MSC-conditioned medium. px: pixel. 
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Thyroid hormone affects VEGF signalling in MSCs in vitro 
As the hypoxia response/VEGF axis critically mediates angiogenesis, we established two reporter gene 
systems to monitor the involvement of HIF-1 and VEGF signalling in thyroid hormone-mediated 
angiogenic effects of MSCs in more detail. We engineered MSCs to express the reporter gene NIS under 
the control of the hypoxia-responsive promoter (HRE-NIS-MSCs) or the VEGF promoter (VEGF-NIS-
MSCs). We could then use radioiodide uptake by NIS in transfected cells as readout of active hypoxia 
or VEGF signalling. To induce promoter activity, HRE-NIS-MSCs were stimulated with the hypoxia-
simulating agent CoCl2 and VEGF-NIS-MSCs with FBS. In a functional assay, both HRE-NIS-MSCs 
and VEGF-NIS-MSCs showed inducible radioiodide uptake activity that was blocked upon treatment 
with the competitive NIS inhibitor perchlorate (Fig. 15A). While untreated HRE-NIS-MSCs and 
wildtype MSCs showed no 125I uptake above background levels, unstimulated VEGF-NIS-MSCs 
showed some basal activity (Fig. 15A).  
We then stimulated HRE-NIS-MSCs with HCC cell-conditioned medium and thyroid hormones with or 
without tetrac in the presence of CoCl2 to simulate hypoxia and thus stabilise newly expressed HIF-1α. 
Compared to HRE-NIS-MSCs treated with HCC cell-conditioned medium only, additional stimulation 
with T3 or T4 led to a slight, non-significant increase in iodide uptake activity (Fig. 15B, left panel). 
VEGF-NIS-MSCs showed a stronger, more robust response to thyroid hormone stimulation, as 
evidenced by a significant tetrac-dependent increase of 1.50- and 1.53-fold for 1 nM and 10 nM T3 and 
1.57- and 1.73-fold for 100 nM and 1000 nM T4, respectively (Fig. 15B, right panel). Tetrac reduced 
125I uptake induced by thyroid hormones in both cell lines, though only reaching statistical significance 
for VEGF-NIS-MSCs. 
To further verify integrin αvβ3 involvement, we applied inhibitors of signalling pathways downstream 
of the integrin in addition to the integrin-specific inhibitor tetrac. The PI3K inhibitor LY 294002 was 
used to probe for T3 signalling via the S1 binding site in the thyroid hormone binding domain of integrin 
αvβ3 and the ERK1/2 (MAPK) pathway inhibitor RAF265 for T3 and T4 signalling via the S2 binding 
site (Fig. 15C). In both HRE-NIS-MSCs and VEGF-NIS-MSCs the T3 effects were blocked upon tetrac, 
LY 294002 and RAF265 treatment, while T4 effects were only blocked by tetrac and RAF265 and not 
by LY 294002 (Fig. 15D). Note that in this set of experiments T3 and T4 effects did reach statistical 
significance in HRE-NIS-MSCs. 
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Figure 15: Hypoxia and VEGF signalling in vitro. Two different reporter constructs were established by 
placing the NIS gene under control of a hypoxia-responsive promoter (HRE-NIS, left panel) or the VEGF 
promoter (VEGF-NIS, right panel). (A) L87 MSCs transfected with these constructs showed inducible 125I 
uptake activity compared to wildtype MSCs. Sensitivity to perchlorate indicates NIS specificity. Stim.: 
stimulated (mean ± SEM.; n=3; *p<0.05; **p<0.01; ***p<0.001). (B) HRE-NIS-MSCs (left panel) or 
VEGF-NIS-MSCs (right panel) were treated with hepatocellular carcinoma cell-conditioned medium only 
(control) or additionally with T3 (1 or 10 nM) or T4 (100 or 1000 nM) with and without 100 nM tetrac (mean 
± SEM; n=3; *p<0.05; **p<0.01). (C) Schematic representation of thyroid hormone signalling versus 
inhibition via integrin αvβ3. (D) Control cells and cells treated with 1 nM T3 or 100 nM T4 were additionally 
treated with 100 nM tetrac, 10 µM LY 294002 or 1 µM RAF265 and 125I uptake activity assessed (mean ± 
SEM; n=3; *p<0.05; **p<0.01 compared to control; #p<0.05; ##p<0.01 with versus without inhibitors). The 
thyroid hormones and the inhibitors were added to the cells simultaneously. 
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Thyroid hormone stimulates VEGF signalling in MSCs in liver tumours in vivo  
Based on the stronger thyroid hormone-dependent effects seen in vitro using the VEGF-NIS-MSCs, 
compared to the HRE-NIS-MSCs, the former were further evaluated in vivo by 124I PET in an orthotopic 
HCC xenograft nude mouse model (Fig. 16A). Mice were subjected to different thyroid hormone 
treatments (euthyroid, hyperthyroid, hypothyroid and euthyroid + tetrac; Fig. 16B). 72 h after systemic 
injection of VEGF-NIS-MSCs, tumoural 124I accumulation and thus functional NIS expression was 
assessed by three-dimensional high-resolution small animal PET (Fig. 16B).  
 
Radioiodide signals in the liver region demonstrated successful tumoural recruitment of VEGF-NIS-
MSCs after systemic application followed by VEGF promoter-driven NIS expression in tumours (Fig. 
17A). Compared to euthyroid mice, the tumours of hyperthyroid mice accumulated markedly more 
radioiodide one hour after 124I injection, while hypothyroid and tetrac-treated mice accumulated less 
radioioide in their liver tumours (Fig. 17A, B). Tracer uptake was also observed in mouse tissues that 
endogenously express NIS (thyroid, stomach, nasal mucosa and salivary glands) as well as in the urinary 
bladder, due to renal radioiodide elimination (Fig. 17A). The competitive NIS inhibitor perchlorate 
inhibited both tumoural NIS expression as well as endogenous expression, thus verifying that tracer 
uptake in tumours was indeed NIS-mediated (Fig. 17A). No 124I uptake above background was observed 
in tumours of mice injected with wildtype MSCs (Fig. 17A).  
Immunofluorescence staining for human NIS in tumours reflected PET imaging results with a 
significantly higher number of NIS positive cells in hyperthyroid mice and significantly less in 
hypothyroid and tetrac-treated animals compared to euthyroid mice (Fig. 17C, D). Normalisation to 
MSC recruitment confirmed the observed effects on NIS expression levels (Fig. 17E).  
Tumour growth was not affected by thyroid hormone status or tetrac treatment in this model (data not 
shown). Thyroid hormone concentrations in serum at sacrifice reflected the different thyroid states of 
the treatment groups (Fig. 17F). The ELISA used could not differentiate between T4 and tetrac, leading 
 
Figure 16: Experimental set-up in vivo. (A) Orthotopic tumours were established by injection of the human 
hepatocellular carcinoma cell line HuH7 into the livers of nude mice. (B) One week after tumour cell 
inoculation, endogenous thyroid hormone production was blocked by MMI/perchlorate via the drinking 
water. Two weeks later, mice were assigned to different thyroid hormone groups that received either 20 ng/g 
body weight T4 (euthyroid), 100 ng/g body weight T4 (hyperthyroid), saline (hypothyroid) or 20 ng/g body 
weight T4 alongside 10 µg/g body weight tetrac (euthyroid + tetrac) i.p. daily. Finally, mice received a single 
tail vein injection of VEGF-NIS-MSCs and radioiodide uptake in the tumour region was assessed by 124I 
PET 72 h later.  
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to false high serum T4 values in tetrac-treated mice (data not shown). Tetrac-treated animals received 
the same body weight-adjusted dose of T4 as the euthyroid group, which leads to highly reproducible 
serum T4 levels in the range of untreated naturally euthyroid mice. 
 
Figure 17: VEGF signalling in vivo. (A) 124I PET imaging of mice bearing intrahepatic HuH7 tumours 
demonstrated tumoural radioiode accumulation (indicated by arrows) in animals that were injected with 
VEGF-NIS-MSCs, while no signal was detected in the tumours of wildtype MSC-treated mice (wt MSCs). 
Endogenous NIS expression led to tracer uptake in the thyroids (t) and stomachs (s) of mice. Signals in the 
bladder (b) are due to renal excretion of the PET tracer. Treatment with the NIS-specific inhibitor perchlorate 
(ClO4-) extinguished tracer uptake both in the tumour and in organs with endogenous NIS expression. (B) 
Tumoural radioiodide uptake was quantified 1 h after radioiodide injection by placing three-dimensional 
regions of interest over the tumours (mean % of the injected dose/ml tumour ± SEM; euthyroid: n=6, 
hyperthyroid: n=6, hypothyroid: n=8, euthyroid + tetrac: n=7; *p<0.05; **p<0.01). (C) Tumoural NIS 
expression was further confirmed by NIS-specific immunofluorescence staining. Magnification: 20×. (D) 
Quantification of NIS staining on tumour sections (diamonds represent counts in a single visual field, red 
lines represent mean ± SEM; n=4/treatment group; *p<0.05). (E) NIS expression relative to MSC recruitment 
was assessed by qPCR (mean ± SEM of ΔΔCt for NIS/mean of ΔΔCts for SV40 and bsd; n=5 for euthyroid 
and hypothyroid mice, n=6 for hyperthyroid and tetrac-treated mice; *p<0.05; **p<0.01). (F) Thyroid 
hormone concentrations in serum samples from the individual treatment groups at sacrifice (mean ± SEM; 
n=4/treatment group; *p<0.05; **p<0.01). 
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To further assess effects on angiogenesis, ex vivo CD31 straining on tumour sections was performed. 
The blood vessel densities of the different treatment groups showed a trend reflecting the effects on 
angiogenesis seen in vitro and in vivo with a significantly decreased tumour vascularisation in 
hypothyroid mice compared to euthyroid mice, and a significantly increased vascularisation in 
hyperthyroid mice as compared to hypothyroid and tetrac-treated mice (Fig. 18A, B). 
4.5 Discussion 
Angiogenesis is pivotal to tumour growth and progression. Therefore, understanding the molecular 
regulation of cellular events involved in angiogenesis has immense clinical implications. MSCs have 
been shown to secrete pro-angiogenic factors in the tumour microenvironment upon their homing to the 
tumour stroma and their differentiation into cancer-associated fibroblast-like and pericyte-like cells [19, 
20]. It is assumed that the angiogenic effect of MSCs is predominantly caused by their secretion of pro-
angiogenic factors [14]. In a previous study, we observed that the thyroid hormones T3 and T4 stimulate 
the differentiation of MSCs towards a tumour-promoting, pro-angiogenic phenotype via a cell surface 
receptor on integrin αvβ3 [20]. The thyroid hormone metabolite tetrac, a specific inhibitor of thyroid 
hormone action at the integrin site, reversed the effects of agonist thyroid hormone. Indeed, thyroid 
hormone has been shown to be pro-angiogenic via integrin αvβ3 expressed on tumour cells and 
endothelial cells in numerous studies [47, 146, 162]. Our data suggested another layer to the story, in 
that non-hematopoietic cells of the tumour stroma, namely MSCs, can be driven towards a more pro-
 
Figure 18: Ex vivo CD31 staining. (A) Immunofluorescence staining for CD31 was performed on tumour 
sections to visualise vascularisation. Magnification: 10×. (B) Quantification of CD31 staining (diamonds 
represent the % CD31 positive area in a single visual field, red lines represent mean ± SEM; n=3-4/treatment 
group; *p<0.05; **p<0.01). 
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angiogenic phenotype by thyroid hormones via their signalling through the αvβ3 integrin. Hence, we 
decided to take a closer look at thyroid hormone regulation of angiogenic effects of MSCs in the current 
study.  
Analysing the response of a broader range of angiogenic factors found in the MSC secretome to thyroid 
hormone versus tetrac treatment, we here show that thyroid hormones, especially T3, stimulate pro-
angiogenic gene expression and protein secretion in MSCs at physiologically relevant hormone 
concentrations. Interestingly, HIF-1α expression was significantly induced by both T3 and T4. The 
transcription factor HIF-1 is a key modulator of a cell’s adaptation to hypoxia and an important 
angiogenesis mediator. It is a heterodimer composed of the constitutively expressed HIF-1β and the 
oxygen-sensitive HIF-1α subunit that is tightly regulated and degraded under normoxia [172]. Under 
hypoxia, HIF-1α accumulates leading to transcriptional activation of genes containing hypoxia response 
elements, such as VEGF [156]. The HIF-1α-related pro-angiogenic activity of thyroid hormones is 
especially interesting in the context of solid tumours that are typically associated with local hypoxia 
[161]. T3 has been reported to induce HIF-1α expression by a PI3K-dependent mechanism in human 
skin fibroblasts, an effect that has been proposed to be mediated by cytoplasmically located TRβ [173, 
174]. Further, T3, and not T4, has been shown to induce HIF-1α expression in human glioma cells, again 
via PI3K [39]. Whether PI3K-dependent induction of HIF-1α expression is initiated at the cell surface 
at integrin αvβ3 or at a cytoplasmically located TR, or both, has, however, not yet been conclusively 
shown [39, 47, 129, 174]. T4, on the other hand, has been shown to induce internalisation of integrin 
αvβ3 in human non-small cell lung cancer and ovarian carcinoma cells, resulting in a complex formed 
between the αv monomer and ERK1/2 (MAPK), leading to nuclear import [175]. Tetrac inhibited 
internalisation of integrin αvβ3. In the nucleus, αv acts as a transcriptional co-activator that helps drive 
the transcription of HIF-1α.  [45, 161, 176]. The pro-angiogenic effect of thyroid hormones on MSCs 
was further confirmed in an in vitro endothelial tube formation assay demonstrating significantly 
enhanced tube formation under treatment with supernatant from T3-stimulated MSCs. The increased 
expression and secretion of pro-angiogenic factors by MSCs under thyroid hormone stimulation 
detected by qPCR and ELISA directly stimulated HUVEC tube formation. The tube formation data also 
reflect the observation that T3 generally seems to have stronger effects in our system. Many of the 
effects on gene expression could be directly blocked by additional treatment with tetrac. The inhibitory 
effects of tetrac on angiogenesis were strikingly apparent in the tube formation assay. Thus, we conclude 
that the observed effects are largely initiated at integrin αvβ3. Interestingly, we observed no tetrac effects 
on basal tube formation, or on the increased tube formation triggered by MSC-conditioned medium. A 
possible explanation for the strong tetrac effects only under parallel treatment with thyroid hormone 
may lie in integrin activation and/or clustering in the cell membrane of MSCs as a result of agonist 
thyroid hormone stimulation. Tetrac would then be able to exert its inhibitory effects only once this 
activation has occurred. In this context, tetrac was shown to prevent radiation-induced activation of the 
β3 monomer in vitro, while it did not affect the basal, non-irradiated activation state [177]. Furthermore, 
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integrin cluster formation and resulting activation is not only known to be essential for extracellular 
matrix adhesion, but has also been proposed to influence integrin-related signalling [178]. Indeed, when 
the binding site for RGD, which provokes integrin clustering, is blocked, thyroid hormone action at the 
integrin is inhibited [133]. Whether thyroid hormone influences integrin cluster formation has not been 
thoroughly investigated to date, though T4 was reported to regulate integrin clustering in astrocytes 
[179, 180]. The observation that co-clustering and resulting crosstalk between integrin αvβ3 and 
angiogenesis-relevant growth factor receptors for VEGF, FGF2, EGF, platelet-derived growth factor 
and IGF1 occurs, adds a further dimension to the complex regulation of angiogenesis by thyroid 
hormones [161, 181]. Tetrac has been proposed to interfere with this crosstalk on the surface of 
endothelial cells and similar effects in MSCs are conceivable [161].  
HIF-1α and VEGF are two master regulators of angiogenesis with central importance in angiogenic 
signalling, whose expression by MSCs has been shown to be regulated by thyroid hormones and tetrac 
in the current study (HIF-1α), and in a previous study (VEGF; [20]). We therefore established hypoxia-
responsive and VEGF-promoter reporter constructs. As reporter gene we used the transmembrane 
protein NIS that transports iodide into thyroid follicular cells and thus provides the molecular basis for 
the diagnostic and therapeutic application of radioiodide in thyroid cancer patients [88]. In our previous 
work, we have gathered extensive experience in targeting NIS to non-thyroidal tumours using 
genetically engineered MSCs as gene transfer vehicles based on their inherent tumour homing capacity 
[66, 70-73, 75, 76]. One of the many advantages of NIS is that it allows detailed, non-invasive in vivo 
tracking of MSCs, as well as quantifiable functional NIS expression, by 123I scintigraphy and 124I PET. 
Based on these studies, we employed this system to study thyroid hormone action on MSC biology 
within the tumour microenvironment. In vitro we observed a thyroid hormone-dependent up-regulation 
of hypoxia-responsive and VEGF promoter activity that was already evident at physiological hormone 
concentrations and could be blocked by tetrac, as well as inhibitors of signalling pathways downstream 
of the hormone binding site at the integrin. These observations further support the involvement of 
integrin αvβ3.  
Based on the more promising in vitro results using the VEGF-NIS reporter construct and the central role 
of VEGF in regulating practically all relevant aspects of tumour angiogenesis, we applied VEGF-NIS-
MSCs in vivo in an orthotopic HCC xenograft mouse model. We then measured 124I uptake by PET in 
mice with different thyroid hormone states. Tumoural radioiodide uptake demonstrated successful 
recruitment of VEGF-NIS-MSCs after systemic application followed by VEGF promoter-driven NIS 
expression. In hyperthyroid animals, a strongly enhanced radioiodide signal was detected compared to 
euthyroid mice, while hypothroidism or treatment with tetrac markedly reduced the signal seen. Ex vivo 
analysis of NIS-specific immunoreactivity and NIS mRNA expression normalised to MSC recruitment, 
reflected the PET imaging results. These data confirm the in vitro data suggesting thyroid hormone-
mediated stimulation of VEGF that is inhibited by tetrac. In addition, tumour vascularisation reflects the 
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pro-angiogenic effects of thyroid hormones seen in vitro and in vivo as evidenced by a lower blood 
vessel density in hypothyroid and tetrac-treated mice as compared to euthyroid and hyperthyroid mice. 
Our data imply that T3 and T4 influence angiogenic signalling via integrin αvβ3 in the tumour 
microenvironment not only in tumour cells and endothelial cells, but also in MSCs, further establishing 
MSCs as thyroid hormone-dependent targets via integrin αvβ3. Stimulation of cancer-related 
angiogenesis is obviously undesirable in cancer patients and thyroid hormones have been proposed to 
limit anti-angiogenic therapy [162, 182]. Growing experimental evidence, supported by clinical data 
and population-based studies, suggests that thyroid hormones are involved in cancer development, 
progression and metastasis, with established effects on cancer cell proliferation and cancer cell defence 
pathways, in addition to angiogenesis [45, 47, 183]. Against this background, understanding the complex 
mechanisms underlying pro-angiogenic effects of thyroid hormones is of paramount importance, not 
least due to the promising anti-angiogenic activity of tetrac. 
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5.1 Abstract 
Thyroid hormones are emerging as critical regulators of tumour growth and progression via a non-
classical signalling pathway initiated at integrin αvβ3 expressed on many tumour cells, proliferating 
endothelial cells, and tumour stroma-associated cells. To assess the contribution of thyroid hormone 
signalling via integrin αvβ3 to tumour growth, we compared the effects of thyroid hormones versus 
tetrac, a specific inhibitor of thyroid hormone action at integrin αvβ3, in two murine xenograft tumour 
models with and without integrin αvβ3 expression. 
Integrin αvβ3-positive human anaplastic thyroid cancer cells SW1736 and integrin αvβ3-negative 
human hepatocellular carcinoma cells HuH7 were injected into the flanks of nude mice. Tumour growth 
was monitored in euthyroid, hyperthyroid, hypothyroid, and euthyroid tetrac-treated mice in both 
models. In SW1736 xenograft mice, hyperthyroidism led to a significantly increased tumour growth 
resulting in a decreased survival compared to euthyroid mice. In hypothyroid and tetrac-treated mice, in 
contrast, tumour growth was significantly reduced and, hence, survival prolonged compared to euthyroid 
and hyperthyroid animals. Both proliferation and vascularisation, as determined by Ki67 and CD31 
immunofluorescence staining, respectively, were significantly increased in tumours from hyperthyroid 
mice as compared to hypothyroid and tetrac-treated mice. No differences in tumour growth, survival, or 
Ki67 staining were observed between the different thyroid hormone states in mice bearing integrin αvβ3-
negative HuH7 xenografts. The blood vessel density, however, was significantly decreased in 
hypothyroid and tetrac-treated mice compared to both euthyroid and hyperthyroid mice. Apoptosis was 
not affected in either tumour model, nor was cell proliferation in vitro.  
Both the reduced tumour growth rate in tetrac-treated mice bearing integrin αvβ3-positive tumours and 
the unaffected growth of integrin αvβ3-negative tumours imply integrin αvβ3-dependency. The 
regulation of tumour growth by thyroid hormones in αvβ3-positive tumours has important implications 
for cancer patients, especially for those with cancer treatment-related or unrelated thyroid dysfunction 
or thyroid cancer patients treated with thyroid-stimulating hormone- (TSH-) suppressive L-thyroxine 
doses.
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5.2 Introduction 
The thyroid hormones 3,5,3’-triiodo-L-thyronine (T3) and L-thyroxine (T4) have a broad spectrum of 
biological activity relating to embryonic development, differentiation, growth, and metabolism in the 
healthy organism. Several decades of both clinical and experimental evidence suggest that they are also 
critical regulators of tumour progression [47, 184]. Indeed, thyroid hormones have been shown to 
stimulate tumour cell proliferation and inhibit apoptosis, besides modulating angiogenesis, 
inflammation, and tumour stroma formation [29, 47, 147, 161, 184-186]. These effects are thought to 
be mediated mainly by non-classical thyroid hormone signalling initiated at integrin αvβ3. This 
heterodimeric transmembrane adhesion receptor links the extracellular matrix to the intracellular 
cytoskeleton and is expressed at high levels on many tumour cells, dividing endothelial cells, and 
stromal cells [20, 187, 188]. Discovered in 2005 by Bergh et al., the thyroid hormone binding site on 
integrin αvβ3 is located on the extracellular domain and shows neither structural nor functional 
homology to the classical nuclear thyroid hormone receptors (TRs) [33, 38, 39]. The binding site is 
subspecialised into two distinct sites: one binds T3 and stimulates the PI3K pathway, while the other 
binds both T3 and T4 and activates MAPK (ERK1/2) signalling [39]. The latter has been shown to 
enhance cell proliferation and decrease apoptosis in tumour cells upon thyroid hormone binding [29, 
39], while angiogenesis may be modulated from both binding sites [39]. The naturally occurring thyroid 
hormone metabolite 3,3’,5,5’-tetraiodothyroacetic acid (tetrac) blocks thyroid hormone binding and thus 
signalling at both binding sites on the integrin [39]. 
Physiological concentrations of T4 and supraphysiological concentrations of T3 have been reported to 
enhance the proliferation of tumour cell lines in vitro, including breast and ovarian cancer, follicular and 
papillary thyroid carcinoma, small cell and non-small cell lung carcinoma, glioma, T-cell lymphoma, 
and multiple myeloma [39, 146, 189-199]. In addition, T3 and T4 have been shown to drive angiogenesis 
via stimulation of endothelial cell proliferation, migration, and vascular tube formation. This can occur 
either directly by stimulation of the endothelial cells themselves, or indirectly by stimulation of the 
secretion of pro-angiogenic modulators by tumour cells and tumour-educated mesenchymal stem cells 
that in turn act on endothelial cells [20, 42, 47, 148, 162, 163, 185]. In all cases, the observed effects on 
proliferation and angiogenesis were attributed to integrin αvβ3-mediated thyroid hormone signalling, as 
shown by inhibitors that selectively block αvβ3, including tetrac. In vivo data support these observations: 
In rodents bearing syngeneic and xenograft tumours, induction of hypothyroidism, by pharmaceutical 
inhibition of thyroid hormone synthesis, radioiodine ablation, or surgical thyroidectomy, led to reduced 
tumour growth in models of breast, prostate, and lung carcinoma, as well as sarcoma, fibrosarcoma, and 
hepatoma [31, 49-54]. Further, T4 has been shown to increase tumour growth in syngeneic mouse 
models of sarcoma and fibrosarcoma [50]. In a murine Lewis lung carcinoma model, T4, but not T3, 
treatment increased tumour growth, an effect that was inhibited by tetrac [200]. In addition, tetrac 
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reduced tumour mass and haemoglobin content in breast, renal, follicular thyroid, medullary thyroid, 
lung, and pancreas carcinoma xenografts in mice via stimulation of apoptosis and inhibition of 
angiogenesis [132, 154, 190, 196, 201-203]. 
Thus, the impact of thyroid hormone signalling via integrin αvβ3 on tumour growth can be attributed to 
a direct response of the cancer cells themselves through increased proliferation and/or inhibition of 
apoptosis, and to indirect effects on the stromal compartment, particularly on angiogenesis, via 
stimulation of integrin αvβ3-positive endothelial cells and stromal cells. In order to better understand 
the contributions of these separate effects on tumour growth and to confirm the central role of tumoural 
integrin αvβ3 expression, we used an integrin αvβ3-positive and an integrin αvβ3-negative tumour cell 
line to compare thyroid hormone versus tetrac effects on tumour growth in murine xenografts in the 
current study. 
5.3 Materials and Methods 
Cell culture 
The human anaplastic thyroid carcinoma cell line SW1736 and the human hepatocellular carcinoma cell 
line HuH7 were cultured in RPMI (Sigma-Aldrich, St. Louis, MO, USA) and DMEM low-glucose 
(Sigma-Aldrich), respectively, supplemented with 10% (v/v) FBS (FBS Superior, Biochrom/Merck 
Millipore, Berlin, Germany) and 100 U/ml penicillin/100 µg/ml streptomycin (Sigma-Aldrich). Both 
cell lines were maintained at 37 °C in a humidified 5% (v/v) CO2 atmosphere. 
Quantitative real-time PCR 
mRNA expression of the two integrin αvβ3 subunit genes ITGAV and ITGB3 was determined by 
quantitative real-time PCR (qRT-PCR) as described previously [20] on a LightCycler 96 (Roche 
Diagnostics, Mannheim, Germany) using the following primers: ACTB, fwd 5’-
AGAAAATCTGGCACCACACC-3’, rev 5’-TAGCACAGCCTGGATAGCAA-3’; R18S, fwd 5’-
CAGCCACCCGAGATTGAGCA-3’, rev 5’-TAGTAGCGACGGGCGGTGTG-3’; ITGAV, fwd 5’-
CACCAGCAGTCAGAGATGGA-3’, rev 5’-GGCAACCGTGTCATTCTTTT-3’; ITGB3, fwd 5’-
AAGGATAACTGTGCCCCAGA-3’, rev 5’-CACAGGCTTGTCCACAAATG-3’. Relative expression 
levels are expressed as ΔΔCt values normalised to internal ACTB (β-actin) and R18S (18S rRNA). 
Samples were run in duplicate for each of four independent replicates. 
Flow cytometry 
Cell surface expression of integrin αvβ3 was assessed by flow cytometry as described previously [204]. 
Per sample, 106 cells were incubated with 0.5 µg of a mouse monoclonal IgG1 antibody against integrin 
αvβ3 (clone 27.1 (VNR-1); Abcam, Cambridge, UK). As secondary antibody an Alexa Fluor 488-
conjugated goat anti-mouse antibody (Abcam) was used.  
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Thyroid hormone treatment in vitro 
SW1736 and HuH7 were serum-starved overnight prior to treatment with physiological or 
supraphysiological total concentrations of thyroid hormones (all from Sigma-Aldrich), i.e. 1 nM or 10 
nM T3 and 100 nM or 1000 nM T4, with and without 100 nM tetrac in medium containing charcoal-
stripped serum (<0.2 pg/ml T3, 0.2-0.6 ng/dl T4). Cell proliferation was assessed by MTT assay 
(Promega, Mannheim, Germany) as described previously [170] after 24, 48, 72, and 96 h of thyroid 
hormone treatment.  
Animals  
All animal experiments were performed in accordance with German animal welfare laws and the 
approval of the regional governmental commission for animals (Regierung von Oberbayern, Munich, 
Germany). Male immunodeficient CD1 nu/nu mice (Charles River, Sulzfeld, Germany) were allowed 
to acclimatise for one week and kept under specific pathogen-free conditions with access to standard 
nude mouse diet (ssniff, Soest, Germany) and water ad libitum. To establish xenograft tumours, five- to 
six-week old mice were implanted with either 15×106 SW1736 or 5×106 HuH7 in 100 µl PBS 
subcutaneously into the right hind flank. Tumour growth was monitored by calliper measurement of 
three dimensions at least every second day and the volume calculated as 4/3 × π × length/2 × width/2 × 
height/2. 
Thyroid hormone treatment in vivo 
Once tumours were visible, mice received drinking water supplemented with 0.02% (w/v) 2-mercapto-
1-methylimidazole (MMI; Sigma-Aldrich) and 1% (w/v) sodium perchlorate (Sigma-Aldrich) to induce 
hypothyroidism and generate the same baseline treatment for all groups [20, 144]. Saccharin (Sigma-
Aldrich) was added at a concentration of 0.3% (w/v) to mask the bitter taste of the anti-thyroid drugs. 
Thyroid hormone treatment was started when tumours reached a size of >100 mm3. Mice were randomly 
assigned to different treatment groups that received daily intraperitoneal injections of 100 ng/g body 
weight L-T4 (Sigma-Aldrich) to induce hyperthyroidism (SW1736 n=6; HuH7 n=7), 20 ng/g body 
weight L-T4 to render mice euthyroid, with (SW1736 n=5; HuH7 n=8) or without (SW1736 n=6; HuH7 
n=8) 10 µg/g body weight tetrac (Sigma-Aldrich), or saline for the hypothyroid group (SW1736 n=5; 
HuH7 n=7). The thyroid hormone status was monitored in final serum samples by ELISA (DRG 
Diagnostics, Marburg, Germany). Mice were sacrificed and dissected when tumours reached a size 
>1500 mm3, or, as was the case for one tetrac-treated mouse bearing an SW1736 tumour, the tumour 
started to exulcerate. 
Ex vivo analysis 
Immunofluorescence staining of frozen tissue sections was performed as described previously [205]. 
For Ki67 (proliferating cells) and CD31 (blood vessels) co-staining, a rabbit polyclonal antibody against 
human Ki67 (Abcam; dilution 1:200) and a rat monoclonal antibody against mouse CD31 (BD 
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Pharmingen, Heidelberg, Germany; dilution 1:100) followed by an Alexa Fluor 488-conjugated anti-
rabbit secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA) and a Cy3-conjugated 
anti-rat secondary antibody (Jackson ImmunoResearch), respectively, were used. To stain for apoptotic 
cells, a terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay was performed 
(Click-iT TUNEL Alexa Fluor 488, Thermo Fisher Scientific, Waltham, MA, USA) according to the 
manufacturer's instructions. Nuclei were counterstained with 5 µg/ml bisbenzimide Hoechst 33258 
(Sigma-Aldrich). Stained sections were mounted with Dako Fluorescence Mounting Medium (Dako, 
Carpinteria, CA, USA) and imaged at 10× (Ki67/CD31 staining) or 20× (TUNEL) magnification on a 
Leica DMI6000 B fluorescence microscope equipped with a Leica DFC365 FX CCD camera, and the 
software Leica Application Suite X (Leica Microsystems, Wetzlar, Germany). A minimum of five visual 
fields was recorded per tumour. The percentage of Ki67-positive and apoptotic nuclei, or the percent 
CD31-positve area per visual field were determined using ImageJ (National Institutes of Health, 
Bethesda, MD, USA).  
Statistics 
All data are expressed as mean ± SEM, mean fold change ± SEM, or, for survival plots, percent. 
Statistical significance was tested by one-way ANOVA followed by Tukey’s Honestly Significant 
Difference post hoc test, except for the qRT-PCR data and mouse survival, where Student’s t-test and 
log-rank test were performed, respectively. p-values <0.05 were considered statistically significant 
(*p<0.05; **p<0.01; ***p<0.001; n/s not significant).   
5.4 Results 
Integrin αvβ3 is expressed on SW1736, but not on HuH7 cells  
Integrin αvβ3 expression in human anaplastic thyroid cancer cells SW1736 and human hepatocellular 
carcinoma cells HuH7 was analysed by qRT-PCR and flow cytometry. In SW1736, mRNA for both 
integrin subunits was detected, while HuH7 only express ITGAV, the gene for the αv subunit, and no 
mRNA for the gene coding for the β3 subunit (ITGB3) was detected (Fig. 19A). Accordingly, cell 
surface expression of integrin αvβ3 was only detected in SW1736 by flow cytometry (Fig. 19B). 
Thyroid hormone stimulation in vitro 
Thyroid hormone (1 and 10 nM T3 or 100 and 1000 nM T4) and/or tetrac (100 nM) treatment had no 
effect on tumour cell proliferation in vitro, neither in integrin αvβ3-positive SW1736, nor in integrin 
αvβ3-negative HuH7 cells after 24, 48, 72, or 96 h of stimulation (data not shown). 
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Thyroid hormone stimulates tumour growth via integrin αvβ3 
Mice bearing either integrin αvβ3-positive anaplastic thyroid carcinoma SW1736 xenograft tumours or 
integrin αvβ3-negative hepatocellular carcinoma HuH7 xenograft tumours were assigned to different 
thyroid hormone treatment groups and tumour growth was observed until a tumour size of 1500 mm3 
was reached (Fig. 20A). One mouse bearing an SW1736 tumour treated with tetrac had to be sacrificed 
prematurely due to ulceration of the tumour. The respective thyroid hormone status was confirmed by 
T4 measurement in serum after sacrifice (Fig. 20B). As the ELISA could not distinguish tetrac from T4, 
serum values for euthyroid tetrac-treated mice are not shown. However, the same body weight-adjusted 
dose of T4 was used for the tetrac-treated group as for the euthyroid group, leading to highly 
reproducible serum T4 levels in the range of untreated naturally euthyroid mice (control in Fig. 20B). 
 
Tumour growth of integrin αvβ3-positive anaplastic thyroid carcinoma SW1736 xenograft tumours was 
significantly increased in hyperthyroid compared to euthyroid mice, while tumour growth was 
 
Figure 19: Integrin αvβ3 expression on SW1736 and HuH7 cells. (A) Average mRNA expression of 
integrin subunits αv (ITGAV) and β3 (ITGB3) in human anaplastic thyroid carcinoma cells SW1736 and 
hepatocellular carcinoma cells HuH7 (n=4, mean ± SEM; ***p<0.001) was determined by qRT-PCR. (B) 
Cell surface expression of integrin αvβ3 was analysed by flow cytometry using an integrin αvβ3-specific 
primary antibody followed by an Alexa Fluor 488-labelled secondary antibody. Controls were incubated 
with the secondary antibody only. 
 
 
Figure 20: Experimental set-up in vivo. (A) SW1736 or HuH7 tumour cells were injected subcutaneously 
into nude mice and endogenous thyroid hormone production was blocked by MMI/perchlorate in the drinking 
water. Mice were assigned to different thyroid hormone treatment groups by daily injections once tumours 
reached a size >100 mm3 and tumour growth was monitored until the tumour size exceeded 1500 mm3. (B) 
The thyroid hormone status of the different groups was verified by serum T4 measurement and compared to 
untreated euthyroid control mice (ctrl). 
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significantly reduced both in hypothyroid and tetrac-treated euthyroid animals (Fig. 21A). This led to a 
significantly increased survival, defined by a maximum tumour size of 1500 mm3, in the hypothyroid 
(median survival 25 days) and the tetrac-treated group (median survival 23 days), and a significantly 
reduced survival in the hyperthyroid group (median survival 11 days) as compared to euthyroid animals 
(median survival 16 days; Fig. 21A). In the integrin αvβ3-negative HuH7 tumour model, in contrast, no 
significant differences in tumour growth or survival were detected between the different treatment 
groups (Fig. 21B).  
 
Effects on tumour growth arise from increased proliferation and angiogenesis 
Ex vivo analysis of frozen tumour sections revealed an increase in proliferating cells and vascularisation 
in the tumours of hyperthyroid mice compared to both hypothyroid and tetrac-treated mice in SW1736 
tumours as evidenced by the results of Ki67 and CD31 staining, respectively (Fig. 22A).  
 
Figure 21: Thyroid hormone status influences tumour growth in murine xenografts via tumoural 
integrin αvβ3 expression. For both (A) integrin αvβ3-positive SW1736 xenografts (euthyroid: n=6, 
hyperthyroid: n=6, hypothyroid: n=5, euthyroid + tetrac: n=5) and (B) integrin αvβ3-negative HuH7 
xenografts (euthyroid: n=8, hyperthyroid: n=7, hypothyroid: n=7, euthyroid + tetrac: n=8), the average 
tumour growth (left panels; mean ± SEM; *p<0.05 versus euthyroid; #p<0.05, ##p<0.01 versus hyperthyroid) 
and survival (right panels; percent; *p<0.05, **p<0.01, n/s not significant) of the different treatment groups 
were compared. One SW1736 tumour-bearing mouse had to be sacrificed prematurely due to tumour 
ulceration (red arrows in (A)). 
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Figure 22: Ex vivo analysis of tumoural cell proliferation, vascularisation, and apoptosis. Tumour cell 
proliferation was assessed by Ki67 immunofluorescence staining and blood vessel density by CD31 staining 
on frozen SW1736 (A) and HuH7 (B) tumour sections. A minimum of five visual fields was quantified per 
tumour (mean ± SEM; *p<0.05, **p<0.01). Magnification: 10×. (C) Apoptosis was analysed by TUNEL 
assay on a minimum of seven visual fields per frozen tumour section at 20× magnification (mean ± SEM). 
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In HuH7 tumours, the blood vessel density was significantly decreased in hypothyroid and tetrac-treated 
animals compared to both euthyroid and hyperthyroid animals (Fig. 22B). Tumour cell proliferation, in 
contrast, was not affected by any of the treatment regimens (Fig. 22B). No significant differences in the 
number of apoptotic cells were detected between the different treatment groups in either of the tumour 
models (Fig. 22C). 
5.5 Discussion 
Growing clinical and experimental evidence suggests that thyroid hormones are implicated in cancer 
development and progression, affecting tumour cell proliferation, survival, and angiogenesis [29, 147, 
161, 185]. Besides canonical thyroid hormone signalling via nuclear receptors, thyroid hormone action 
can also be exerted via the plasma membrane receptor integrin αvβ3. The integrin is highly expressed 
on many cancer cells, proliferating endothelial cells, and stromal cells in the tumour milieu [20, 187, 
188]. Hence, it stands to reason that signalling via integrin αvβ3 is linked to cancer-relevant thyroid 
hormone effects. Indeed, previous studies in tumour models expressing integrin αvβ3 have conclusively 
demonstrated that thyroid hormones and tetrac, a T4 derivative that functions as a specific inhibitor of 
thyroid hormone action at integrin αvβ3, modulate tumour growth and angiogenesis. To our knowledge, 
thyroid hormone effects specifically on integrin αvβ3-negative tumours, however, have not been 
examined to date. To evaluate the contribution of integrin αvβ3 expression on tumour cells to thyroid 
hormone effects on tumour growth in vivo, we employed an integrin αvβ3-positive and an integrin αvβ3-
negative murine xenograft tumour model in the current study.  
We here show that only for the integrin-positive tumour cell line SW1736 tumour growth was influenced 
by thyroid hormone status and tetrac. While hyperthyroid mice showed a significantly faster tumour 
growth, both hypothyroid and tetrac-treated euthyroid mice showed a significantly reduced tumour 
growth as compared to euthyroid mice. Accordingly, the study endpoint of tumour sizes exceeding 1500 
mm3 was reached significantly later in hypothyroid and tetrac-treated euthyroid mice, and significantly 
earlier in hyperthyroid mice as compared to euthyroid animals. These results confirm observations made 
in a number of different tumour models in vitro and in vivo [31, 39, 49-54, 132, 146, 154, 189-203] that 
were attributed to effects on tumour cell proliferation [39, 54, 146, 189-199, 201], apoptosis [132, 203], 
and angiogenesis [132, 154, 190, 196, 200, 202, 203]. To assess the mechanisms contributing to the 
differences observed in the current study, we evaluated these same parameters, i.e. tumour cell 
proliferation, apoptosis, and angiogenesis, ex vivo on tumour sections.  
Tumour cell proliferation was influenced by thyroid hormone status only in the integrin-positive 
SW1736 tumours with a significantly decreased number of proliferating cells in tumours of hypothyroid 
and tetrac-treated mice as compared to hyperthyroid mice. Surprisingly, considering this in vivo 
observation, we did not detect effects on tumour cell proliferation in vitro. This may stem from the 
oversimplification of the system under observation in 2D cell culture, where crucial components such 
Tumour growth stimulation by thyroid hormones 
68 
 
as extracellular matrix and stromal cell interactions, as well as concentration gradients of oxygen, 
nutrients, and effector molecules are virtually non-existent [206]. Apoptosis was not significantly 
influenced in either of the models, though in SW1736 tumours a trend with lowest apoptosis rates in 
euthyroid animals and highest in tetrac-treated animals was observed that may have additionally slightly 
contributed to the differences in tumour growth rates.  
Vascularisation, in contrast, was decreased in tumours of the hypothyroid and tetrac-treated groups in 
both the integrin-positive SW1736 and the integrin-negative HuH7 tumour model. This is not surprising, 
as proliferating endothelial cells are known to express high levels of integrin αvβ3 and, indeed, 
endothelial cell proliferation, migration, and vascular tube formation have been shown to be modulated 
by thyroid hormones via integrin αvβ3 [42, 148, 162, 163]. However, though tumour vascularisation 
was influenced in integrin αvβ3-negative HuH7 tumours, this effect was not sufficient to significantly 
influence tumour growth. This observation is in accordance with a previous study, where, analysing 
thyroid hormone effects on tumour angiogenesis in an orthotopic HuH7 mouse model, we found that 
differences in angiogenesis did not affect tumour growth [185]. Taking a closer look at tumour growth 
and survival in the HuH7 model, the hypothyroid and especially the tetrac-treated group seem to initially 
(for the first 10-13 days) slightly lag behind the euthyroid and hyperthyroid groups, though differences 
were not statistically significant. In tetrac-treated animals, where this effect is more pronounced, median 
survival amounted to 22 days, compared to 13, 12, and 15 days in the eu-, hyper-, and hypothyroid 
groups, respectively. Following this initial lag, however, tetrac-treated mice caught up with the other 
groups and no significant differences in overall survival were observed. Yalcin et al. made the 
interesting observation that mouse xenografts of human medullary thyroid cancer show an acute reaction 
to tetrac treatment within the first few days that the authors’ attribute to the anti-angiogenic activity of 
tetrac [203]. This acute phase is followed by a long-term progressive, albeit weaker, inhibiting effect on 
tumour growth thought to be caused by the pro-apoptotic activity of tetrac on the tumour cells 
themselves [203]. As we do see effects on angiogenesis in the HuH7 model, the initial slight delay in 
tumour growth may stem from this acute response. 
The differences in tumour growth and, as a consequence, survival between the integrin αvβ3-positive 
and -negative tumour models along with the fact that in the integrin-positive tumour cell line tetrac 
inhibited tumour cell proliferation in euthyroid mice to the same extent as the induction of 
hypothyroidism, are further compelling evidence for pathway initiation at integrin αvβ3. Obviously, 
stimulation of tumour growth, be it by endogenous or exogenously applied thyroid hormones, is 
undesirable in cancer patients. In this context, a myriad of population-based and clinical studies have 
examined the potential link between thyroid state and the risk of developing cancer and cancer 
progression and survival. Overall, data remain inconclusive, ranging from no detectable effects to both 
higher and lower cancer risk and better and worse prognosis in existing cancers for both hyper- and 
hypothyroidism [47]. Compelling clinical evidence for a tumour-promoting effect of thyroid hormones, 
however, stems from the observation that cancer patients that develop hypothyroidism as an unwanted 
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side effect of tyrosine kinase inhibitor, interleukin-2 or radiation treatment, often show a more 
favourable outcome [47]. Against this background, T4 supplementation as standard hormone 
replacement therapy for hypothyroidism and the application of thyrotropin (TSH)-suppressive doses of 
T4 in differentiated thyroid cancer patients may have to be reconsidered – at least in those patients with 
tumoural integrin αvβ3 expression [47, 184]. The affinity for T4 is far higher than for T3 at integrin 
αvβ3 [41]. Indeed, several experimental studies have observed that T3 in the physiological concentration 
range does not elicit effects on tumour growth, suggesting that T3 supplementation may have an 
advantage over T4 supplementation, at least in a subset of patients [29, 41, 58, 184, 200]. In addition, 
as integrin αvβ3 is rarely expressed at high levels on normal cells and allows targeting of multiple 
cancer-relevant mechanisms from a single receptor site, blocking integrin αvβ3 function without 
affecting physiologic thyroid hormone signalling at nuclear thyroid hormone receptors is a feasible 
alternative.  
The comparison of the effects on tumours derived from αvβ3-positive and αvβ3-negative tumour cells 
demonstrates that integrin expression on the tumour cells themselves is more critical than effects on 
angiogenesis via the endothelium itself. These observations highlight the importance of tumoural 
receptor status and identify a possible explanation for the discrepancies in clinical studies examining 
thyroid hormone effects on cancer. 
5.6 Acknowledgements 
We are grateful to Dr. Barbara von Ungern-Sternberg and Rosel Oos (Department of Nuclear Medicine, 
LMU Munich, Munich, Germany) for their assistance with animal care and to Dr. Sarah Urnauer 
(Department of Internal Medicine IV, LMU Munich, Munich, Germany) for performing flow cytometry 
experiments. 
Targeting NIS to anaplastic thyroid carcinoma 
70 
 
VI. CHAPTER 5 
 
Reintroducing the sodium iodide symporter (NIS) to anaplastic thyroid 
carcinoma 
 
Kathrin A Schmohl1*, Patrick Dolp1*, Christina Schug1, Kerstin Knoop1, Kathrin Klutz1, Nathalie 
Schwenk1, Peter Bartenstein2, Peter J Nelson1, Manfred Ogris3, Ernst Wagner4 and Christine Spitzweg1 
 
1Department of Internal Medicine IV, University Hospital of Munich, LMU Munich, Munich, Germany 
2Department of Nuclear Medicine, University Hospital of Munich, Munich, Germany 
3Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria 
4Department of Pharmacy, LMU Munich, Munich, Germany 
*KAS and PD contributed equally 
 
This chapter is a pre-copy-edited version of a peer-reviewed article published in Thyroid 2017;27:1534-
43. 
 
Parts of this chapter are included in the doctoral thesis of Patrick Dolp. Kathrin A Schmohl performed 
NIS stainings and the therapy study. Patrick Dolp performed in vitro iodide uptake studies, in vivo 
scintigraphies and the therapy study. The manuscript was written by Kathrin A Schmohl.
Targeting NIS to anaplastic thyroid carcinoma 
71 
 
6.1 Abstract 
Anaplastic thyroid carcinoma (ATC), the most aggressive form of thyroid cancer, is unresponsive to 
radioiodide therapy. In the current study, we aimed to extend the diagnostic and therapeutic application 
of radioiodide beyond the treatment of differentiated thyroid cancer by targeting the functional sodium 
iodide symporter (NIS) to ATC. 
We employed nanoparticle vectors (polyplexes) based on linear polyethylenimine (LPEI), shielded by 
polyethylene glycol (PEG) and coupled to the synthetic peptide GE11 as an epidermal growth factor 
receptor (EGFR)-specific ligand in order to target a NIS-expressing plasmid (LPEI-PEG-GE11/NIS) to 
EGFR overexpressing human thyroid carcinoma cell lines. Using ATC xenograft mouse models, we 
evaluated transfection efficiency by 123I scintigraphy and potential for systemic radioiodide therapy after 
systemic polyplex application. 
In vitro iodide uptake studies in SW1736 and Hth74 ATC cells, and, for comparison, in more 
differentiated follicular (FTC-133) and papillary (BCPAP) thyroid carcinoma cells demonstrated high 
transfection efficiency and EGFR-specificity of LPEI-PEG-GE11/NIS that correlated well with EGFR 
expression levels. After systemic polyplex injection, in vivo 123I gamma camera imaging revealed 
significant tumour-specific accumulation of radioiodide in an SW1736 and an Hth74 xenograft mouse 
model. Radioiodide accumulation was found to be higher in SW1736 tumours, reflecting in vitro results, 
EGFR expression levels and results from ex vivo analysis of NIS staining. Administration of 131I in 
LPEI-PEG-GE11/NIS-treated SW1736 xenograft mice resulted in significantly reduced tumour growth 
associated with prolonged survival compared to control animals.  
Our data open the exciting prospect of NIS-mediated radionuclide imaging and therapy of ATC after 
non-viral reintroduction of the NIS gene. The high tumour-specificity after systemic application makes 
our strategy an attractive alternative for the treatment of highly metastatic ATC. 
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6.2 Introduction 
The sodium iodide symporter (NIS) is an intrinsic transmembrane protein that actively transports iodide 
from the blood into thyroid follicular cells as the first step in thyroid hormone synthesis [88]. Functional 
NIS expression provides the molecular basis for the diagnostic and therapeutic application of 
radioiodide, which has successfully been in use since 1946 to treat thyroid cancer patients [62]. This 
approach still represents the most effective form of anticancer radiotherapy in clinical use to date and 
makes differentiated thyroid carcinoma one of the most manageable cancers [61, 65]. Anaplastic 
(undifferentiated) thyroid carcinoma (ATC) cells, in contrast, have lost the ability to concentrate iodide 
and are subsequently unresponsive to radioiodide therapy [207]. ATC is the most lethal form of thyroid 
cancer and one of the most aggressive solid tumours in humans, characterised by rapid progression, 
early dissemination and a high propensity for distant metastasis [207]. Typically, ATC is treated with a 
multimodal therapeutic approach, consisting of surgery, chemotherapy and loco-regional radiotherapy, 
though with limited success [208, 209], clearly demonstrating the need for new therapeutic strategies. 
Cloning of NIS in 1996 was the first step in the development of a novel cytoreductive gene therapy 
strategy based on targeting functional NIS to both thyroidal and extrathyroidal malignancies, thus 
extending an established and highly effective anti-cancer strategy beyond the treatment of differentiated 
thyroid cancer [63, 64, 68]. We and others have shown that selective NIS gene transfer into tumour cells 
allows systemic application of radionuclides resulting in tumour-specific radionuclide concentration that 
can be used both for non-invasive imaging as well as therapy [66, 67, 70-72, 77-79, 82, 83, 87, 99, 205, 
210].  Clinical development of the NIS gene therapy concept is dependent on highly specific and efficient 
tumour targeting at low toxicity and requires systemic application of the therapeutic gene, especially for 
the treatment of disseminated cancer. However, the biostability and delivery efficiency of ‘naked’ 
nucleic acids are very low, limiting their systemic applicability [69]. Cationic polymers, such as linear 
polyethylenimine (LPEI), are a class of non-viral gene delivery vehicles that form sub-micrometre 
complexes with nucleic acids called polyplexes and thus stabilize the DNA by eliminating unwanted 
interactions with blood components and other non-target sites [69]. After intravenous application, 
nanoparticle concentration builds up in the plasma with a long half-life, as nanoparticles escape both 
renal clearance and penetration of normal endothelium due to their size [85]. LPEI-based polyplexes are 
internalised with high efficiency and exhibit intrinsic endosomolytic activity allowing efficient release 
into the cytoplasm followed by nuclear import of the therapeutic gene. Tumour targeting is based on the 
so-called enhanced permeability and retention (EPR) effect that drives passive accumulation of 
polyplexes due to the leaky vasculature prevalent in tumours in conjunction with a tumour’s slow venous 
return and poor lymphatic clearance [69, 84, 85]. Due to inter- and intratumoural heterogeneity, 
nanoparticle-based drugs that rely on the EPR effect alone for efficient delivery have their limitations 
in the clinical setting and efficiency will vary from patient to patient [211]. However, tumour specificity 
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and delivery efficacy can be further increased using ligands that bind to receptors overexpressed on 
tumour cells. To this end, we attached the epidermal growth factor receptor- (EGFR-) specific ligand 
GE11 to LPEI via a polyethylene glycol (PEG) link that facilitates surface shielding of polyplexes and 
thus reduces cytotoxicity [86]. GE11 polyplexes undergo efficient clathrin-mediated endocytosis and 
are quickly transported to the nucleus [212]. In our previous work, LPEI-PEG-GE11 polymers were 
shown to be highly efficient NIS gene delivery vehicles in a high EGFR expressing liver cancer 
xenograft mouse model, as well as an advanced genetically engineered mouse model of pancreatic ductal 
adenocarcinoma, as evidenced by tumour-specific radioiodide accumulation and therapeutic efficacy of 
131I [87, 210].  
As EGFR is typically overexpressed on ATC cells [213], we used the LPEI-PEG-GE11 nanoparticle 
vectors for NIS gene transfer to ATC in the present study to capitalise on the dual diagnostic and 
therapeutic function of NIS. 
6.3 Materials and Methods 
EGFR and NIS immunohistochemistry of human anaplastic tumour tissue 
In total, nine different tumours stored in the database of the Institute of Pathology from anaplastic 
thyroid carcinoma patients, which had been operated on between 2003 and 2012, were examined. 
Immunohistochemical staining of EGFR was performed on a BenchMark XT slide staining system 
(Ventana Medical Systems, Tucson (AZ), USA) using a monoclonal (IgG1) mouse-antibody (clone: 
3C6; Ventana Medical Systems). Evaluation of the staining pattern was performed by visual scoring. 
No staining resulted in a score of 0; little, non-circumferential staining in more than 10% of the tumour 
cells was scored as 1+; weak, but thin circumferential staining in more than 10% of the tumour cells was 
rated with the score 2+; a score of 3+ signifies an intense, thick circumferential staining in more than 
10% of the tumour cells. Scores of 0 were rated as negative, while scores of 1+, 2+ and 3+ indicated a 
weak, moderate and strong positive expression of EGFR, respectively [214]. NIS staining was 
performed as described previously using a mouse monoclonal antibody (Millipore, Damrstadt, 
Germany) diluted 1:500 [215]. 
Cell lines 
Anaplastic thyroid carcinoma cell lines SW1736 and Hth74, follicular thyroid carcinoma cell line FTC-
133 and papillary thyroid carcinoma cell line BCPAP were grown in RPMI (Thermo Fisher Scientific, 
Waltham (MA), USA) supplemented with 10% (v/v) fetal bovine serum (FBS; PAA, Colbe, Germany) 
and 100 U/mL penicillin/100 µg/mL streptomycin (Thermo Fisher Scientific, Waltham (MA), USA). 
Cells were maintained at 37°C and 5% (v/v) CO2 in an incubator with 95% humidity. Cell culture 
medium was replaced every second day and cells were passaged at 70% confluence.  
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Flow cytometry 
For analysis of cell surface EGFR expression by flow cytometry, cells were trypsinised, re-suspended 
in FACS buffer (phosphate-buffered saline supplemented with 10% (v/v) FBS) and diluted to a density 
of 6×105 cells/100 µL. Cells were incubated with a mouse monoclonal anti-human EGFR antibody 
(Dako, Hamburg, Germany) or control antibody (mouse IgG; Dako) for 1.5 hours at 4°C. Cells were 
washed with FACS buffer and incubated with an Alexa488 conjugated polyclonal goat anti-mouse 
antibody (1:400; Dianova, Hamburg, Germany) for 1 hour at 4°C. To discriminate live and dead cells, 
propidium iodide (Sigma-Aldrich, Taufkirchen, Germany) was added before acquisition. Analysis was 
performed on a BD FACSCanto II flow cytometer (BD, Heidelberg, Germany). Cell aggregates and 
debris were excluded from analysis by appropriate gating. 
Polyplex formation 
LPEI-based polymers were condensed with plasmid DNA at specific conjugate to plasmid ratios (c/p) 
in HEPES-buffered glucose as described previously [216] and incubated on ice for 20 minutes before 
use. Final DNA concentrations were 2 μg/mL for in vitro studies and 200 μg/mL for in vivo studies.  
Transient transfection 
For in vitro transfection experiments, cells were grown to 70-80% confluency, washed and incubated 
with LPEI-PEG-GE11/NIS polyplexes at c/p 0.8 in the absence of serum and antibiotics for 4 h. As 
controls, cells were transfected with LPEI-PEG-Cys/NIS, a polyplex without the active EGFR-targeting 
ligand or non-coding LPEI-PEG-GE11/antisenseNIS (NIS sequence back to front). LPEI-PEG-
GE11/NIS-transfected cells treated with the NIS-specific inhibitor perchlorate (1 mM potassium 
perchlorate; Merck, Darmstadt, Germany) served as additional control. After further incubation in full 
growth medium for 24 h, transfection efficiency was measured by iodide uptake activity. 
125I uptake assay 
Iodide uptake was analysed as described previously [169, 170]. 
Establishment of SW1736 and Hth74  xenografts 
Female CD1 nu/nu mice (Charles River, Sulzfeld, Germany) were maintained under pathogen-free 
conditions with free access to standard nude mouse diet containing 2.2 mg/kg iodine (ssniff, Soest, 
Germany) and water ad libitum. Tumours were established by subcutaneous injection of 5×106 tumour 
cells in 100 µL phosphate-buffered saline into the flank region. Tumours were measured twice a week 
and tumour volumes were calculated using the equation: tumour volume = length × width × height × 
0.52. To reduce thyroidal iodide uptake and thus enhance tumoural uptake, animals were orally pre-
treated with 5 mg/L L-thyroxine (Sigma-Aldrich) for 10 days prior to radioiodide (123I, 131I) application 
as described previously [78, 82, 99]. The experimental protocol was approved by the regional 
governmental commission for animals (Regierung von Oberbayern, Munich, Germany).  
Targeting NIS to anaplastic thyroid carcinoma 
75 
 
Radioiodide uptake in vivo 
Once subcutaneous tumours reached a diameter of 8-10 mm (approx. 10-12 weeks after tumour cell 
injection), two rounds of LPEI-PEG-GE11/NIS (n=3 per tumour model) were injected intravenously 
(i.v.) via the tail vein 48 h and 24 h prior to intraperitoneal (i.p.) injection of 18.5 MBq (0.5 mCi) 123I 
(GE Healthcare, Braunschweig, Germany). As a control, a subset of mice (n=1 per tumour model) 
received 2 mg/mouse of the competitive NIS inhibitor sodium perchlorate (Sigma-Aldrich) 30 minutes 
before 123I injection. Radioiodide biodistribution was assessed using a gamma camera equipped with a 
UXHR collimator (e.cam; Siemens, Erlangen, Germany). Regions of interest were quantified by 
measuring the percentage of the total injected radioiodide dose per gram (% ID/g) tumour. The retention 
time of radioiodide in the tumour was determined by serial scanning. Dosimetric calculations for 131I 
were done according to the Medical Internal Radiation Dose (MIRD) technique with a RADAR dose 
factor (http://www.doseinfo-radar.com). 
Indirect immunofluorescence assay  
Immunofluorescence staining of frozen tissue sections from LPEI-PEG-GE11/NIS-treated mice was 
performed as described previously [170] using a rabbit polyclonal NIS-specific primary antibody (Acris 
Antibodies, Herford, Germany; 1:1,000) and a Alexa488-conjugated secondary antibody (Jackson 
ImmunoResearch, Suffolk, UK; 1:400). Sections were imaged at 40× magnification on an Axiovert 135 
TV fluorescence microscope equipped with an AxioCam MRm CCD camera and AxioVision Rel. 4.8 
software (Carl Zeiss, Munich, Germany). 
In vivo 131I therapy study 
Therapy trials were initiated in SW1736 xenografts eight weeks after tumour cell injection at tumour 
diameters of approx. 5-10 mm. A cycle consisting of polyplex administration on two consecutive days 
and a single radioiodide application 24 h later was repeated for a total of three times: polyplexes LPEI-
PEG-GE11/NIS or, as controls, LPEI-PEG-GE11/antisenseNIS or NaCl, were administered 
systemically via the tail vein on days 0/1, 3/4 and 7/8 followed by i.p. application of 55.5 MBq (1.5 
mCi) 131I (GE Healthcare), or, as control, saline, on days 2, 5 and 9 (LPEI-PEG-GE11/NIS + 131I, n=10; 
LPEI-PEG-GE11/antisenseNIS + 131I, n=10; LPEI-PEG-GE11/NIS + NaCl, n=15; NaCl + NaCl, n=11). 
Mice were sacrificed when at least one endpoint criterion was reached, i.e. when a tumour volume >1500 
mm3 was reached or when tumours started to exulcerate. 
Statistics 
All in vitro experiments were performed in triplicate. Results are expressed as mean ± S.E.M., mean-
fold change ± S.E.M or, for visual EGFR scoring of human ATC samples and survival plots, percent. 
Statistical significance was tested by two-tailed Student’s t-test, or, for tumour volumes, one-way 
ANOVA, followed by Tukey’s Honestly Significant Difference test. Statistical significance of Kaplan-
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Meier plots was analysed by log-rank test. p-values <0.05 were considered statistically significant 
(*p<0.05; **p<0.01; ***p<0.001). 
6.4 Results 
EGFR and NIS immunoreactivity of human ATC tissue 
In total, nine anaplastic thyroid tumours from different patients were examined and ranked according to 
their EGFR expression. Seven (78%) of the nine examined tumours were categorised as 3+ (Fig. 23A, 
C), while one tumour (11%) was classified as 2+ and one (11%) showed no EGFR-specific 
immunoreactivity (Fig. 23B, C). Immunohistochemical staining for NIS revealed no differences in NIS 
staining between EGFR positive (score 3+) and EGFR negative (score 0) ATC tissue (Fig. 23D, E). 
Graves’ tissue served as positive control for NIS staining (Fig. 23F). 
 
EGFR-targeted NIS gene transfer in vitro 
Two different human anaplastic thyroid cancer cell lines and, for comparison, more differentiated 
follicular and papillary thyroid carcinoma cell lines were examined for their EGFR expression levels by 
flow cytometry. SW1736 cells showed high EGFR expression, while intermediate EGFR levels were 
measured on Hth74, FTC-133 and BCPAP cells (Fig. 24A).  
 
Figure 23. EGFR and NIS expression in human ATC.  Human ATC samples (n=9) were ranked according 
to their EGFR expression. Highly EGFR-positive sections were classified as 3+ (A), while a score of 0 
indicated no EGFR-specific staining (B). (C) Quantification of visual scores. NIS staining of human ATC 
sections revealed no NIS-specific immunoreactivity without differences between highly EGFR positive (D) 
and EGFR negative (E) samples. Graves’ tissue served as positive control for NIS staining (F).  
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Twenty-four hours after transient transfection with LPEI-PEG-GE11/NIS, NIS-specific iodide uptake 
was detected in all four cell lines. SW1736 cells showed a 25-fold, Hth74 and BCPAP cells a 10-fold 
increase and FTC-133 cells a 7-fold increase in 125I uptake compared to background levels measured in 
untransfected cells. The NIS-specific inhibitor perchlorate completely blocked iodide uptake in all cell 
lines. After transfection with unspecific LPEI-PEG-Cys/NIS, iodide uptake was significantly reduced 
compared to EGFR-targeted polyplexes LPEI-PEG-GE11/NIS. Cells transfected with LPEI-PEG-
GE11/antisenseNIS showed no gain in uptake compared to untransfected cells (Fig. 24B). The amount 
of iodide uptake correlated well with EGFR levels measured by flow cytometry. Comparing the two 
ATC cell lines to each other, SW1736 cells showed a significantly higher iodide uptake than Hth74 cells 
(Fig. 24B). 
EGFR- targeted NIS gene transfer in vivo  
24 hours after two rounds of systemic NIS gene transfer via i.v. application of LPEI-PEG-GE11/NIS, 
123I uptake was evaluated on a gamma camera. Serial scanning revealed maximum tumoural iodide 
accumulation one hour post 123I injection based on NIS-mediated iodide influx from the blood 
circulation. Over time, iodide content in the circulation decreased due to renal clearance. In the tumour, 
the radioiodide recirculated to a certain extent, as iodide lost by one tumour cell was taken up by 
 
Figure 24. EGFR-targeted NIS gene transfer in vitro. (A) Human ATC cell lines SW1736 and Hth74, 
follicular thyroid carcinoma cell line FTC-133 and papillary thyroid carcinoma cell line BCPAP showed 
high (SW1736) to intermediate (Hth74, FTC-133, BCPAP) EGFR expression levels as determined by flow 
cytometry. (B) In vitro transfection with LPEI-PEG-GE11/NIS showed a significant increase in perchlorate-
sensitive 125I accumulation compared to transfection with untargeted LPEI-PEG-Cys/NIS (mean ± S.E.M.; 
n=3; *p<0.05, **p<0.01). No iodide uptake above the background levels observed for untransfected cells 
was detected after transfection with non-coding LPEI-PEG-GE11/antisenseNIS. 
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neighbouring NIS-transduced cells. Due to lack of iodide organification, however, tumoural iodide 
content slowly decreased over time, as 123I was completely cleared from the circulation (Fig. 25A-C).  
 
A maximum 123I uptake of 5.6-7.8% ID/g was observed for SW1736 tumours, whereas Hth74 tumours 
accumulated 4.5-5.8% ID/g (Fig. 25A-C). For 131I, this translates to a tumour-absorbed dose of 35.1 
mGy/MBq/g tumour with an effective half-life of 3.1 h in the SW1736 model and 25.0 mGy/MBq/g 
tumour with an effective half-life of 2.7 h in the Hth74 model. Pre-treatment of LPEI-PEG-GE11/NIS 
transfected xenografts with perchlorate inhibited tumoural accumulation of radioiodide in both models 
 
Figure 25.  In vivo imaging of NIS-mediated iodide uptake. 123I scintigraphy revealed tumour-specific 
radioiodide uptake in SW1736 (A) and Hth74 (B) xenografts after injection of LPEI-PEG-GE11/NIS that 
was perchlorate sensitive. SG: salivary glands. (C) Radionuclide retention time in tumours was determined 
by serial scanning over 12 h (mean ± S.E.M.; n=3 each; *p<0.05). 
Targeting NIS to anaplastic thyroid carcinoma 
79 
 
(Fig. 25A, B). Physiological iodide uptake in the thyroid, salivary glands and stomach was also blocked 
upon perchlorate treatment. Radioiodide accumulation in the bladder is due to renal elimination of 
radioiodide (Fig. 25A, B). 
 
After gamma camera imaging, mice were sacrificed and dissected. In both SW1736 and Hth74 tumours 
from LPEI-PEG-GE11-treated mice, immunofluorescence staining revealed areas of NIS-specific 
staining, and the amount of NIS-positive cells in SW1736-derived tumours seemed higher than in Hth74 
tumours (Fig. 26). SW1736 tumours transfected with LPEI-PEG-GE11/antisenseNIS, in contrast, 
showed no NIS-specific immunoreactivity (Fig. 26). 
131I therapy after in vivo NIS gene transfer 
Mice harbouring SW1736 xenograft tumours were treated with three cycles of LPEI-PEG-GE11/NIS 
followed by 131I 24 h later (Fig. 27A). Mice injected with LPEI-PEG-GE11/NIS and saline, LPEI-PEG-
GE11/antisense-NIS and 131I or saline only served as controls and exhibited a continuous, exponential 
tumour growth (Fig. 27B). Mice injected with LPEI-PEG-GE11/NIS and 131I, in contrast, showed a 
significant delay in tumour growth which resulted in prolonged survival (Fig. 27B, C). Thirty-five days 
after therapy start the last control mouse was sacrificed, while 60% of mice injected with LPEI-PEG-
GE11/NIS and 131I were still alive (Fig. 27C). Median survival times were 42 days for the therapy group, 
28 days for both LPEI-PEG-GE11/antisenseNIS + 131I- and NaCl + NaCl-treated animals, and 18 days 
for the LPEI-PEG-GE11/NIS + NaCl group. 
 
Figure 26.  Ex vivo NIS staining. Immunofluorescence staining verified more robust NIS gene transfer to 
SW1736 tumours as compared to Hth74 tumours. No NIS-specific staining was detected after transfection 
of non-coding antisenseNIS. 40× magnification. 
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Figure 27. Therapeutic application of 131I after NIS gene transfer in vivo. Mice harbouring SW1736 
xenograft tumours were treated with three cycles of dual i.v. injections of polyplexes followed by i.p. 
injection of 55.5 MBq 131I (A). (B) Mice treated with LPEI-PEG-GE11/NIS + 131I (mean ± S.E.M; n=10) 
showed a stabilisation in tumour volumes compared to control groups LPEI-PEG-GE11/antisenseNIS + 131I 
(mean ± S.E.M; n=10; *p<0.05), LPEI-PEG-GE11/NIS + NaCl (n=15; mean ± S.E.M.; **p<0.01) and NaCl 
+ NaCl (n=11; mean ± S.E.M.; **p<0.01). (C) This led to an increased overall and median survival in the 
therapy group compared to control groups LPEI-PEG-GE11/antisenseNIS + 131I (*p<0.05), LPEI-PEG-
GE11/NIS + NaCl (**p<0.01) and NaCl + NaCl (*p<0.05). 
Targeting NIS to anaplastic thyroid carcinoma 
81 
 
6.5 Discussion 
Besides its key role in healthy thyroid physiology, NIS-mediated iodide uptake provides the molecular 
basis for diagnostic imaging and targeted radionuclide therapy for the treatment of differentiated thyroid 
carcinomas. This concept, however, has proven ineffective in poorly differentiated and undifferentiated 
forms of thyroid cancer that lose the ability to accumulate iodide due to reduced or absent expression of 
functional NIS [217]. A very elegant and obvious therapy approach is to reinstate NIS expression and 
thus make it susceptible to radioiodide therapy either by redifferentiation aimed at recovery of 
endogenous NIS expression or by transfection with exogenous NIS.  
Substances for the induction of redifferentiation in dedifferentiated thyroid cancer that have been tested 
to date include retinoids, thiazolidinediones, such as rosiglitazone, and regulators of epigenetic 
modifications, i.e. histone deacetylase (HDAC) inhibitors and DNA methyltransferase inhibitors [218-
223]. Clinical success rates, however, have remained unexpectedly low for all of these compounds [222, 
224]. More recently, the MAPK kinase inhibitor selumetinib and the selective BRAF inhibitor 
dabrafenib were shown to induce clinically relevant levels of radioiodide uptake in patients with 
radioiodine-refractory differentiated thyroid cancer [225, 226].  
The alternative strategy of exogenously introducing NIS was made available by the cloning of the NIS 
gene in 1996 [63, 64].  Early work in tumourigenic Fisher rat thyroid follicular cells transfected stably 
with rat NIS demonstrated iodide uptake capacity in vitro and in vivo [227]. Similarly, after transfection 
of human ATC cells with NIS and subsequent injection into nude mice, tumours could be imaged by 
scintigraphy and were susceptible to radionuclide therapy [228-230]. Intratumoural injection of NIS 
using adenoviral vectors in a medullary thyroid carcinoma xenograft mouse model and measles virus 
vectors in an ATC xenograft mouse model restored radioiodide uptake as shown by gamma camera or 
SPECT imaging, respectively, and therapeutic efficacy of 131I [215, 231]. For the development of this 
concept towards clinical application, especially in metastatic disease, however, systemic application of 
NIS followed by safe, efficient and tumour-specific delivery are essential.  
Our previous work has focused on systemic delivery of the NIS gene to extrathyroidal tumours using 
viral vectors, mesenchymal stem cells and synthetic polymers as gene transfer vehicles [66, 70-72, 77-
79, 82, 83, 87, 99, 205, 210]. Based on the high efficiency of EGFR-targeted LPEI-PEG-GE11 polymers 
for tumour-specific delivery of functional NIS to a liver cancer xenograft mouse model, as well as an 
advanced genetically engineered mouse model of pancreatic ductal adenocarcinoma in our earlier 
studies and the high expression levels of EGFR in human ATC tissue samples, we chose these synthetic 
polymers as delivery vehicles for the NIS gene to ATC. High EGFR expression on ATC was confirmed 
by FACS analysis of human ATC cell lines SW1736 and Hth74. Both cell lines express wild type EGFR 
protein, though Hth74 harbour a heterozygous silent polymorphism in the EGFR gene [232, 233]. 
Transient in vitro transfection of these cells with LPEI-PEG-GE11/NIS led to significant perchlorate-
sensitive and therefore NIS-mediated radioiodide uptake. In comparison, iodide uptake was significantly 
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lower after transfection with non-targeted LPEI-PEG-Cys/NIS, demonstrating improved transfection 
efficiency using the peptide ligand GE11. NIS-dependency was further confirmed by the absence of 
iodide uptake activity using non-coding antisenseNIS DNA. The higher EGFR levels detected on 
SW1736 cells by FACS were reflected in higher iodide uptake activity as compared to Hth74 cells. 
Similar results were obtained in more differentiated follicular and papillary thyroid carcinoma cell lines, 
demonstrating the feasibility of this strategy for NIS gene transfer in EGFR-positive radioiodine 
refractory thyroid carcinoma in general.  
Transferring these results to systemic vector application in vivo, intravenous administration of LPEI-
PEG-GE11/NIS resulted in significant perchlorate-sensitive, tumour-specific iodide uptake in xenograft 
mouse models derived from both ATC cell lines, although, again, SW1736 showed higher 123I uptake, 
as determined by gamma camera imaging and confirmed by immunofluorescence staining. The 
biological half-life measured in ATC tumours was similar to what we have observed in previous studies 
in other tumour models, which is clearly long enough for a significant therapy effect [71, 72, 205, 210]. 
The radiation dose that reaches the tumour depends on the rate of iodide uptake, its retention time in the 
tumour cell, i.e. iodide efflux, iodide recirculation within the tumour and iodide organification [234]. 
Due to loss of thyroid peroxidase (TPO) and thyroglobulin expression in ATC as a result of 
dedifferentiation, we did not see any iodide organification in neither of the ATC xenografts. However, 
the iodide retention time is longer than one would expect without organification, as the iodide is 
recirculated within the tumour. A possible approach to enhance iodide retention time and the delivered 
dose in non-organifying tissues, is co-transfection of NIS and TPO [234]. In this context, co-expression 
of both genes decreased iodide efflux in non-small cell lung cancer cell lines and enhanced tumour cell 
apoptosis as compared to single transfection with NIS [235]. In contrast, after co-infection of human 
cervix carcinoma cells with two adenoviral vectors encoding NIS and TPO, no increase in iodide 
retention time was detected, though active TPO was produced and a significant increase in organification 
was observed [236]. To date, there is no clear evidence that TPO-mediated organification does indeed 
enhance the efficacy of NIS-based gene therapy. No clear data exist to prove that organification is a 
crucial prerequisite for successful 131I therapy. On the contrary, our results in the current study as well 
as in earlier studies in various non-organifying tumour entities, demonstrate that iodide organification 
is not required for accumulation of therapeutically effective radioiodide doses.  
The differences in both in vitro and in vivo data between the two ATC cell lines used here are presumably 
due to differences in EGFR expression levels. Tumour heterogeneity is a typical problem seen in clinical 
practice – indeed, of the nine patient samples analysed for EGFR receptor expression in this study, one 
tumour showed slightly lower EGFR receptor expression, while one showed no expression at all. For 
this reason we are constantly broadening our arsenal of targeting strategies, so that different targeting 
ligands can be applied depending on receptor status. In this context, a further interesting candidate for 
ATC targeting is transferrin, as the transferrin receptor is highly expressed on ATC [237-239]. 
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Due to the more promising results in SW1736, the subsequent evaluation of the therapeutic effectiveness 
of 131I after LPEI-PEG-GE11-mediated systemic NIS gene delivery was performed in this model only. 
After three cycles of two applications of LPEI-PEG-GE11/NIS followed by a application of 131I in 
SW1736 xenograft tumour carrying mice, we were able to demonstrate a significant delay in tumour 
growth in therapy animals compared to control groups, which was accompanied by a significant increase 
in survival time.  
Taken together, our data clearly show the great potential of EGFR-targeted synthetic polymers to target 
NIS to ATC. Systemic application is of particular importance in ATC, as it rapidly metastasises to distant 
sites and, at the time of diagnosis, metastases, predominantly in the lung, liver, bone and brain are 
already present in 50 % of patients [209]. To our knowledge, this is the first study demonstrating 
successful reinstatement of NIS expression and therefore susceptibility to radioiodide uptake in ATC 
after systemic application of the therapeutic gene, an important prerequisite for clinical development. 
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7.1 Abstract 
The theranostic sodium iodide symporter (NIS) gene allows detailed molecular imaging of transgene 
expression and application of therapeutic radionuclides. As a crucial step towards clinical application, 
we investigated tumour specificity and transfection efficiency of epidermal growth factor receptor 
(EGFR)-targeted polyplexes as systemic NIS gene delivery vehicles in an advanced genetically 
engineered mouse model of pancreatic ductal adenocarcinoma (PDAC) that closely reflects human 
disease. PDAC was induced in mice by pancreas-specific activation of constitutively active KrasG12D 
and deletion of Trp53. We used tumour-targeted polyplexes (LPEI-PEG-GE11/NIS) based on linear 
polyethylenimine, shielded by polyethylene glycol and coupled with the EGFR-specific peptide ligand 
GE11, to target a NIS-expressing plasmid to high EGFR-expressing PDAC. In vitro iodide uptake 
studies in cell explants from murine EGFR-positive and EGFR-ablated PDAC lesions demonstrated 
high transfection efficiency and EGFR-specificity of LPEI-PEG-GE11/NIS. In vivo 123I gamma camera 
imaging and three-dimensional high-resolution 124I PET showed significant tumour-specific 
accumulation of radioiodide after systemic LPEI-PEG-GE11/NIS injection. Administration of 131I in 
LPEI-PEG-GE11/NIS-treated mice resulted in significantly reduced tumour growth compared to 
controls as determined by magnetic resonance imaging, though survival was not significantly prolonged. 
This study opens the exciting prospect of NIS-mediated radionuclide imaging and therapy of PDAC 
after systemic non-viral NIS gene delivery.   
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7.2 Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related 
mortality in developed countries despite its comparably low incidence of less than 3 %, clearly 
demonstrating the lack of effective therapeutic strategies. The five-year survival rate is around 7 % for 
all stages of the disease and drops to below 2 % and a median survival of less than a year for patients 
with metastatic disease, mostly due to late diagnosis at the stage of inoperability and the unusually high 
resistance of PDAC to conventional radiation- and chemotherapy [240, 241]. Despite intensive scientific 
and industrial efforts, so far no significant extension of survival could be achieved by any of the 
numerous therapy approaches tested [242].  
The genetic and morphological changes in the carcinogenesis of PDAC are well known and include the 
initiation and progression of premalignant lesions to invasive and metastatic pancreatic cancer [242-
245]. The genetic hallmark of PDAC development is an activating mutation in the KRAS oncogene, 
followed by other genetic changes, commonly including inactivation of the tumour suppressors TP53, 
CDKN2A (P16INK4A) and SMAD4, and activation of several growth factor receptors, such as the 
epidermal growth factor receptor (EGFR) [242, 246].  
Against this background, several complex genetically modified mouse models of PDAC that mirror the 
typical changes found in human patients, have been generated in recent years [242, 243, 247-249]. One 
such model is the Ptf1a+/Cre;Kras+/LSL-G12D;Trp53loxP/loxP (Kras;p53) mouse. Here, PDAC is induced by 
pancreas-specific activation of constitutively active KrasG12D in combination with conditional deletion 
of Trp53 [247]. To restrict these genetic modifications to the pancreas, mice with the mutated alleles are 
interbred with animals that express the Cre recombinase driven by the pancreas-specific promoter for 
Ptf1a, a subunit of pancreas transcription factor 1 (Ptf1) that is required to commit cells to a pancreatic 
fate during embryonic development [243, 250]. Thus, the activation of the oncogenic KrasG12D via 
excision of a transcriptionally inhibitory LSL (loxP-STOP-loxP) construct and deletion of the floxed 
tumour suppressor Trp53 occur in the pancreas only, leading to ductal lesions with complete penetrance 
[243, 251]. The development of endogenous mouse models away from the usual transplant models 
represents a significant step in the evolution of preclinical models [252]. The morphological and 
molecular composition of endogenous tumours far better reflects human disease, making them highly 
suitable to predict the clinical effectiveness of a specific treatment strategy. 
The sodium iodide symporter (NIS; SLC5A5) mediates the uptake of iodide into thyroid follicular cells 
allowing both diagnostic and therapeutic application of radioiodide in thyroid cancer patients [253, 254]. 
In our previous work, we have extensively investigated the dual reporter/therapy capacity of NIS in 
various non-thyroidal tumours and have proven the feasibility of extrathyroidal radioiodide therapy after 
tumour-selective NIS gene transfer [66, 70, 71, 77-79, 82, 83, 87, 99, 205]. Transfection of cancer cells 
with the NIS gene allows non-invasive monitoring of functional NIS expression and in vivo 
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biodistribution before the application of a therapeutic dose of radioiodide. One of the major hurdles of 
efficient and safe application of the NIS gene therapy concept in the clinical setting is optimal tumour-
specific targeting in the presence of low toxicity and high transfection efficiency of gene delivery 
vectors, with the ultimate goal of systemic vector application.  
In a previous study, we used synthetic polyplexes based on pseudodentritic oligoamines with high 
intrinsic tumour affinity for NIS gene therapy in a syngeneic neuroblastoma mouse model as well as a 
subcutaneous human hepatocellular carcinoma mouse model [82, 83]. After systemic NIS gene transfer, 
the tumour-selective accumulation of radioiodide was sufficient for a significant therapeutic effect. In 
addition to an intrinsic tumour affinity due to the so-called enhanced permeability and retention (EPR) 
effect based on ‘leaky’ tumour vasculature, the tumour targeting of polyplexes can be further optimised 
by the attachment of tumour-specific ligands. To this end, in a subsequent study, we used LPEI-PEG-
GE11 polymers composed of linear polyethylenimine (LPEI), shielded by polyethylene glycol (PEG) 
and coupled to the synthetic peptide GE11 as an EGFR-specific ligand for NIS gene delivery [87]. After 
systemic application of these polymers condensed with NIS DNA, tumour-specific radioiodide 
accumulation demonstrated effective and EGFR-specific tumour targeting in a high EGFR-expressing 
xenograft mouse model of hepatocellular carcinoma. After the injection of a therapeutic dose of 131I, 
tumoural iodide uptake was sufficiently high for a significant delay of tumour growth and prolongation 
of animal survival [87].  
Based on our previous work and the well-known characteristic upregulation of EGFR in PDAC, we 
investigated the potential of EGFR-targeted polyplexes for systemic NIS gene therapy in an advanced 
endogenous mouse model of PDAC as a next step towards clinical application.  
7.3 Materials and Methods 
Establishment of genetically modified mice 
Establishment of the Kras;p53 (Ptf1a+/Cre;Kras+/LSL-G12D;Trp53lox/loxP) and Kras;p53;Egfr 
(Ptf1a+/Cre;Kras+/LSL-G12D;Trp53loxP/loxP;Egfrfl/fl) strains has been described previously [243, 250, 251, 
255, 256]. Mouse strains were maintained on a mixed C57BL/6;129/Sv background. Animals were kept 
under specific pathogen-free conditions with access to mouse chow and water ad libitum. Both male and 
female mice at 5-7.5 weeks of age were used for experiments. The experimental protocol was approved 
by the regional governmental commission for animals (Regierung von Oberbayern, Munich, Germany).  
Preparation and culture of PDAC cell explants 
Cell explants from primary PDAC of Kras;p53 and Kras;p53;Egfr mice were isolated as described 
previously [257] and cultured in DMEM high glucose medium (Invitrogen, Karlsruhe, Germany) 
supplemented with 10% fetal bovine serum (v/v; PAA, Colbe, Germany), 100 U/mL penicillin/100 
µg/mL streptomycin (Invitrogen) and 1% non-essential amino acids (v/v; Invitrogen). Cells were 
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maintained at 37°C and 5% CO2 in an incubator with 95% humidity. Cell culture medium was replaced 
every second day and explants were passaged at 85% confluency.  
Plasmid and polymer synthesis and polyplex formation 
The human NIS-encoding plasmid and LPEI-based conjugates were cloned and synthesised, 
respectively, as described previously [87]. Plasmid DNA was condensed with polymers at indicated 
conjugate to plasmid (c/p) ratios (w/w) in HEPES-buffered glucose (HBG: 20 mmol/L HEPES, 5% 
glucose (w/v), pH 7.4) as described previously [216] and incubated at room temperature for 20 min 
before use. Final DNA concentrations were 2 μg/mL for in vitro studies and 200 μg/mL for in vivo 
studies.  
Transient transfection 
For in vitro transfection experiments, PDAC cell explants were grown to 60-80% confluency. Explants 
were incubated for 4 hours with polyplexes in the absence of serum and antibiotics followed by 
incubation with complete growth medium for 24 h. Either LPEI-PEG-GE11/NIS (EGFR-targeting of 
NIS due to the EGFR-specific ligand GE11), LPEI-PEG-Cys/NIS (no active targeting of NIS to EGFR, 
as the ligand GE11 is replaced by a cysteine residue), or LPEI-PEG-GE11 alone (polymer without NIS 
DNA) were added in c/p ratios as indicated. Transfection efficiency was evaluated by measurement of 
iodide uptake activity as described below. Transfections were done in triplicate for each separate 
explant.  
In vitro 125I uptake assay 
Following transfections, iodide uptake of PDAC cell explants was determined at steady-state conditions 
as described previously [169, 258]. Results were normalised to cell viability that was measured using 
the commercially available MTS-assay (Promega, Mannheim, Germany) as described previously [170]. 
Radioiodide uptake after systemic NIS gene transfer in vivo 
For the proof-of-principle of NIS-mediated tumour-specific radioiodide accumulation in vivo, 
polyplexes (LPEI-PEG-GE11/NIS, c/p 0.8) were applied via the tail vein (i.v.) at a DNA dose of 2.5 
mg/kg (50 μg DNA in 250 μL HBG). Mice received 18.5 MBq 123I (GE Healthcare, Braunschweig, 
Germany) intraperitoneally (i.p.) 24 h (n=9) or 48 h (n=7) after polyplex injection and radioiodide 
distribution was monitored by serial imaging on a gamma camera (Forte, ADAC Laboratories, Milpitas, 
CA, USA) equipped with a VXHR (ultra-high resolution) collimator as described previously [170]. 
Regions of interest were quantified and expressed as a fraction of the total amount of applied 
radionuclide per gram tumour tissue. The retention time within the tumour was determined by serial 
scanning after radioiodide injection. A subset of mice (n=2 for each time point) was pretreated i.p. with 
2 mg of the competitive NIS inhibitor sodium perchlorate (NaClO4; Sigma-Aldrich, Taufkirchen, 
Germany) 30 min before 123I administration. Dosimetric calculations for 131I were made using the 
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Medical Internal Radiation Dose (MIRD) technique and a RADAR dose factor (http://www.doseinfo-
radar.com).In order to achieve better discrimination between uptake in the tumour and the adjacent 
stomach, 24 or 48 h after i.v. injection of polyplexes (LPEI-PEG-GE11/NIS, each time point n=5; LPEI-
PEG-GE11/antisenseNIS, each time point n=1) mice received 10 MBq 124I (Perkin Elmer, Waltham, 
MA, USA) i.p. and radioiodide biodistribution was monitored by static acquisition 3 h post injection 
using a micro PET system (Inveon, Siemens Preclinical Solutions, Erlangen, Germany). Mean tumoural 
radioiodide uptake was calculated in MBq/mL by manually placing 3D regions of interest in the tumour. 
Analysis of NIS mRNA expression by quantitative real-time PCR (qPCR) 
Total RNA was isolated from PDAC or non-target tissues (liver, lung) using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s recommendations. Single-stranded oligo 
(dT)-primer cDNA was generated using Super Script III Reverse Transcriptase (Invitrogen). qPCR was 
performed with the cDNA from 1 μg RNA using SYBR Green PCR master mix (Qiagen) in a Rotor 
Gene 6000 (Corbett Research, Morthlake, New South Wales, Australia). The following primers were 
used: NIS, forward 5′-ACACCTTCTGGACCTTCGTG-3′, reverse 5′-
GTCGCAGTCGGTGTAGAACA-3′ and GAPDH, forward 5′-GAGAAGGCTGGGGCTCATTT-3′, 
reverse 5′-CAGTGGGGACACGGAAGG-3′. Relative expression levels were calculated using the 
comparative ΔΔCt method and internal GAPDH for normalization. 
Analysis of tissue sections 
Immunohistochemical and immunofluorescence staining of NIS was performed using a mouse 
monoclonal antibody directed against human NIS (kindly provided by John C Morris, Mayo Clinic, 
Rochester, MN, USA) as described previously [66, 215].  
Radioiodide therapy 
Starting when mice were around 30 d of age, tumour sizes were assessed weekly by high resolution 
magnetic resonance imaging (MRI) on a 3T clinical scanner (Philips Ingenia 3.0T; Royal Philips 
Electronics, Eindhoven, The Netherlands). Once tumours reached the inclusion size of 200-450 mm3, 
therapy trials were started. To this end, 48 h after systemic administration of LPEI-PEG-GE11/NIS or, 
as control, LPEI-PEG-GE11/antisenseNIS, a therapeutic dose of 55.5 MBq 131I (GE Healthcare) was 
administered i.p. (LPEI-PEG-GE11/NIS + 131I n=6; LPEI-PEG-GE11/antisenseNIS + 131I n=3). A 
second control group received saline only (n=4). The cycle consisting of systemic NIS gene transfer 
followed by radioiodide was repeated for a total of three times on days 0/2, 4/6 and 7/9. Mice from all 
groups were sacrificed when at least one endpoint criterion was reached. Endpoint criteria included a 
tumour volume >1000 mm3, a body weight loss >15%, as well as a number of general physical, clinical 
and behavioural criteria. Body condition was monitored by independent animal care personnel blind to 
treatment and hypothesis. 
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Statistics 
Results are reported as mean ± S.E.M., mean-fold change ± S.E.M. or, for survival plots, percent. 
Statistical significance was generally tested by two-tailed Student’s t-test except for the therapy study. 
For tumour volumes, one-way ANOVA was performed, followed by Tukey’s Honestly Significant 
Difference test. Statistical significance of Kaplan-Meier plots was analysed by log-rank test. p-values 
<0.05 were considered statistically significant (*p<0.05; **p<0.01; ***p<0.001; n/s not significant). 
7.4 Results 
Iodide uptake studies in vitro 
In order to optimise transfection conditions for LPEI-PEG-GE11 polymers condensed with the NIS 
plasmid (LPEI-PEG-GE11/NIS) in high EGFR-expressing PDAC cell explants derived from Kras;p53 
mice (Fig. 28A), radioiodide uptake activity was evaluated 24 h after polyplex application (data not 
shown). A c/p ratio of 0.8 resulted in highest transfection efficiency at lowest cytotoxicity. Therefore, 
this c/p ratio was used in all subsequent experiments. Twenty-four hours after transfection with LPEI-
PEG-GE11/NIS, cell explants from three different mice showed a 22-26-fold increase in 125I 
accumulation as compared to cells incubated with the empty control vector LPEI-PEG-GE11 (Fig. 28B). 
Transfection with untargeted LPEI-PEG-Cys/NIS (targeting ligand GE11 replaced by a cysteine 
residue) resulted in significantly lower iodide uptake activity compared to EGFR-targeted LPEI-PEG-
GE11/NIS (Fig. 28B). In both cases, iodide uptake was blocked upon additional treatment with the NIS-
specific inhibitor perchlorate. 
 
 
Figure 28. Iodide uptake in PDAC cell explants in vitro.  Kras;p53 mice develop PDAC that occupies a 
large portion of the abdominal cavity below the stomach (A). (B) PDAC cell explants from three separate 
mice (three technical replicates per mouse) transfected in vitro with LPEI-PEG-GE11/NIS showed a 
significant increase in perchlorate- (ClO4--) sensitive 125I accumulation compared to transfection with LPEI-
PEG-Cys/NIS (mean ± S.E.M.; *p<0.05; **p<0.01; ***p<0.001). No iodide uptake above background levels 
was observed in cells transfected with LPEI-PEG-GE11 alone. (C) Transfection of EGFR-ablated PDAC 
cell explants from two mice (three technical replicates per mouse) with LPEI-PEG-GE11/NIS and LPEI-
PEG-Cys/NIS showed no significant differences between transfection with targeted or untargeted 
polyplexes, demonstrating EGFR-specificity of the targeting ligand GE11 (mean ± S.E.M.). 
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To further verify EGFR-specificity of the targeting ligand GE11, we performed additional iodide uptake 
studies in EGFR-ablated PDAC cell explants from Kras;p53;Egfr mice. No significant difference 
between transfection with targeted LPEI-PEG-GE11/NIS or untargeted LPEI-PEG-Cys/NIS polyplexes 
was observed (Fig. 28C). Polyplex-mediated NIS gene transfer did not affect cell viability for any of the 
treatment conditions compared to untreated cells as measured by MTS assay (data not shown).  
123I scintigraphy and 124I PET imaging of EGFR-targeted NIS gene delivery 
Functional NIS expression in mice with high EGFR-expressing PDAC was imaged by whole body 123I 
gamma camera and 124I PET imaging. Polyplexes were administered i.v. either 24 or 48 h before 
injection of the respective radionuclide for imaging. 
 
In vivo 123I gamma camera imaging revealed high levels of NIS-mediated radionuclide accumulation in 
pancreatic tumours both at 24 and 48 h after systemic injection of EGFR-targeted LPEI-PEG-GE11/NIS 
(Fig. 29A, B). Tumours accumulated 10.8 ± 0.7 % of the injected dose per gram (ID/g) with an average 
 
Figure 29. In vivo imaging of NIS-mediated iodide uptake. 123I scintigraphy revealed pancreatic tumoural 
radioiodide uptake 24 h (A) and 48 h (B) after injection of mice with LPEI-PEG-GE11/NIS that was not seen 
after injection with non-coding LPEI-PEG-GE11/antisenseNIS (C). Iodide uptake was perchlorate-sensitive 
(D) and therefore indeed NIS-mediated. (E) Radionuclide retention time in tumours was determined by serial 
scanning over 10 h (mean ± S.E.M.; 24 h: n=9, 48 h: n=7). 124I PET-imaging confirmed findings of 
scintigraphy and allowed better differentiation between tumoural and stomach radioiodide uptake (F, H). 
After injection of the control vector LPEI-PEG-GE11/antisenseNIS (G, I), no pancreatic iodide uptake 
activity above background levels could be detected. Significantly higher radioiodide accumulation 48 h after 
gene transfer as compared to 24 h was confirmed by PET (mean ± S.E.M.; n=5 each; *p<0.05) (J). SG: 
salivary glands. 
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biological half-life of 4 h at 24 h and 14.2 ± 1.4 % ID/g with an average biological half-life of 4.5 h at 
48 h (Fig. 29E). For 131I, a tumour-absorbed dose of 74.7 mGy/MBq/g tumour with an effective half-
life of 3.2 h (24 h after polyplex administration) and 96.5 mGy/MBq/g tumour, effective half-life 4.5 h 
(48 h after polyplex administration), was calculated. In contrast, injection of non-coding control 
polyplexes LPEI-PEG-GE11/antisenseNIS (NIS sequence back to front) resulted in no significant 
tumoural radioiodide accumulation (Fig. 29C). In addition to 123I uptake in the tumour, radioiodide 
accumulation was also observed in the stomach, the thyroid and the salivary glands, as they 
physiologically express NIS, as well as in the urinary bladder due to renal radionuclide elimination (Fig. 
29A-C). To further confirm that tumoural iodide uptake was indeed NIS-mediated, LPEI-PEG-
GE11/NIS-injected mice were additionally treated with the competitive NIS-inhibitor perchlorate 30 
min before 123I administration, which completely blocked polyplex-mediated tumoural iodide 
accumulation in addition to physiological uptake in the stomach, the thyroid gland and the salivary 
glands (Fig. 29D). 
To better distinguish tumoural uptake from iodide accumulation in the stomach, we additionally 
employed three-dimensional high-resolution 124I PET to image radioiodide biodistribution. Again, 
systemic injection of LPEI-PEG-GE11/NIS resulted in strong transfection of tumour tissue at both time 
points (Fig. 29F, H), an effect that was not seen in mice treated with LPEI-PEG-GE11/antisenseNIS 
(Fig. 29G, I). Quantification of tumoural 124I uptake again revealed significantly higher radioiodide 
accumulation 48 h after i.v. injection of LPEI-PEG-GE11/NIS as compared to 24 h after NIS gene 
transfer (Fig. 29J). 
Ex vivo analysis of NIS expression in PDAC 
48 h after polyplex administration, mice were sacrificed and dissected. Tumours and non-target organs 
(liver, lung) were analysed for NIS mRNA expression by qPCR. A 20-fold increase in NIS mRNA 
expression was detected in PDAC lesions from mice injected with LPEI-PEG-GE11/NIS as compared 
to untreated tumours (Fig. 30A). In contrast, no significant NIS mRNA expression above background 
levels was observed in non-target organs and tumours of mice treated with the control vector LPEI-
PEG-GE11/antisenseNIS (Fig. 30A). In tumours from LPEI-PEG-GE11/NIS-treated mice, areas of 
NIS-specific immunoreactivity were observed surrounding ductal lesions by immunohistochemical and 
immunofluorescence staining using a human NIS-specific antibody (Fig. 30B). NIS staining was found 
to be both cell membrane-associated and cytoplasmic. In contrast, tumours from mice treated with the 
control vector LPEI-PEG-GE11/antisenseNIS showed no NIS-specific immunoreactivity (Fig. 30B).  
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NIS-mediated 131I therapy of PDAC 
PDAC-bearing mice were treated with three cycles of LPEI-PEG-GE11/NIS followed by 131I 48 h later 
– the optimal time point for radionuclide injection based on the imaging studies. Controls were injected 
with non-coding LPEI-PEG-GE11/antisenseNIS and 131I or saline only. Tumour progression was 
monitored by MRI. Mice in the therapy group showed a significant stabilization of tumour growth and, 
in two cases, even a reduction in tumour volume (Fig. 31A, D), while aggressive tumour growth was 
observed in both control groups (Fig. 31B-D). This led to an enhanced survival in the therapy group that 
lived up to 28 days post therapy start with a median survival of 25 days, as compared to the antisenseNIS 
group that survived up to 13 days with a median survival of 11 days and saline controls that lived up to 
21 days, median survival 21 days (Fig. 31E). The effect on mouse survival was, however, not significant. 
 
Figure 30. Analysis of NIS mRNA and protein distribution ex vivo. NIS-specific qPCR analysis revealed 
a 20-fold increase of NIS mRNA expression in pancreatic tumours of mice injected with LPEI-PEG-
GE11/NIS as compared to tumours of untreated mice. In contrast, NIS mRNA was not increased in non-
target organs and in tumours of mice injected with the control vector LPEI-PEG-GE11/antisenseNIS (mean-
fold change ± S.E.M.; ***p<0.001) (A). Both immunohistochemical (B, upper three panels; magnification: 
10×, 20× and 40×) and immunofluorescence staining (B, bottom panel; magnification: 200×) of sections of 
pancreatic tumours revealed areas of NIS-specific immunoreactivity after systemic application of LPEI-
PEG-GE11/NIS. In contrast, tumours treated with the control vector LPEI-PEG-GE11/antisenseNIS showed 
no NIS-specific immunoreactivity. 
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7.5 Discussion 
While the incidence of PDAC is gradually increasing, the prognosis of patients with pancreatic cancer 
has not significantly changed over the last 20 years – despite numerous advances in diagnostic imaging, 
surgical techniques and chemotherapeutic strategies [242, 259]. Intensified chemotherapy protocols in 
patients with advanced pancreatic cancer show a significant, yet still unsatisfactory survival benefit 
[260]. So far, no targeted agent or approach has changed this fatal course of the disease, even though 
preclinical trials in in vitro cell culture systems and in vivo xenograft models had shown promising 
results [242, 260]. These set-backs can mainly be attributed to the complexity of the disease. The 
homogeneous molecular equipment, simple stromal architecture and immune deficiency of xenograft 
models limits their transferability to the clinical setting. Endogenously grown tumours, in contrast, are 
genetically and morphologically heterogeneous, less vascularised and harbour a far more complex 
microenvironment with high immunosuppression and extensive desmoplasia [261, 262]. Genetically 
engineered mouse models that closely reflect the key aspects of pancreatic carcinogenesis have been 
 
Figure 31. Therapeutic application of 131I after NIS gene transfer in vivo. Kras;p53 mice were treated 
with three cycles of i.v. injection of polyplexes on days 0/4/7 followed by i.p. injection of 55.5 MBq 131I 48 
h later, on days 2/6/9. Tumour sizes were monitored weekly by MRI. Exemplary MRI images of endpoint 
tumour sizes from an LPEI-PEG-GE11/NIS + 131I- (A), an LPEI-PEG-GE11/antisenseNIS + 131I- (B) and a 
NaCl + NaCl-treated Kras;p53 mouse are shown (C). Tumours are highlighted by red dotted lines. (D) Mice 
treated with LPEI-PEG-GE11/NIS + 131I (n=6) showed a stabilization in tumour volume compared to control 
groups LPEI-PEG-GE11/antisenseNIS + 131I (n=3; mean ± S.E.M.; *p<0.05) and NaCl + NaCl (n=4; 
**p<0.01). Mean tumour volumes (solid lines) and volumes for individual mice (dotted lines) are shown. 
(E) Injection of LPEI-PEG-GE11/NIS + 131I led to an increased overall and median survival in the therapy 
group (n=6) compared to control groups injected with LPEI-PEG-GE11/antisenseNIS + 131I (n=3; n/s) or 
NaCl + NaCl (n=4; n/s). 
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shown to correlate well with data from clinical trials and provide an exciting new platform to predict 
human tumour responses to treatment [252].  
After the proof-of-principle of our polyplex-mediated NIS gene therapy concept in different 
subcutaneous xenograft tumour models [82, 83, 87], the genetically engineered mouse model of PDAC 
used in this study provides an important step towards further development towards clinical application. 
Based on the known activity of EGFR in PDAC and this model, we chose EGFR-targeted LPEI-PEG-
GE11 polymers as delivery vehicles for the NIS gene [87, 263, 264]. 
Transfection of PDAC explant cell cultures with LPEI-PEG-GE11/NIS led to significant perchlorate-
sensitive and therefore NIS-mediated radioiodide accumulation. The empty vector LPEI-PEG-GE11 did 
not result in iodide accumulation above background levels, further confirming NIS-dependency of 
radioiodide accumulation. Iodide uptake was significantly reduced after transfection with non-targeted 
LPEI-PEG-Cys/NIS, demonstrating improved transfection efficiency using the targeting ligand GE11. 
EGFR-specificity of targeting was further substantiated by the observation that in EGFR-negative 
cultures derived from Kras;p53;Egfr mice, no significant difference between transfection with EGFR-
targeted or non-targeted vectors was observed. Translating these promising in vitro results to systemic 
vector application in vivo, intravenous administration of LPEI-PEG-GE11/NIS resulted in a significant 
perchlorate-sensitive tumour-specific iodide uptake in mice harbouring endogenous PDAC tumours, as 
demonstrated by 123I gamma camera imaging. Three-dimensional 124I PET imaging with increased 
sensitivity and resolution was employed for more accurate quantification of tumoural radioiodide 
uptake, as radionuclide signals from pancreatic lesions partially overlap with stomach signals based on 
physiological gastric NIS expression. Results from PET imaging confirmed gamma camera imaging 
results with strong radioiodide signals in pancreatic tumours. Control experiments with LPEI-PEG-
GE11/antisenseNIS showed no significant tumoural radioiodide accumulation above background levels, 
confirming NIS-specificity of tumoural tracer uptake. These molecular imaging data were further 
corroborated by NIS-specific immunohistochemistry and immunofluorescence as well as qPCR 
analysis.  
Both the abundance and the permeability of the tumour’s vasculature are crucial for sufficient transgene 
delivery into the tumour [265, 266]. One of the main factors thought to hamper efficient drug delivery 
to PDAC, is its highly desmoplastic stroma alongside its high interstitial pressure and poor 
vascularization [267]. Thus, the enhanced permeability and retention effect that is caused by the 
irregular, ‘leaky’ tumour vasculature and is usually exploited for passive targeting of therapeutic agents 
to tumour sites, is limited in PDAC [266, 268]. For this reason, an additional tumour-targeting strategy 
is particularly important. Our imaging data convincingly demonstrate that targeting our polyplexes to 
EGFR allows strong transfection of pancreatic tumours with NIS. In a previous study, using the same 
vector construct in a subcutaneous hepatocellular carcinoma xenograft model, a tumour-absorbed dose 
of 47 mGy/MBq/g was calculated for 131I 24 h after polyplex administration [87], while in the current 
study, a dose of 74.7 mGy/MBq/g tumour 24 h post polyplex injection was achieved. We mainly 
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attribute this significantly enhanced tumoural radioiodide uptake to the very high EGFR expression in 
PDAC. NIS staining was restricted to areas of high EGFR expression surrounding ductal lesions [246]. 
This focal pattern of transgene expression further underlines the advantage of NIS as therapy gene in 
this setting, as the high radionuclide bystander effect allows destruction of tumour cells beyond 
transfected cells. 
Building on these promising results, the next logical step was to evaluate the therapeutic effectiveness 
of 131I in the PDAC mouse model after LPEI-PEG-GE11-mediated systemic NIS gene delivery. We were 
able to demonstrate stabilization, and, in two cases, even a pronounced reduction, of tumour growth 
after application of three cycles of LPEI-PEG-GE11/NIS followed by 131I. Mouse survival was 
prolonged in the therapy group, especially compared to the non-coding LPEI-PEG-GE11/antisenseNIS-
treated control group, although without reaching statistical significance, despite the strong effects on 
tumour growth. Interestingly, while animals in the saline group had to be sacrificed due to compromised 
well-being owing to excessive tumour growth, the non-coding control group showed signs of ill health 
at much lower tumour volumes and had to be sacrificed. Similarly, effects on animal health were 
observed in the therapy group, though to a lower extent. We attribute this observation to toxicity of the 
LPEI-based conjugates, possibly combined with effects from 131I. Due to the stabilization of tumour 
growth in therapy animals, they fared better than the non-coding control group that was potentially 
affected by side effects from polyplex and radioiodide injection in addition to rapid tumour growth. To 
date, the use of LPEI-based polymers did not affect animal health in any of our previous studies, nor 
was viability of PDAC cell explants affected in the current study. LPEI has been shown to exhibit certain 
cytotoxic effects both in vitro and in vivo [269-273], though LPEI-based polyplexes have already been 
tested in a clinical trial for bladder cancer therapy and no adverse effects were reported [274]. Similarly, 
we have so far only encountered side effects from 131I in one previous study with the objective to 
radioablate mouse thyroids under intentional stimulation of thyroidal radioiodide uptake [143]. 
Symptoms developed with a delay of seven days after radioiodide application, while in the current study, 
animal health deteriorated from the beginning of treatment [143]. However, our earlier work was done 
in subcutaneous xenograft models, where tumour growth per se has no impact on animal health. In 
contrast, Kras;p53 mice with their extremely aggressive pancreatic tumour growth and subsequent rapid 
health deterioration, seem to react more unfavourably to the polyplexes and/or radioiodide treatment. 
LPEI is seen as the ‘gold standard’ for non-viral DNA delivery, as it shows such high transfection 
efficiency and flexibility at relatively low toxicity, compared to other viral and non-viral gene delivery 
approaches. To further refine our approach and solve the toxicity issue, we are currently developing 
sequence-defined polymers with higher biocompatibility for targeted NIS gene delivery [205].  
In conclusion, our data clearly show the high potential of EGFR-targeted nanoparticle vectors to target 
the NIS gene to PDAC. After systemic application of LPEI-PEG-GE11/NIS, we were able to reach 
sufficient iodide concentrations at the tumour site to (1) produce a strong enough signal to image 
pancreatic tumours in situ and (2) provoke a therapeutic effect. Based on its role as potent and well 
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characterised reporter gene, NIS allows non-invasive imaging and detailed characterization of in vivo 
biodistribution of functional NIS expression as an essential prerequisite for exact planning and 
monitoring of clinical gene therapy trials with the aim of individualization of the NIS gene therapy 
concept in the clinical setting. 
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VIII. SUMMARY 
While a great amount of attention is being given to the fight against cancer and considerable advances 
have been made, many cancers remain deadly diseases. Understanding tumour biology is fundamental 
to disease management and the development of effective therapeutic strategies. The work presented in 
this thesis touches on both tumour biology, specifically on thyroid hormone effects on tumours and 
tumour-associated mesenchymal stem cells (MSCs), and on the development of treatment strategies, 
specifically on the evaluation of non-viral tumour-targeted gene delivery vehicles for systemic sodium 
iodide symporter (NIS) gene therapy.  
Initially, an effective protocol for radioiodide ablation of the mouse thyroid gland was established, thus 
generating a hypothyroid in vivo model that is tailored to the use of NIS as reporter gene, in which 
interference from both endogenous thyroid hormones and thyroidal NIS are avoided. 
Subsequently, thyroid hormone effects on MSCs in the tumour milieu were investigated. Non-classical 
thyroid hormone signalling via cell surface receptor integrin αvβ3 has been shown to drive tumour cell 
proliferation and survival, as well as angiogenesis and inflammation. This phenomenon is of course 
undesirable in cancer patients and, indeed, over the past century, several clinical and experimental 
studies have implicated thyroid hormones in cancer progression. Integrin αvβ3 is abundantly expressed 
on most cancer cells and the growing endothelium associated with tumours, but also on MSCs. These 
multipotent progenitor cells actively home to growing tumours where they differentiate into carcinoma-
associated fibroblast (CAF)-like cells and blood vessel-stabilising pericytes, and thus support the 
tumour’s fibrovascular network. Integrin αvβ3 expression on MSCs makes them susceptible to thyroid 
hormone stimulation. Indeed, the work presented here demonstrates that thyroid hormones stimulate the 
differentiation of MSCs towards a CAF-/pericyte-like and hypoxia-responsive, pro-angiogenic 
phenotype, characterised by the secretion of numerous paracrine pro-angiogenic factors, in addition to 
driving their migration, invasion, and recruitment to the tumour microenvironment in an experimental 
hepatocellular carcinoma model in vitro and in vivo. The deaminated thyroid hormone metabolite tetrac, 
a specific inhibitor of thyroid hormone action at the integrin site, reverses these effects. The modulation 
of MSC signalling and recruitment by thyroid hormones via integrin αvβ3 adds a further layer to the 
multifaceted effects of thyroid hormones on tumour progression, and suggests a novel mechanism for 
the anti-tumour activity of tetrac. In addition, modulation of MSC recruitment is of clinical interest in 
tissue regeneration and in the field of cancer gene therapy, where MSCs are being used as Trojan horses 
to deliver therapeutic payloads, including the NIS gene, into tumours. 
To assess the relevance of integrin αvβ3 expression on the cancer cells themselves as opposed to effects 
on angiogenesis and the tumour stroma in general, we compared the effects of thyroid hormones versus 
tetrac in two murine xenograft tumour models with and without integrin αvβ3 expression. Tumour 
growth was significantly increased in hyperthyroid mice and significantly decreased in hypothyroid and 
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tetrac-treated euthyroid mice, resulting in either a reduced or prolonged survival, respectively, compared 
to euthyroid mice in αvβ3-positive human anaplastic thyroid cancer xenografts. Both proliferation and 
vascularisation were significantly increased in tumours from hyperthyroid mice as compared to 
hypothyroid and tetrac-treated mice. No differences in tumour growth, survival, or proliferation were 
observed between the different thyroid hormone states in mice bearing αvβ3-negative hepatocellular 
carcinoma xenografts. The blood vessel density, however, was significantly decreased in hypothyroid 
and tetrac-treated mice compared to both euthyroid and hyperthyroid mice in this model.  
The modulation of MSC recruitment, differentiation, and angiogenic signalling, in addition to the 
regulation of tumour growth in αvβ3-positive tumours by thyroid hormones via integrin αvβ3 have 
important implications for the management of cancer patients, especially for those with thyroid 
dysfunction and thyroid cancer patients treated with thyroid-stimulating hormone-suppressive L-
thyroxine doses. 
Addressing the second topic of the thesis, selective transfer of the theranostic NIS gene into tumour cells 
allows systemic application of radionuclides for non-invasive imaging as well as therapy. For clinical 
development of the NIS gene therapy approach, tumour targeting needs to be highly specific and efficient 
at low toxicity, and requires systemic application for the treatment of metastatic disease. To investigate 
the potential of targeting the epidermal growth factor receptor (EGFR), which is highly expressed on 
many cancer cells, for systemic non-viral NIS gene transfer, the well-established cationic polymer linear 
polyethylenimine (LPEI) was shielded with polyethylene glycol (PEG) and coupled to the EGFR-
specific peptide ligand GE11. Two different tumour models were used, specifically anaplastic thyroid 
carcinoma xenografts that have lost the ability to express NIS in the process of dedifferentiation, and, 
as a further step towards clinical application, an advanced genetically engineered mouse model of 
pancreatic ductal adenocarcinoma (PDAC) that closely mirrors human disease. In both models, high 
NIS- and EGFR-specific iodide uptake was achieved in vitro and in vivo. This resulted in a significant 
delay in tumour growth in both models in subsequent 131I therapy studies that was accompanied by a 
significantly prolonged survival in the anaplastic thyroid carcinoma model. The work reported here was 
the first study to demonstrate successful re-instatement of NIS-mediated radioiodide uptake in anaplastic 
thyroid carcinoma after systemic application of NIS as a theranostic gene. Further, the successful 
targeting and tumour growth reduction in PDAC proves the applicability of this approach in a highly 
complex model that closely emulates human PDAC. Taken together, these data in two highly aggressive 
tumour entities clearly demonstrate the great potential of EGFR-targeted nanoparticle vectors to 
selectively deliver NIS to EGFR-expressing tumours after systemic application, an important 
prerequisite for the treatment of metastatic disease by NIS gene therapy.  
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16. Schmohl KA, Müller AM, Nelson PJ, Spitzweg C. Thyroid hormone effects on mesenchymal stem 
cell biology in the tumour microenvironment. Exp Clin Endocrinol Diabetes 2019 [Epub ahead of 
print]. 
17. Schmohl KA, Nelson PJ, Spitzweg C. Tetrac as an anti-angiogenic agent in cancer. Endocr Relat 
Cancer 2019;26:R287-304. 
9.3 Oral Presentations 
2019 
03/2019 62. Deutscher Kongress für Endokrinologie, Göttingen, Germany 
Schmohl KA, Schwenk N, Bartenstein P, Nelson PJ, Spitzweg C. Non-genomic effects 
of thyroid hormones on mesenchymal stem cells in tumour angiogenesis 
02/2019 18th Retreat of the Dept. of Medicine IV, LMU Munich, Frauenchiemsee, Germany 
Schmohl KA, Müller AM, Dohmann M, Spellerberg R, Urnauer S, Schwenk N, Ziegler 
SI, Nelson PJ, Spitzweg C. Non-genomic effects of thyroid hormones on mesenchymal 
stem cells in tumour angiogenesis 
2018 
10/2018 88th Annual Meeting of the American Thyroid Association, Washington DC, USA 
Schmohl KA, Urnauer S, Schwenk N, Bartenstein P, Nelson PJ, Spitzweg C. Non-
genomic effects of thyroid hormones on mesenchymal stem cells in tumour 
angiogenesis (highlighted oral presentation) 
09/2018 41st Annual Meeting of the European Thyroid Association, Newcastle, UK 
Schmohl KA, Urnauer S, Schwenk N, Bartenstein P, Nelson PJ, Spitzweg C. Non-
genomic effects of thyroid hormones on mesenchymal stem cells in tumour 
angiogenesis 
06/2018 6th Annual Meeting of the Priority Programme Thyroid Trans Act, Berlin, Germany 
Schmohl KA, Nelson PJ, Spitzweg C. Plasma membrane-mediated non-genomic 
effects of T4, T3 and thyroid hormone metabolite tetrac on different aspects of 
mesenchymal stem cell biology and their signalling pathways 
05/2018 20th European Congress of Endocrinology, Barcelona, Spain  
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Schmohl KA (invited speaker). Tetrac as an antiangiogenic agent in cancer 
2017 
10/2017 87th Annual Meeting of the American Thyroid Association, Victoria, BC, Canada 
Schmohl KA, Dohmann M, Wechselberger A, Nelson PJ, Spitzweg C. Non-genomic 
effects of thyroid hormones on mesenchymal stem cells and angiogenesis 
09/2017 40th Annual Meeting of the European Thyroid Association, Belgrade, Serbia 
Schmohl KA, Dohmann M, Wechselberger A, Nelson PJ, Spitzweg C. Non-genomic 
effects of thyroid hormones on mesenchymal stem cells and angiogenesis 
06/2017 5th Annual Meeting of the Priority Programme Thyroid Trans Act, Bremen, Germany 
Schmohl KA, Nelson PJ, Spitzweg C. Plasma membrane-mediated non-genomic 
effects of T4, T3 and thyroid hormone metabolite tetrac on different aspects of 
mesenchymal stem cell biology and their signalling pathways 
05/2017 Aktuelles zum Thema Schilddrüse – Update 2017, Munich, Germany 
Schmohl KA. Beeinflussen Schilddrüsenhormone das Tumorwachstum? – from Bench 
to Bedside (Do thyroid hormones influence tumour growth? – from bench to bedside) 
03/2017 60. Deutscher Kongress für Endokrinologie, Würzburg, Germany 
Schmohl KA, Dohmann M, Wechselberger A, Nelson PJ, Spitzweg C. Non-genomic 
effects of thyroid hormones on mesenchymal stem cells and angiogenesis 
02/2017 17th Retreat of the Dept. of Medicine IV, LMU Munich, Frauenchiemsee, Germany 
Schmohl KA, Müller AM, Wechselberger A, Rühland S, Dohmann M, Schwenk N, 
Nelson PJ, Spitzweg C. Thyroid hormones and tetrac – new regulators of tumour stroma 
formation via integrin αvβ3 
2016 
06/2016 4th Annual Meeting of the Priority Programme Thyroid Trans Act, Essen, Germany 
Schmohl KA, Müller AM, Wechselberger A, Nelson PJ, Spitzweg C. Plasma 
membrane-mediated non-genomic effects of T4, T3 and thyroid hormone metabolite 
tetrac on different aspects of mesenchymal stem cell biology and their signalling 
pathways 
05/2016 18th European Congress of Endocrinology, Munich, Germany 
Schmohl KA, Dohmann M, Wechselberger A, Nelson PJ, Spitzweg C. Non-genomic 
effects of thyroid hormones on endothelial cell tube formation 
Publications 
104 
 
2015 
11/2015 Retreat of the Dept. of Medicine II, LMU Munich, Munich, Germany 
Schmohl KA, Müller AM, Wechselberger A, Rühland S, Salb N, Dohmann M, 
Schwenk N, Nelson PJ, Spitzweg C. Thyroid hormones and tetrac – new regulators of 
tumour stroma formation via integrin αvβ3 
04/2015 3rd Annual Meeting of the Priority Programme Thyroid Trans Act, Berlin, Germany 
Schmohl KA, Müller AM, Wechselberger A, Nelson PJ, Spitzweg C. Plasma 
membrane-mediated non-genomic effects of T4, T3 and thyroid hormone metabolite 
tetrac on the tumour microenvironment 
2014 
12/2014 30. Arbeitstagung Experimentelle Schilddrüsenforschung (AESF), Bremen, Germany 
Schmohl KA, Müller AM, Salb N, Rühland S, Wechselberger A, Schwenk N, Nelson 
PJ, Spitzweg C. Analysis of the effects of T3, T4 and tetrac on mesenchymal stem cell 
biology 
06/2014 96th Annual Meeting of the Endocrine Society, Chicago, IL, USA 
Schmohl KA, Müller AM, Salb N, Knoop K, Wechselberger A, Schwenk N, Nelson 
PJ, Spitzweg C. Effects of thyroid hormones T3 and T4 on mesenchymal stem cell 
biology 
04/2014 2nd Annual Meeting of the Priority Programme Thyroid Trans Act, Essen, Germany 
Schmohl KA & Müller AM. Regulation of the tumour microenvironment by thyroid 
hormones 
9.4 Poster Presentations 
2019 
10/2019 89th Annual Meeting of the American Thyroid Association, Chicago, IL, USA 
Schmohl KA, Han Y, Tutter M, Schwenk N, Nelson PJ, Spitzweg C. Stimulation of 
tumour growth by thyroid hormone depends on integrin αvβ3 expression 
2018 
10/2018 88th Annual Meeting of the American Thyroid Association, Washington DC, USA 
Schmohl KA, Kitzberger C, Kälin RE, Glaß R, Nelson PJ, Spitzweg C. Mesenchymal 
stem cell-mediated sodium iodide symporter (NIS) reporter gene delivery in an 
orthotopic glioblastoma mouse model 
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2018 Annual Trainee Poster Contest winner, best basic research poster 
05/2018 20th European Congress of Endocrinology, Barcelona, Spain 
Schmohl KA, Dohmann M, Schwenk N, Bartenstein P, Nelson PJ, Spitzweg C. Non-
genomic effects of thyroid hormones on mesenchymal stem cells in tumour 
angiogenesis 
03/2018 100th Annual Meeting of the Endocrine Society, Chicago, IL, USA 
Schmohl KA, Urnauer S, Schwenk N, Bartenstein P, Nelson PJ, Spitzweg C. Non-
genomic effects of thyroid hormones on mesenchymal stem cells in tumour 
angiogenesis 
2017 
04/2017 99th Annual Meeting of the Endocrine Society, Orlando, FL, USA 
Schmohl KA, Dohmann M, Wechselberger A, Nelson PJ, Spitzweg C. Non-genomic 
effects of thyroid hormones on endothelial cell tube formation 
2016 
09/2016 86th Annual Meeting of the American Thyroid Association, Denver, CO, USA 
Schmohl KA, Grünwald GK, Gupta A, Trajkovic-Arsic M, Klutz K, Schwenk N, 
Braren R, Senekowitsch-Schmidtke R, Schwaiger M, Wagner E, Ogris M, Siveke J, 
Spitzweg C. Systemic epidermal growth factor receptor-targeted sodium iodide 
symporter (NIS) gene delivery in a genetically engineered mouse model of pancreatic 
ductal adenocarcinoma 
09/2016 86th Annual Meeting of the American Thyroid Association, Denver, CO, USA 
Schmohl KA, Dohmann M, Wechselberger A, Nelson PJ, Spitzweg C. Non-genomic 
effects of thyroid hormones on endothelial cell tube formation 
05/2016 DACH-Tagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften 
für Endokrinologie 2016, Munich, Germany 
Schmohl KA, Dohmann M, Wechselberger A, Nelson PJ, Spitzweg C. Non-genomic 
effects of thyroid hormones on endothelial cell tube formation 
04/2016 98th Annual Meeting of the Endocrine Society, Boston, MA, USA 
Schmohl KA, Dohmann M, Wechselberger A, Nelson PJ, Spitzweg C. Non-genomic 
effects of thyroid hormones on endothelial cell tube formation 
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2015 
10/2015 15th International Thyroid Congress (ITC), Orlando, FL, USA 
Schmohl KA, Dohmann M, Wechselberger A, Nelson PJ, Spitzweg C. Non-genomic 
effects of thyroid hormones on endothelial cell tube formation 
03/2015 58. Symposium der Deutschen Gesellschaft für Endokrinologie, Lübeck, Germany 
Schmohl KA, Müller AM, Salb N, Rühland S, Wechselberger A, Schwenk N, Nelson 
PJ, Spitzweg C. Analysis of the effects of T3, T4 and tetrac on mesenchymal stem cell 
biology 
2014 
12/2014 1st International Conference of Thyroid Trans Act (TTA IC), Bremen, Germany 
Schmohl KA, Müller AM, Salb N, Rühland S, Wechselberger A, Schwenk N, Nelson 
PJ, Spitzweg C. Analysis of the effects of T3, T4 and tetrac on mesenchymal stem cell 
biology 
10/2014 84th Annual Meeting of the American Thyroid Association, Coronado, CA, USA 
Schmohl KA, Müller AM, Salb N, Knoop K, Wechselberger A, Schwenk N, Nelson 
PJ, Spitzweg C. Influence of thyroid hormones T3 and T4 on the hypoxia response 
network 
09/2014 38th Annual Meeting of the European Thyroid Association, Santiago de Compostela, 
Spain 
Schmohl KA, Müller AM, Salb N, Wechselberger A, Knoop K, Schwenk N, Nelson 
PJ, Spitzweg C. Effects of thyroid hormones T3 and T4 on mesenchymal stem cell 
differentiation and migration 
03/2014 57. Symposium der Deutschen Gesellschaft für Endokrinologie, Dresden, Germany 
Schmohl KA, Müller AM, Knoop K, Schwenk N, Wechselberger A, Nelson PJ, 
Spitzweg C. Effects of thyroid hormones T3 and T4 on mesenchymal stem cell 
differentiation 
2013 
10/2013 83th Annual Meeting of the American Thyroid Association, San Juan, Puerto Rico 
Müller AM*, Schmohl KA*, Knoop K, Schwenk N, Wechselberger A, Nelson PJ, 
Spitzweg C. Effects of thyroid hormones T3 and T4 on mesenchymal stem cell 
differentiation. *equal contribution 
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9.5 Grants and Awards 
2019 
10/2019 E. Chester Ridgway Trainee Grant, American Thyroid Association for the 89th Annual 
Meeting of the American Thyroid Association, Chicago, IL, USA 
Travel grant, Deutsche Gesellschaft für Endokrinologie for the 89th Annual Meeting of 
the American Thyroid Association, Chicago, IL, USA 
2018 
10/2018 2018 Annual Trainee Poster Contest winner, best basic research poster at the 88th 
Annual Meeting of the American Thyroid Association, Washington DC, USA 
10/2018 E. Chester Ridgway Trainee Grant, American Thyroid Association for the 88th Annual 
Meeting of the American Thyroid Association, Washington DC, USA 
Travel grant, Deutsche Gesellschaft für Endokrinologie for the 88th Annual Meeting of 
the American Thyroid Association, Washington DC, USA 
09/2018 Travel grant, European Thyroid Association for the 41st Annual Meeting of the 
European Thyroid Association, Newcastle, UK 
05/2018 Invited speaker, European Society of Endocrinology at the 20th European Congress of 
Endocrinology, Barcelona, Spain 
2017 
10/2017 E. Chester Ridgway Trainee Grant, American Thyroid Association for the 87th Annual 
Meeting of the American Thyroid Association, Victoria, BC, Canada 
09/2017 Travel grant, European Thyroid Association for the 40th Annual Meeting of the 
European Thyroid Association, Belgrade, Serbia 
03/2017 Travel grant, Deutsche Gesellschaft für Endokrinologie for the 60. Deutscher Kongress 
für Endokrinologie, Würzburg, Germany 
2016 
09/2016 Travel grant, GlaxoSmithKline Stiftung for the 86th Annual Meeting of the American 
Thyroid Association, Denver, CO, USA 
E. Chester Ridgway Trainee Grant, American Thyroid Association for the 86th Annual 
Meeting of the American Thyroid Association, Denver, CO, USA 
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Travel grant, Deutsche Gesellschaft für Endokrinologie for the 86th Annual Meeting of 
the American Thyroid Association, Denver, CO, USA 
2015 
10/2015 E. Chester Ridgway Trainee Grant, American Thyroid Association for the 15th 
International Thyroid Congress (ITC), Orlando, FL, USA 
Travel grant, Deutsche Gesellschaft für Endokrinologie for the 15th International 
Thyroid Congress (ITC), Orlando, FL, USA 
Travel grant, European Thyroid Association for the 15th International Thyroid Congress 
(ITC), Orlando, FL, USA 
03/2015 Travel grant, Deutsche Gesellschaft für Endokrinologie for the 58. Symposium der 
Deutschen Gesellschaft für Endokrinologie, Lübeck, Germany 
2014 
03/2014 Travel grant, Deutsche Gesellschaft für Endokrinologie for the 57. Symposium der 
Deutschen Gesellschaft für Endokrinologie, Dresden, Germany
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